doc_id,sentence_id,product_a,product_a_alias,product_b,product_b_alias,sentence_text,publication_date,journal,section,sent_index,count,recency_weight,study_type,study_type_weight,combined_weight,evidence_weight,labels,matched_terms,context_rule_hits,indications,direction_type,product_a_role,product_b_role,direction_triggers,narrative_type,narrative_subtype,narrative_confidence,sentiment_label,sentiment_score,sentiment_model,sentiment_inference_ts,confidence_breakdown
med:pmid:41501364,med:pmid:41501364:sec:abstract:sent:1,enalapril,enalapril,sacubitril_valsartan,ARNI,"In a large-scale randomized controlled study of heart failure (HF), angiotensin receptor-neprilysin inhibitors (ARNI) reduced cardiovascular events compared to enalapril, but resulted in more symptomatic hypotension.",2026-01-08,,abstract,1,1,1.0,other,1.0,1.0,1.0,"['compared to', 'randomized']","{""comparative_terms"": [""compared to""], ""study_context"": [""randomized""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 1.0, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 1.0, 'final_confidence': 1.0}"
med:pmid:41501364,med:pmid:41501364:sec:abstract:sent:4,enalapril,angiotensin converting enzyme inhibitors,sacubitril_valsartan,ARNI,"Among 166 patients treated with newly prescribed renin-angiotensin system inhibitor (75.7 ± 13.4 years, 57.2% men, and ejection fraction 39 ± 17%), 114 were treated with newly prescribed ARNI (ARNI group) and 52 were treated with newly prescribed angiotensin converting enzyme inhibitors or angiotensin receptor blockers but without ARNI (ACEi/ARB group).",2026-01-08,,abstract,4,1,1.0,other,1.0,1.0,1.0,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 1.0, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 1.0, 'final_confidence': 1.0}"
med:pmid:41501364,med:pmid:41501364:sec:abstract:sent:5,enalapril,ACEi,sacubitril_valsartan,ARNI,The initial day of prescription was day 4 [2-6] for the ARNI group and day 3 [1-6] for the ACEi/ARB group.,2026-01-08,,abstract,5,1,1.0,other,1.0,1.0,1.0,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 1.0, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 1.0, 'final_confidence': 1.0}"
med:pmid:41501364,med:pmid:41501364:sec:abstract:sent:6,enalapril,ACEi,sacubitril_valsartan,ARNI,"Three days after the initiation of each drug, systolic BP dropped from 132 ± 24 to 117 ± 19 mmHg (ARNI group, p < 0.001) and 131 ± 19 to 117 ± 21 mmHg (ACEi/ARB group, p < 0.001).",2026-01-08,,abstract,6,1,1.0,other,1.0,1.0,1.0,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 1.0, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 1.0, 'final_confidence': 1.0}"
med:pmid:41501364,med:pmid:41501364:sec:abstract:sent:9,enalapril,ACEi,sacubitril_valsartan,ARNI,Early changes in BP after ARNI initiation were comparable with those in the ACEi/ARB group.,2026-01-08,,abstract,9,1,1.0,other,1.0,1.0,1.0,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 1.0, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 1.0, 'final_confidence': 1.0}"
med:pmid:41335448,med:pmid:41335448:sec:conclusion:sent:13,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In patients with HF with reduced ejection fraction due to Chagas disease, there was no significant difference in clinical outcomes between sacubitril/valsartan and enalapril, but there was a greater reduction in NT-proBNP at 12 weeks in patients in the sacubitril/valsartan group.",2026-01-01,,conclusion,13,1,0.9867947312196229,randomized controlled trial,1.6,1.5788715699513967,1.5788715699513967,['no significant difference'],"{""comparative_terms"": [""no significant difference""], ""claim_strength_terms"": {""suggestive"": [""greater reduction""]}}","['comparative_terms', 'claim_strength:suggestive']",[],,,,[],comparative,comparative_efficacy,0.6,POS,2.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 0.9867947312196229, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.5788715699513967, 'final_confidence': 1.5788715699513967}"
med:pmid:41335448,med:pmid:41335448:sec:methods:sent:5,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Patients were randomized to receive sacubitril/valsartan (target dose, 200 mg twice daily) or enalapril (target dose, 10 mg twice daily), in addition to standard therapy.",2026-01-01,,methods,5,1,0.9867947312196229,randomized controlled trial,1.6,1.5788715699513967,1.5788715699513967,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.9867947312196229, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.5788715699513967, 'final_confidence': 1.5788715699513967}"
med:pmid:41335448,med:pmid:41335448:sec:results:sent:10,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,A total of 102 patients (22.1% [7.7% wins]) in the sacubitril/valsartan group and 111 (24.1% [6.9% wins]) in the enalapril group experienced a first hospitalization for HF.,2026-01-01,,results,10,1,0.9867947312196229,randomized controlled trial,1.6,1.5788715699513967,1.5788715699513967,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 0.9867947312196229, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.5788715699513967, 'final_confidence': 1.5788715699513967}"
med:pmid:41335448,med:pmid:41335448:sec:results:sent:11,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Patients in the sacubitril/valsartan group had a median (IQR) decrease in NT-proBNP of 30.6% (-54.3% to -0.9%) at 12 weeks, leading to 22.5% wins, while those in the enalapril group had a 5.5% (-31.9% to 37.5%) decrease (7.2% wins).",2026-01-01,,results,11,1,0.9867947312196229,randomized controlled trial,1.6,1.5788715699513967,1.5788715699513967,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 0.9867947312196229, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.5788715699513967, 'final_confidence': 1.5788715699513967}"
med:pmid:41335448,med:pmid:41335448:sec:results:sent:12,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The resulting stratified win ratio was 1.52 (95% CI, 1.28-1.82; P < .001) for sacubitril/valsartan compared with enalapril.",2026-01-01,,results,12,1,0.9867947312196229,randomized controlled trial,1.6,1.5788715699513967,1.5788715699513967,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 0.9867947312196229, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.5788715699513967, 'final_confidence': 1.5788715699513967}"
med:pmid:41335448,med:pmid:41335448:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Overall, 462 participants were randomized to receive sacubitril/valsartan and 460 to receive enalapril (mean [SD] age, 64.2 [10.8] years; 387 [42.0%] were female).",2026-01-01,,results,8,1,0.9867947312196229,randomized controlled trial,1.6,1.5788715699513967,1.5788715699513967,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.9867947312196229, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.5788715699513967, 'final_confidence': 1.5788715699513967}"
med:pmid:41335448,med:pmid:41335448:sec:results:sent:9,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Over a median (IQR) follow-up of 25.2 (18.4-33.2) months, cardiovascular death occurred in 110 patients (23.8% [18.3% wins in the hierarchical comparison]) in the sacubitril/valsartan group and 117 patients (25.4% [17.5% wins]) in the enalapril group.",2026-01-01,,results,9,1,0.9867947312196229,randomized controlled trial,1.6,1.5788715699513967,1.5788715699513967,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 0.9867947312196229, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.5788715699513967, 'final_confidence': 1.5788715699513967}"
med:pmid:41335448,med:pmid:41335448:sec:title:sent:0,enalapril,Enalapril,sacubitril_valsartan,Sacubitril/Valsartan,"Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial.",2026-01-01,,results,0,1,0.9867947312196229,randomized controlled trial,1.6,1.5788715699513967,1.5788715699513967,"['vs', 'clinical trial', 'randomized', 'trial']","{""comparative_terms"": [""vs""], ""study_context"": [""clinical trial"", ""randomized"", ""trial""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 0.9867947312196229, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.5788715699513967, 'final_confidence': 1.5788715699513967}"
med:pmid:41455057,med:pmid:41455057:sec:abstract:sent:2,enalapril,angiotensin converting enzyme inhibitors,sacubitril_valsartan,angiotensin receptor neprilysin inhibitors,"In the last fifty years different therapeutic strategies, including angiotensin converting enzyme inhibitors (ACEi), type 1 angiotensin II receptor blockers (ARBs) and angiotensin receptor neprilysin inhibitors (ARNi), have been developed to counteract this neurohormonal dysregulation.",2025-12-27,,abstract,2,1,0.9774692939481615,review,0.9,0.8797223645533454,0.8797223645533454,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.9774692939481615, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.8797223645533454, 'final_confidence': 0.8797223645533454}"
med:pmid:41408894,med:pmid:41408894:sec:results:sent:10,enalapril,ACEi,sacubitril_valsartan,ARNI,"Among HFmrEF, 88% were on beta-blockers, 34% on ACEi/ARB, 49% on ARNI, 63% on MRA, and 59% on SGLT2i.",2025-12-17,,results,10,1,0.9590819691638153,other,1.0,0.9590819691638153,0.9590819691638153,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.9590819691638153, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.9590819691638153, 'final_confidence': 0.9590819691638153}"
med:pmid:41408894,med:pmid:41408894:sec:results:sent:11,enalapril,ACEi,sacubitril_valsartan,ARNI,"In the HFpEF group, 76% were on beta-blockers, 49% on ACEi/ARB, 18% on ARNI, 49% on MRA and 40% on SGLT2i.",2025-12-17,,results,11,1,0.9590819691638153,other,1.0,0.9590819691638153,0.9590819691638153,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.9590819691638153, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.9590819691638153, 'final_confidence': 0.9590819691638153}"
med:pmid:41408894,med:pmid:41408894:sec:results:sent:6,enalapril,ACEi,sacubitril_valsartan,ARNI,"Among HFrEF, prescription frequencies were: 90% for beta-blockers; 19% for angiotensin-converting enzyme inhibitors (ACEi)/angiotensin II receptor blockers (ARB); 61% for angiotensin receptor-neprilysin inhibitors (ARNI); 72% for mineralocorticoid receptor antagonists (MRA); and 69% for sodium-glucose co-transporter 2 inhibitors (SGLT2i).",2025-12-17,,results,6,1,0.9590819691638153,other,1.0,0.9590819691638153,0.9590819691638153,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.9590819691638153, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.9590819691638153, 'final_confidence': 0.9590819691638153}"
med:pmid:41379379,med:pmid:41379379:sec:abstract:sent:1,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"Chronic heart failure with reduced ejection fraction (HFrEF) is a progressive syndrome associated with substantial residual morbidity and mortality despite contemporary guideline-directed medical therapy (GDMT) - angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs)/angiotensin receptor-neprilysin inhibitors (ARNIs), beta-blockers, mineralocorticoid receptor antagonists (MRAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) [1].",2025-12-11,,abstract,1,1,0.9482160191351572,review,0.9,0.8533944172216414,0.8533944172216414,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.9482160191351572, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.8533944172216414, 'final_confidence': 0.8533944172216414}"
med:pmid:41249923,med:pmid:41249923:sec:results:sent:12,enalapril,ACEi,sacubitril_valsartan,ARNI,"Sensitivity analyses excluding one study showed significant improvements in ACEi/ARB/ARNI prescriptions (OR: 1.36, [95% CI: 1.10, 1.69]).",2025-11-17,,results,12,1,0.9059694118059841,review,0.9,0.8153724706253858,0.8153724706253858,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],evidence,real_world,0.49999999999999994,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.9059694118059841, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.8153724706253858, 'final_confidence': 0.8153724706253858}"
med:pmid:41249923,med:pmid:41249923:sec:results:sent:14,enalapril,ACEi,sacubitril_valsartan,ARNI,"Subgroup analyses showed significant improvements in ACEi/ARB/ARNI (OR:1.35, [95% CI: 1.03, 1.77)]) and beta-blockers (OR:1.48, [95% CI: 1.31, 1.68)]) prescriptions along with reduced total mortality (OR: 0.86, [95% CI: 0.76, 0.98]) in hospitals.",2025-11-17,,results,14,1,0.9059694118059841,review,0.9,0.8153724706253858,0.8153724706253858,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],comparative,comparative_efficacy,0.6000000000000001,POS,1.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.9059694118059841, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.8153724706253858, 'final_confidence': 0.8153724706253858}"
med:pmid:41249923,med:pmid:41249923:sec:results:sent:16,enalapril,ACEi,sacubitril_valsartan,ARNI,"In another subgroup analyses, shorter follow-up periods were associated with improvement in ACEi/ARB/ARNI (OR:1.38, [95% CI: 1.08, 1.77]), beta-blockers (OR: 1.45, [95% CI: 1.28, 1.61]) prescriptions and total mortality (OR: 0.86, [95% CI: 0.75, 0.99]).",2025-11-17,,results,16,1,0.9059694118059841,review,0.9,0.8153724706253858,0.8153724706253858,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],comparative,comparative_efficacy,0.6000000000000001,POS,1.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.9059694118059841, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.8153724706253858, 'final_confidence': 0.8153724706253858}"
med:pmid:41303015,med:pmid:41303015:sec:introduction:sent:10,enalapril,ACEI,sacubitril_valsartan,ARNI,"ARNI/ACEI/ARB therapy was optimized in 48.4% of the subjects, with optimization rates of 37.9%, 40.2%, and 44.1% for beta-blockers, MRAs, and SGLT2is, respectively.",2025-11-11,,introduction,10,1,0.8957052022048388,other,1.0,0.8957052022048388,0.8957052022048388,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8957052022048388, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8957052022048388, 'final_confidence': 0.8957052022048388}"
med:pmid:41303015,med:pmid:41303015:sec:introduction:sent:11,enalapril,ACEI,sacubitril_valsartan,ARNI,"However, only 38 (22.0%) patients reached the level of treatment corresponding to ""SGLT2i and ARNI/ACEI/ARB and betablocker and MRA in doses ≥ 50%"".",2025-11-11,,introduction,11,1,0.8957052022048388,other,1.0,0.8957052022048388,0.8957052022048388,['combination'],"{""combination"": [""arni/acei/arb""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 0.8957052022048388, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8957052022048388, 'final_confidence': 0.8957052022048388}"
med:pmid:41303015,med:pmid:41303015:sec:introduction:sent:9,enalapril,ACEI,sacubitril_valsartan,ARNI,"In the analysis for the whole group (regardless of ejection fraction [EF]), ARNI (angiotensin receptor-neprilysin inhibitor)/ACEI (angiotensin-converting enzyme inhibitor)/ARB (angiotensin receptor blocker) use increased from 63.3% of the subjects at admission to 81.3% at discharge, beta-blocker use increased from 70.6% to 92.6%, MRA (mineralocorticoid receptor antagonist) use increased from 43.1% to 75.8%, and SGLT2i (sodium-glucose co-transporter 2 inhibitor) use increased from 30.1% to 75.0%.",2025-11-11,,introduction,9,1,0.8957052022048388,other,1.0,0.8957052022048388,0.8957052022048388,[],,[],[],,,,[],,,,POS,4.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 0.8957052022048388, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8957052022048388, 'final_confidence': 0.8957052022048388}"
med:pmid:41377094,med:pmid:41377094:sec:results:sent:8,enalapril,ACEi,sacubitril_valsartan,ARNI,"In multivariable regression analysis, older age was the only independent socio-demographic predictor of under-prescription both overall and for ACEi/ARB/ARNI (OR0.70; 95% CI 0.55-0.89), beta-blockers (OR0.59; 95% CI 0.41-0.84) and SGLT2i (OR0.66, 95% CI 0.47-0.93), while also associated with a loop diuretics use (OR1.56; 95% CI 1.13-2.17).",2025-11-04,,results,8,1,0.883877174261742,other,1.0,0.883877174261742,0.883877174261742,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],evidence,real_world,0.49999999999999994,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 0.883877174261742, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.883877174261742, 'final_confidence': 0.883877174261742}"
med:pmid:40839760,med:pmid:40839760:sec:results:sent:5,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Changes in LSS severity at 8 months were analysed using ordinal logistic regression models to estimate the effect of sacubitril/valsartan vs. enalapril or valsartan.,2025-11-01,,results,5,1,0.878855954288881,randomized controlled trial,1.6,1.4061695268622096,1.4061695268622096,['vs'],"{""comparative_terms"": [""vs""]}",['comparative_terms'],[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.878855954288881, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.4061695268622096, 'final_confidence': 1.4061695268622096}"
med:pmid:41287294,med:pmid:41287294:sec:abstract:sent:14,enalapril,ACEI,sacubitril_valsartan,ARNI,"No significant between-group differences were observed in drug utilization rate of β-blockers, ACEI/ARB/ARNI, or sodium-glucose cotransporter 2 inhibitors during follow-up (all <i>P</i>>0.05), while mineralocorticoid receptor antagonists use showed a declining trend in both groups.",2025-11-01,,abstract,14,1,0.878855954288881,other,1.0,0.878855954288881,0.878855954288881,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.878855954288881, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.878855954288881, 'final_confidence': 0.878855954288881}"
med:pmid:41287294,med:pmid:41287294:sec:abstract:sent:15,enalapril,ACEI,sacubitril_valsartan,ARNI,"Although the core hospital-treated group had higher target dose achievement rates for β-blockers (65.4% vs. 49.3%, <i>P</i>=0.042) and ACEI/ARB/ARNI (79.8% vs. 65.8%, <i>P</i>=0.046) than the two-way referral group, multivariate logistic regression indicated that the two-way referral model was not a negative predictor for these outcomes (all <i>P</i>>0.05).",2025-11-01,,abstract,15,1,0.878855954288881,other,1.0,0.878855954288881,0.878855954288881,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.878855954288881, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.878855954288881, 'final_confidence': 0.878855954288881}"
med:pmid:41287294,med:pmid:41287294:sec:abstract:sent:5,enalapril,ACEI,sacubitril_valsartan,ARNI,"Patients underwent followed-up, with primary endpoints including follow-up rate, drug (β-blockers, angiotension converting enzyme inhibitor (ACEI)/angiotensin Ⅱ receptor blockers (ARB)/angiotensin receptor-neprilysin inhibitor (ARNI), sodium-glucose cotransporter 2 inhibitors and mineralocorticoid receptor antagonists) utilization rate and target dose achievement rate.",2025-11-01,,abstract,5,1,0.878855954288881,other,1.0,0.878855954288881,0.878855954288881,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.878855954288881, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.878855954288881, 'final_confidence': 0.878855954288881}"
med:pmid:41287294,med:pmid:41287294:sec:abstract:sent:9,enalapril,ACEI,sacubitril_valsartan,ARNI,Multivariate logistic regression was used to identify factors influencing target dose achievement rate for β-blockers and ACEI/ARB/ARNI therapies in CHF patients.,2025-11-01,,abstract,9,1,0.878855954288881,other,1.0,0.878855954288881,0.878855954288881,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.878855954288881, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.878855954288881, 'final_confidence': 0.878855954288881}"
med:pmid:41151613,med:pmid:41151613:sec:abstract:sent:2,enalapril,ACE inhibitor,sacubitril_valsartan,sacubitril/valsartan,"Since 2021, evidence‑based management of heart failure with reduced ejection fraction (HFrEF) has centred on four pharmacological ""pillars"": β‑blockers, sacubitril/valsartan (or an ACE inhibitor), mineralocorticoid‑receptor antagonists, and sodium-glucose co‑transporter‑2 (SGLT‑2) inhibitors.",2025-10-28,,abstract,2,1,0.8722053386067754,review,0.9,0.7849848047460979,0.7849848047460979,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.8722053386067754, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.7849848047460979, 'final_confidence': 0.7849848047460979}"
med:pmid:41136931,med:pmid:41136931:sec:results:sent:9,enalapril,ACEI,sacubitril_valsartan,ARNI,"Target dose attainment varied by drug class: 78% for beta-blockers, 63% for ACEI/ARB/ARNI, 96% for MRAs, and 100% for ivabradine.",2025-10-24,,results,9,1,0.865605050499667,other,1.0,0.865605050499667,0.865605050499667,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.865605050499667, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.865605050499667, 'final_confidence': 0.865605050499667}"
med:pmid:41084891,med:pmid:41084891:sec:results:sent:7,enalapril,ACEI,sacubitril_valsartan,ARNI,"In this subgroup, the use of angiotensin receptor‑neprilysin inhibitor (ARNI) / angiotensin‑converting enzyme inhibitor (ACEI) / angiotensin receptor blocker (ARB) increased from 81.5% of the patients at admission to 88.9% at discharge, of β‑blocker from 85% to 94.4%, of mineralocorticoid receptor antagonist (MRA) from 69.7% to 86.1%, and of sodium‑glucose cotransporter 2 inhibitor (SGLT2i) from 59.2% to 83.6%.",2025-10-14,,results,7,1,0.8493220211533232,observational study,1.2,1.0191864253839877,1.0191864253839877,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8493220211533232, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 1.0191864253839877, 'final_confidence': 1.0191864253839877}"
med:pmid:41084891,med:pmid:41084891:sec:results:sent:8,enalapril,ACEI,sacubitril_valsartan,ARNI,"ARNI/ACEI/ARB therapy was optimized in 36.2% of the participants, while the rates of optimization were 24.7%, 27.2%, and 24.4% for β‑blockers, MRA, and SGLT2i, respectively.",2025-10-14,,results,8,1,0.8493220211533232,observational study,1.2,1.0191864253839877,1.0191864253839877,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8493220211533232, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 1.0191864253839877, 'final_confidence': 1.0191864253839877}"
med:pmid:41084891,med:pmid:41084891:sec:results:sent:9,enalapril,ACEI,sacubitril_valsartan,ARNI,"However, only 64 patients (22.3%) attained the 4‑pillar GDMT of SGLT2i, ARNI/ACEI/ARB, β‑blockers, and MRA at doses equal to or above 50% of the target dose.",2025-10-14,,results,9,1,0.8493220211533232,observational study,1.2,1.0191864253839877,1.0191864253839877,['combination'],"{""combination"": [""arni/acei/arb"", ""gdmt""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.8493220211533232, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 1.0191864253839877, 'final_confidence': 1.0191864253839877}"
med:pmid:41079061,med:pmid:41079061:sec:methods:sent:6,enalapril,ACE inhibitors,sacubitril_valsartan,ARNI,"Medications analyzed included ACE inhibitors (ACEi), angiotensin receptor blockers (ARB), beta-blockers (BB), mineralocorticoid receptor antagonists (MRA), angiotensin receptor-neprilysin inhibitors (ARNI), and sodium-glucose co-transporter 2 inhibitors (SGLT2i).",2025-10-09,,methods,6,1,0.8412957326244546,observational study,1.2,1.0095548791493454,1.0095548791493454,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8412957326244546, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 1.0095548791493454, 'final_confidence': 1.0095548791493454}"
med:pmid:41079061,med:pmid:41079061:sec:results:sent:9,enalapril,ACEi,sacubitril_valsartan,ARNI,"The most expensive medication regime for HF in Venezuela was ARNI-based GDMT with a median monthly cost of 393.81USD, followed by ARB-based GDMT and ACEi-based GDMT costing $100.88USD and $82.23USD respectively.",2025-10-09,,results,9,1,0.8412957326244546,observational study,1.2,1.0095548791493454,1.0095548791493454,['combination'],"{""combination"": [""gdmt""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.8412957326244546, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 1.0095548791493454, 'final_confidence': 1.0095548791493454}"
med:pmid:41016569,med:pmid:41016569:sec:conclusion:sent:7,enalapril,ACEI,sacubitril_valsartan,ARNI,"Compared with ACEI/ARB, ARNI demonstrated enhanced preservation of cardiac function, attenuation of adverse ventricular remodeling, and maintenance of ventricular geometry following myocardial infarction.",2025-09-26,,conclusion,7,1,0.8207805751280809,other,1.0,0.8207805751280809,0.8207805751280809,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.8207805751280809, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8207805751280809, 'final_confidence': 0.8207805751280809}"
med:pmid:41016569,med:pmid:41016569:sec:introduction:sent:1,enalapril,ACEI,sacubitril_valsartan,ARNI,To compare the effects of early angiotensin receptor-neprilysin inhibitor (ARNI) versus angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) therapy on left ventricular remodeling and heart failure progression in patients with acute anterior wall myocardial infarction.,2025-09-26,,introduction,1,1,0.8207805751280809,other,1.0,0.8207805751280809,0.8207805751280809,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8207805751280809, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8207805751280809, 'final_confidence': 0.8207805751280809}"
med:pmid:41016569,med:pmid:41016569:sec:methods:sent:2,enalapril,ACEI,sacubitril_valsartan,ARNI,Patients were stratified by treatment into ARNI (n = 97) and ACEI/ARB (n = 71) groups.,2025-09-26,,methods,2,1,0.8207805751280809,other,1.0,0.8207805751280809,0.8207805751280809,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8207805751280809, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8207805751280809, 'final_confidence': 0.8207805751280809}"
med:pmid:41016569,med:pmid:41016569:sec:results:sent:4,enalapril,ACEI,sacubitril_valsartan,ARNI,The ARNI group demonstrated significantly greater improvements in left ventricular end-diastolic diameter and relative wall thickness versus the ACEI/ARB group.,2025-09-26,,results,4,1,0.8207805751280809,other,1.0,0.8207805751280809,0.8207805751280809,['versus'],"{""comparative_terms"": [""versus""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.8207805751280809, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8207805751280809, 'final_confidence': 0.8207805751280809}"
med:pmid:41079587,med:pmid:41079587:sec:conclusion:sent:13,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"Early sacubitril/valsartan use was associated with reduced 1-year AF risk vs. ACEI/ARB in AMI complicated by MR, suggesting a potential role in this population; prospective trials are needed to confirm causality.",2025-09-26,,conclusion,13,1,0.8207805751280809,other,1.0,0.8207805751280809,0.8207805751280809,"['vs', 'risk']","{""comparative_terms"": [""vs""], ""risk_terms"": [""risk""]}","['comparative_terms', 'risk_terms']",[],,,,[],comparative,comparative_safety,0.9,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.8207805751280809, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8207805751280809, 'final_confidence': 0.8207805751280809}"
med:pmid:41079587,med:pmid:41079587:sec:introduction:sent:2,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,Evidence remains limited regarding whether early administration of sacubitril/valsartan confers additional protection against new-onset AF in this high-risk population to traditional ACEI/ARB therapy.,2025-09-26,,introduction,2,1,0.8207805751280809,other,1.0,0.8207805751280809,0.8207805751280809,['risk'],"{""risk_terms"": [""risk""]}",['risk_terms'],[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.8207805751280809, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8207805751280809, 'final_confidence': 0.8207805751280809}"
med:pmid:41079587,med:pmid:41079587:sec:methods:sent:4,enalapril,ACEI,sacubitril_valsartan,Sacubitril/Valsartan,"In this single-center retrospective cohort, 1,065 in-patients with AMI complicated by MR (June 2021-December 2023) were categorized by discharge prescription into the Sacubitril/Valsartan group (<i>n</i> = 427) or the ACEI/ARB group (<i>n</i> = 638).The primary endpoint was new-onset AF within 1 year.",2025-09-26,,methods,4,1,0.8207805751280809,other,1.0,0.8207805751280809,0.8207805751280809,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8207805751280809, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8207805751280809, 'final_confidence': 0.8207805751280809}"
med:pmid:41079587,med:pmid:41079587:sec:results:sent:9,enalapril,ACEI,sacubitril_valsartan,Sacubitril/Valsartan,"Despite a higher baseline risk profile in the Sacubitril/Valsartan group, the 1-year cumulative incidence of AF was lower than in the ACEI/ARB group (CIF 10.8% vs. 17.9%; Gray's test <i>P</i> = 0.002).",2025-09-26,,results,9,1,0.8207805751280809,other,1.0,0.8207805751280809,0.8207805751280809,"['vs', 'risk']","{""comparative_terms"": [""vs""], ""risk_terms"": [""risk""]}","['comparative_terms', 'risk_terms']",[],,,,[],comparative,comparative_safety,0.9,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.8207805751280809, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8207805751280809, 'final_confidence': 0.8207805751280809}"
med:pmid:41296625,med:pmid:41296625:sec:conclusion:sent:10,enalapril,ACEi,sacubitril_valsartan,ARNI,ATTRwt-CA patients on beta-blockers or ACEi/ARB/ARNI at diagnosis did not have a shorter survival.,2025-09-26,,conclusion,10,1,0.8207805751280809,other,1.0,0.8207805751280809,0.8207805751280809,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],positioning,combination,0.85,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.8207805751280809, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8207805751280809, 'final_confidence': 0.8207805751280809}"
med:pmid:41296625,med:pmid:41296625:sec:conclusion:sent:11,enalapril,ACEi,sacubitril_valsartan,ARNI,Beta-blockers were discontinued less often than were ACEi/ARB/ARNI.,2025-09-26,,conclusion,11,1,0.8207805751280809,other,1.0,0.8207805751280809,0.8207805751280809,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.8207805751280809, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8207805751280809, 'final_confidence': 0.8207805751280809}"
med:pmid:41296625,med:pmid:41296625:sec:results:sent:5,enalapril,ACEi,sacubitril_valsartan,ARNI,"At diagnosis, 60% of patients were on beta-blockers, 58% on ACEi/ARB/ARNI, and 35% on MRA.",2025-09-26,,results,5,1,0.8207805751280809,other,1.0,0.8207805751280809,0.8207805751280809,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.8207805751280809, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8207805751280809, 'final_confidence': 0.8207805751280809}"
med:pmid:41296625,med:pmid:41296625:sec:results:sent:6,enalapril,ACEi,sacubitril_valsartan,ARNI,"Patients on beta-blockers had more often NYHA class III/IV, a greater burden of comorbidities, and lower LVEF, and those on ACEi/ARB/ARNI had more comorbidities.",2025-09-26,,results,6,1,0.8207805751280809,other,1.0,0.8207805751280809,0.8207805751280809,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],positioning,combination,0.85,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.8207805751280809, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8207805751280809, 'final_confidence': 0.8207805751280809}"
med:pmid:41296625,med:pmid:41296625:sec:results:sent:7,enalapril,ACEi,sacubitril_valsartan,ARNI,"Nonetheless, the survival of patients on beta-blockers or ACEi/ARB/ARNI was not significantly shorter over a 2.5-year follow-up (1.6-3.8) (P = 0.577 and P = 0.977, respectively), and patients on both drugs did not have a worse outcome than those not receiving any neurohormonal drug (P = 0.575).",2025-09-26,,results,7,1,0.8207805751280809,other,1.0,0.8207805751280809,0.8207805751280809,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],comparative,comparative_efficacy,0.8,POS,1.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 0.8207805751280809, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8207805751280809, 'final_confidence': 0.8207805751280809}"
med:pmid:40993994,med:pmid:40993994:sec:results:sent:4,enalapril,ACEI,sacubitril_valsartan,ARNI,"In the total population, from admission to discharge there was a increase in the use of angiotensin receptor-neprilysin inhibitor (ARNI) (17.1% to 34.3%), beta-blockers (69.4% to 92.4%), mineralocorticoid receptor antagonists (MRA) (44.0% to 82.1%) and sodium-glucose co-transporter 2 inhibitors (SGLT2i) (30.8% to 79.9%), with a reduction in angiotensin-converting enzyme inhibitor (ACEI) use (all p < 0.05).",2025-09-24,,results,4,1,0.8176691082423277,other,1.0,0.8176691082423277,0.8176691082423277,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8176691082423277, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8176691082423277, 'final_confidence': 0.8176691082423277}"
med:pmid:40993994,med:pmid:40993994:sec:results:sent:5,enalapril,ACEI,sacubitril_valsartan,ARNI,"Similar trends were observed across HF phenotypes, including HFrEF (increased use of ARNI, 26.3% to 55.1%, beta-blockers, 69.8% to 95.3%, MRA 49.5% to 89.0%, and SGLT2I 36.2% to 79.8%, and lower ACEI use, all p < 0.05).",2025-09-24,,results,5,1,0.8176691082423277,other,1.0,0.8176691082423277,0.8176691082423277,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8176691082423277, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8176691082423277, 'final_confidence': 0.8176691082423277}"
med:pmid:41007826,med:pmid:41007826:sec:introduction:sent:1,enalapril,ACEI,sacubitril_valsartan,ARNI,"Angiotensin receptor-neprilysin inhibitor (ARNI) has a well-established advantage over angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) therapy in patients (pts) with heart failure with reduced ejection fraction (HFrEF), but in pts after acute myocardial infarction (AMI) with left ventricular (LV) systolic dysfunction, the advantage of ARNI has not been clearly proven.",2025-09-15,,introduction,1,1,0.8038128281526327,other,1.0,0.8038128281526327,0.8038128281526327,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.8038128281526327, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8038128281526327, 'final_confidence': 0.8038128281526327}"
med:pmid:41007826,med:pmid:41007826:sec:introduction:sent:10,enalapril,ACEI,sacubitril_valsartan,ARNI,"At the 6-week follow-up, in both subgroups, a significant improvement in the median LVEF values was achieved-from a median LVEF value of 30% (27.3; 38) to 37% (30; 43; <i>p</i> = 0.0008) in the ARNI subgroup and from a median LVEF value of 36% (33; 39) to 45% (42; 52; <i>p</i> < 0.0001) in the ACEI/ARB subgroup.",2025-09-15,,introduction,10,1,0.8038128281526327,other,1.0,0.8038128281526327,0.8038128281526327,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8038128281526327, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8038128281526327, 'final_confidence': 0.8038128281526327}"
med:pmid:41007826,med:pmid:41007826:sec:introduction:sent:11,enalapril,ACEI,sacubitril_valsartan,ARNI,"The median ΔLVEF in the ACEI/ARB subgroup was higher [10% (6; 12)] than in the ARNI subgroup [6% (2; 10.25), <i>p</i> = 0.018].",2025-09-15,,introduction,11,1,0.8038128281526327,other,1.0,0.8038128281526327,0.8038128281526327,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8038128281526327, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8038128281526327, 'final_confidence': 0.8038128281526327}"
med:pmid:41007826,med:pmid:41007826:sec:introduction:sent:12,enalapril,ACEI,sacubitril_valsartan,ARNI,"Similarly, the median relative ΔLVEF was higher in the ACEI/ARB subgroup [30% (15.4; 40)] than in the ARNI group [17.5% (7; 31.9), <i>p</i> = 0.047].",2025-09-15,,introduction,12,1,0.8038128281526327,other,1.0,0.8038128281526327,0.8038128281526327,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8038128281526327, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8038128281526327, 'final_confidence': 0.8038128281526327}"
med:pmid:41007826,med:pmid:41007826:sec:introduction:sent:15,enalapril,ACEI,sacubitril_valsartan,ARNI,"Regardless of the significant improvement in the baseline LVEF observed in patients receiving both ACEI/ARB and ARNI at the 6-week follow-up, the absolute and relative increases in the LVEF were higher in subjects treated with ACEI/ARB.",2025-09-15,,introduction,15,1,0.8038128281526327,other,1.0,0.8038128281526327,0.8038128281526327,[],"{""claim_strength_terms"": {""confirmatory"": [""significant improvement""]}}",['claim_strength:confirmatory'],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.8038128281526327, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8038128281526327, 'final_confidence': 0.8038128281526327}"
med:pmid:41007826,med:pmid:41007826:sec:introduction:sent:2,enalapril,ACEI,sacubitril_valsartan,ARNI,The efficacy of ARNI is compared with that of ACEI/ARB therapy in patients with their first AMI in terms of improvement of post-infarction LV systolic function.,2025-09-15,,introduction,2,1,0.8038128281526327,other,1.0,0.8038128281526327,0.8038128281526327,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],,,,POS,2.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.8038128281526327, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8038128281526327, 'final_confidence': 0.8038128281526327}"
med:pmid:41007826,med:pmid:41007826:sec:introduction:sent:5,enalapril,ACEI,sacubitril_valsartan,ARNI,The study population was categorized into pts receiving ARNI and ACEI/ARB.,2025-09-15,,introduction,5,1,0.8038128281526327,other,1.0,0.8038128281526327,0.8038128281526327,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.8038128281526327, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8038128281526327, 'final_confidence': 0.8038128281526327}"
med:pmid:41007826,med:pmid:41007826:sec:introduction:sent:7,enalapril,ACEI,sacubitril_valsartan,ARNI,"Finally, two groups (ARNI vs. ACEI/ARB) of 30 pts were obtained and analyzed at baseline and at a 6-week follow-up.",2025-09-15,,introduction,7,1,0.8038128281526327,other,1.0,0.8038128281526327,0.8038128281526327,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8038128281526327, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8038128281526327, 'final_confidence': 0.8038128281526327}"
med:pmid:41007826,med:pmid:41007826:sec:title:sent:0,enalapril,ACEI,sacubitril_valsartan,Sacubitril/Valsartan,Impact of Sacubitril/Valsartan (ARNI) Compared with ACEI/ARB in Patients with Acute Myocardial Infarction on Post-Infarction Left Ventricular Systolic Dysfunction: A Retrospective Analysis.,2025-09-15,,introduction,0,1,0.8038128281526327,other,1.0,0.8038128281526327,0.8038128281526327,"['compared with', 'retrospective']","{""comparative_terms"": [""compared with""], ""study_context"": [""retrospective""], ""real_world_terms"": [""retrospective""]}","['comparative_terms', 'study_context', 'real_world_terms']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.8038128281526327, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8038128281526327, 'final_confidence': 0.8038128281526327}"
med:pmid:40916703,med:pmid:40916703:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC).",2025-09-08,,introduction,1,1,0.7931982637077621,other,1.0,0.7931982637077621,0.7931982637077621,"['compared with', 'trial']","{""comparative_terms"": [""compared with""], ""study_context"": [""trial""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.7931982637077621, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7931982637077621, 'final_confidence': 0.7931982637077621}"
med:pmid:40916703,med:pmid:40916703:sec:results:sent:4,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Participants were randomized 1:1 to sacubitril/valsartan (97/103 mg bid) or enalapril (10 mg bid).,2025-09-08,,results,4,1,0.7931982637077621,other,1.0,0.7931982637077621,0.7931982637077621,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7931982637077621, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7931982637077621, 'final_confidence': 0.7931982637077621}"
med:pmid:40916703,med:pmid:40916703:sec:title:sent:0,enalapril,enalapril,sacubitril_valsartan,Sacubitril/valsartan,Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial.,2025-09-08,,results,0,1,0.7931982637077621,other,1.0,0.7931982637077621,0.7931982637077621,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7931982637077621, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7931982637077621, 'final_confidence': 0.7931982637077621}"
ppr:doi:10.20944/preprints202509.0619.v1,ppr:doi:10.20944/preprints202509.0619.v1:sec:conclusion:sent:13,enalapril,ACEI,sacubitril_valsartan,ARNI,Regardless of significant improvement of baseline LVEF observed in patients receiving both ACEI/ARB and ARNI in 6 week follow-up the value of absolute and relative LVEF increase were higher in subjects treated with ACEI/ARB.,2025-09-08,,conclusion,13,1,0.7931982637077621,other,1.0,0.7931982637077621,0.7931982637077621,[],"{""claim_strength_terms"": {""confirmatory"": [""significant improvement""]}}",['claim_strength:confirmatory'],[],,,,[],,,,POS,2.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 0.7931982637077621, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7931982637077621, 'final_confidence': 0.7931982637077621}"
ppr:doi:10.20944/preprints202509.0619.v1,ppr:doi:10.20944/preprints202509.0619.v1:sec:introduction:sent:1,enalapril,angiotensin converting enzyme inhibitor,sacubitril_valsartan,ARNI,"/Objectives: Angiotensin receptor-neprilysin inhibitor (AR-NI) has a well-established advantage over angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) therapy in patients (pts) with heart failure with reduced ejection fraction (HFrEF), but in pts after acute myocardial infarction (AMI) with left ventricular (LV) systolic dysfunction the advantage of ARNI has not been clearly proven.",2025-09-08,,introduction,1,1,0.7931982637077621,other,1.0,0.7931982637077621,0.7931982637077621,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7931982637077621, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7931982637077621, 'final_confidence': 0.7931982637077621}"
ppr:doi:10.20944/preprints202509.0619.v1,ppr:doi:10.20944/preprints202509.0619.v1:sec:introduction:sent:2,enalapril,ACEI,sacubitril_valsartan,ARNI,To com-pare of the efficacy of ARNI versus ACEI/ARB therapy in patients with the first AMI in terms of improvement of post-infarction LV systolic function.,2025-09-08,,introduction,2,1,0.7931982637077621,other,1.0,0.7931982637077621,0.7931982637077621,['versus'],"{""comparative_terms"": [""versus""]}",['comparative_terms'],[],,,,[],,,,POS,2.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 0.7931982637077621, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7931982637077621, 'final_confidence': 0.7931982637077621}"
ppr:doi:10.20944/preprints202509.0619.v1,ppr:doi:10.20944/preprints202509.0619.v1:sec:methods:sent:4,enalapril,ACEI,sacubitril_valsartan,ARNI,The study population was catego-rized into pts receiving ARNI and ACEI/ARB.,2025-09-08,,methods,4,1,0.7931982637077621,other,1.0,0.7931982637077621,0.7931982637077621,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 0.7931982637077621, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7931982637077621, 'final_confidence': 0.7931982637077621}"
ppr:doi:10.20944/preprints202509.0619.v1,ppr:doi:10.20944/preprints202509.0619.v1:sec:methods:sent:6,enalapril,ACEI,sacubitril_valsartan,ARNI,Finally two groups (ARNI vs ACEI/ARB) of 30 pts were obtained and an-alysed at baseline and in 6-week follow-up.,2025-09-08,,methods,6,1,0.7931982637077621,other,1.0,0.7931982637077621,0.7931982637077621,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7931982637077621, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7931982637077621, 'final_confidence': 0.7931982637077621}"
ppr:doi:10.20944/preprints202509.0619.v1,ppr:doi:10.20944/preprints202509.0619.v1:sec:results:sent:10,enalapril,ACEI,sacubitril_valsartan,ARNI,"Median ΔLVEF in the ACEI/ARB subgroup was higher [10% (6; 12)] than in the ARNI subgroup [6% (2; 10.25), p=0.018].",2025-09-08,,results,10,1,0.7931982637077621,other,1.0,0.7931982637077621,0.7931982637077621,[],"{""claim_strength_terms"": {""confirmatory"": [""p=""]}}",['claim_strength:confirmatory'],[],,,,[],comparative,comparative_efficacy,0.6000000000000001,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 0.7931982637077621, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7931982637077621, 'final_confidence': 0.7931982637077621}"
ppr:doi:10.20944/preprints202509.0619.v1,ppr:doi:10.20944/preprints202509.0619.v1:sec:results:sent:11,enalapril,ACEI,sacubitril_valsartan,ARNI,"Similarly median relative ΔLVEF was higher in the ACEI/ARB subgroup [30% (15.4; 40)] than in the ARNI group [17.5% (7; 31.9), p=0.047].",2025-09-08,,results,11,1,0.7931982637077621,other,1.0,0.7931982637077621,0.7931982637077621,[],"{""claim_strength_terms"": {""confirmatory"": [""p=""]}}",['claim_strength:confirmatory'],[],,,,[],comparative,comparative_efficacy,0.6000000000000001,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 0.7931982637077621, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7931982637077621, 'final_confidence': 0.7931982637077621}"
ppr:doi:10.20944/preprints202509.0619.v1,ppr:doi:10.20944/preprints202509.0619.v1:sec:results:sent:9,enalapril,ACEI,sacubitril_valsartan,ARNI,In 6-week follow-up in both subgroups a significant improvement in the median LVEF values was achieved: from median LVEF value 30% (27.3; 38) up to 37% (30; 43; p=0.0008) in ARNI and from median LVEF value 36% (33; 39) up to 45% (42; 52; p&amp;lt;0.0001) in ACEI/ARB subgroup.,2025-09-08,,results,9,1,0.7931982637077621,other,1.0,0.7931982637077621,0.7931982637077621,[],"{""claim_strength_terms"": {""confirmatory"": [""p="", ""significant improvement""]}}",['claim_strength:confirmatory'],[],,,,[],comparative,comparative_efficacy,0.6000000000000001,POS,1.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 0.7931982637077621, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7931982637077621, 'final_confidence': 0.7931982637077621}"
ppr:doi:10.20944/preprints202509.0619.v1,ppr:doi:10.20944/preprints202509.0619.v1:sec:title:sent:0,enalapril,ACEI,sacubitril_valsartan,Sacubitril/Valsartan,Impact of Sacubitril/Valsartan (ARNI) Compared with ACEI/ARB in Patients with Acute Myocardial Infarction on Post-Infarction Left Ventricular Systolic Dysfunction: A Retrospective Analysis,2025-09-08,,results,0,1,0.7931982637077621,other,1.0,0.7931982637077621,0.7931982637077621,"['compared with', 'retrospective']","{""comparative_terms"": [""compared with""], ""study_context"": [""retrospective""], ""real_world_terms"": [""retrospective""]}","['comparative_terms', 'study_context', 'real_world_terms']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 0.7931982637077621, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7931982637077621, 'final_confidence': 0.7931982637077621}"
med:pmid:40910162,med:pmid:40910162:sec:results:sent:8,enalapril,ACE inhibitor,sacubitril_valsartan,ARNi,"A combination of angiotensin receptor blocker/neprilysin inhibitors (ARNi)+β-blockers (BB)+sodium-glucose cotransporter 2 inhibitors (SGLT2i; MD, +5.3 [+0.4, +10.3]) was the most effective at improving quality of life followed by ARNi+BB+mineralocorticoid receptor antagonists (MRA)+SGLT2i (MD, +7.1 [-1.0 to +15.2]), ACE inhibitor+BB+MRA+SGLT2i (MD, +5.3 [-2.6, to +13.3]), and ACE inhibitor+BB+MRA+ivabradine (MD, +5.2 [-3.1 to +13.6]), which were not statistically significant.",2025-09-05,,results,8,1,0.7886921817767578,review,0.9,0.709822963599082,0.709822963599082,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7886921817767578, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.709822963599082, 'final_confidence': 0.709822963599082}"
med:pmid:40981086,med:pmid:40981086:sec:abstract:sent:10,enalapril,ACE inhibitors,sacubitril_valsartan,Sacubitril/Valsartan,"While most physicians (66%) knew the target doses for Sacubitril/Valsartan, 83% of them were unaware that the clinical benefit of sacubitril/valsartan at doses below 50% of the target compared to ACE inhibitors remains uncertain and is not well supported by current evidence.",2025-09-05,,abstract,10,1,0.7886921817767578,other,1.0,0.7886921817767578,0.7886921817767578,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.7886921817767578, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7886921817767578, 'final_confidence': 0.7886921817767578}"
med:pmid:40981086,med:pmid:40981086:sec:abstract:sent:12,enalapril,ACE inhibitors,sacubitril_valsartan,sacubitril/valsartan,"This finding raises questions about the clinical and economic value of initiating sacubitril/valsartan without subsequent dose optimization, especially given the uncertainty surrounding the efficacy of suboptimal dosing compared to ACE inhibitors.",2025-09-05,,abstract,12,1,0.7886921817767578,other,1.0,0.7886921817767578,0.7886921817767578,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.7886921817767578, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7886921817767578, 'final_confidence': 0.7886921817767578}"
med:pmid:40908036,med:pmid:40908036:sec:abstract:sent:5,enalapril,ACE inhibitors,sacubitril_valsartan,ARNI,"The cornerstone of HFrEF management consists of four key medication classes: ACE inhibitors or angiotensin receptor-neprilysin inhibitor (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRA) and sodium-glucose co-transporter 2 inhibitors (SGLT2i).",2025-09-04,,abstract,5,1,0.7871958502452487,review,0.9,0.7084762652207239,0.7084762652207239,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.7871958502452487, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.7084762652207239, 'final_confidence': 0.7084762652207239}"
med:pmid:41049960,med:pmid:41049960:sec:introduction:sent:1,enalapril,ACEI,sacubitril_valsartan,angiotensin receptor neprilysin inhibitors,"Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) includes a combination of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB)/angiotensin receptor neprilysin inhibitors (ARNI), beta-blockers, mineralocorticoid receptor agonists (MRA), and sodium-glucose co-transporter 2 inhibitors (SGLT2i).",2025-09-02,,introduction,1,1,0.7842116984574725,other,1.0,0.7842116984574725,0.7842116984574725,['combination'],"{""combination"": [""gdmt""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.7842116984574725, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7842116984574725, 'final_confidence': 0.7842116984574725}"
med:pmid:41049960,med:pmid:41049960:sec:methods:sent:6,enalapril,ACEI,sacubitril_valsartan,ARNI,"GDMT use and dosing (none, <50%, ≥50 to <100%, 100% target dose) for beta-blockers, ACEI/ARB/ARNI, MRA, and SGLT2i were assessed.",2025-09-02,,methods,6,1,0.7842116984574725,other,1.0,0.7842116984574725,0.7842116984574725,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7842116984574725, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7842116984574725, 'final_confidence': 0.7842116984574725}"
med:pmid:41049960,med:pmid:41049960:sec:results:sent:12,enalapril,ACEI,sacubitril_valsartan,ARNI,"Increasing age was linked to lower odds of ACEI/ARB/ARNI use, while higher systolic blood pressure (SBP) favored treatment.",2025-09-02,,results,12,1,0.7842116984574725,other,1.0,0.7842116984574725,0.7842116984574725,['combination'],"{""combination"": [""acei/arb/arni""], ""endpoint_terms"": [""blood pressure""]}","['relationship:combination', 'endpoint_terms']",[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.7842116984574725, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7842116984574725, 'final_confidence': 0.7842116984574725}"
med:pmid:41049960,med:pmid:41049960:sec:results:sent:8,enalapril,ACEI,sacubitril_valsartan,ARNI,"Among 236 eligible patients, only 16.5%, 10.2%, 31.4%, and 42.8% were receiving target doses of beta-blockers, ACEI/ARB/ARNI, MRA, and SGLT2i, respectively.",2025-09-02,,results,8,1,0.7842116984574725,other,1.0,0.7842116984574725,0.7842116984574725,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7842116984574725, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7842116984574725, 'final_confidence': 0.7842116984574725}"
med:pmid:41070303,med:pmid:41070303:sec:conclusion:sent:10,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,LBBP combined with sacubitril/valsartan is more effective in treating elderly CHD with CHF than LBBP combined with enalapril.,2025-09-01,,conclusion,10,1,0.7827238674393727,other,1.0,0.7827238674393727,0.7827238674393727,['combination'],"{""combination"": [""combined with""]}",['relationship:combination'],[],add_on,add_on,add_on,['combination_with'],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.7827238674393727, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7827238674393727, 'final_confidence': 0.7827238674393727}"
med:pmid:41070303,med:pmid:41070303:sec:introduction:sent:2,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,This study compares the efficacy and safety of LBBP combined with sacubitril/valsartan and LBBP combined with enalapril in treating elderly coronary heart disease (CHD) patients with chronic heart failure (CHF).,2025-09-01,,introduction,2,1,0.7827238674393727,other,1.0,0.7827238674393727,0.7827238674393727,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7827238674393727, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7827238674393727, 'final_confidence': 0.7827238674393727}"
med:pmid:41070303,med:pmid:41070303:sec:methods:sent:4,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Based on the postoperative treatment regimen, patients were divided into the LBBP & sacubitril/valsartan and the LBBP & enalapril groups.",2025-09-01,,methods,4,1,0.7827238674393727,other,1.0,0.7827238674393727,0.7827238674393727,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.7827238674393727, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7827238674393727, 'final_confidence': 0.7827238674393727}"
med:pmid:41070303,med:pmid:41070303:sec:results:sent:7,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Of them, 53 patients comprised the LBBP & sacubitril/valsartan group and 58 patients comprised the LBBP & enalapril group.",2025-09-01,,results,7,1,0.7827238674393727,other,1.0,0.7827238674393727,0.7827238674393727,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.7827238674393727, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7827238674393727, 'final_confidence': 0.7827238674393727}"
med:pmid:41070303,med:pmid:41070303:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"After treatment, levels of LVEDd, LVEF, NT proBNP, sSt2 and MMP-9 in the LBBP & sacubitril/valsartan group were significantly improved compared to those in the LBBP & enalapril group (all P<0.05).",2025-09-01,,results,8,1,0.7827238674393727,other,1.0,0.7827238674393727,0.7827238674393727,['compared to'],"{""comparative_terms"": [""compared to""], ""claim_strength_terms"": {""confirmatory"": [""p<""]}}","['comparative_terms', 'claim_strength:confirmatory']",[],,,,[],comparative,comparative_efficacy,0.6,POS,1.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.7827238674393727, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7827238674393727, 'final_confidence': 0.7827238674393727}"
med:pmid:41070303,med:pmid:41070303:sec:title:sent:0,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,The efficacy and safety of left bundle branch pacing combined with sacubitril/valsartan or enalapril in the treatment of elderly coronary heart disease with chronic heart failure.,2025-09-01,,results,0,1,0.7827238674393727,other,1.0,0.7827238674393727,0.7827238674393727,"['combination', 'safety']","{""combination"": [""combined with""], ""risk_terms"": [""safety""]}","['relationship:combination', 'risk_terms']",[],add_on,add_on,add_on,['combination_with'],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.7827238674393727, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7827238674393727, 'final_confidence': 0.7827238674393727}"
med:pmid:41284794,med:pmid:41284794:sec:abstract:sent:8,enalapril,ACE inhibitor,sacubitril_valsartan,ARNI,"The last NICE guidelines in 2018 proposed as a second stage one or more of the following interventions delivered by a specialist: angiotensin receptor/neprilysin antagonist (ARNI) instead of ACE inhibitor, ivabradine if in sinus rhythm with a heart rate >70 bpm, a combined hydralazine and nitrate if the patient is of Afro-Caribbean origin, and/or digoxin.",2025-09-01,,abstract,8,1,0.7827238674393727,review,0.9,0.7044514806954355,0.7044514806954355,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.7827238674393727, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.7044514806954355, 'final_confidence': 0.7044514806954355}"
med:pmid:40849246,med:pmid:40849246:sec:introduction:sent:5,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Treatment with sacubitril/valsartan from admission or after hospital discharge was compared, with enalapril being the comparator.",2025-08-22,,introduction,5,1,0.767999928737488,other,1.0,0.767999928737488,0.767999928737488,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.767999928737488, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.767999928737488, 'final_confidence': 0.767999928737488}"
med:pmid:40849246,med:pmid:40849246:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The results of the base cases of the three comparisons made showed that sacubitril/valsartan produced benefits in years of life gained and quality-adjusted life years compared to enalapril showing incremental cost-utility ratio below €20,000/QALY and that this ratio was better in scenarios starting sacubitril/valsartan in the hospital setting once decompensation was resolved.",2025-08-22,,results,8,1,0.767999928737488,other,1.0,0.767999928737488,0.767999928737488,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,POS,2.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.767999928737488, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.767999928737488, 'final_confidence': 0.767999928737488}"
med:pmid:40869719,med:pmid:40869719:sec:abstract:sent:4,enalapril,ACE inhibitors,sacubitril_valsartan,ARNIs,"The review examines the efficacy of pharmacological therapies and their impact on readmission rates, highlighting key interventions such as diuretics, beta-blockers, ACE inhibitors, ARBs, ARNIs, SGLT2 inhibitors, and intravenous iron supplementation.",2025-08-21,,abstract,4,1,0.7665428551971142,review,0.9,0.6898885696774028,0.6898885696774028,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7665428551971142, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.6898885696774028, 'final_confidence': 0.6898885696774028}"
med:pmid:40835081,med:pmid:40835081:sec:abstract:sent:8,enalapril,ACEi,sacubitril_valsartan,ARNi,"The use of guideline-directed medical therapy at discharge was suboptimal in both groups, but even lower in Chagas patients, particularly for beta-blockers (52% vs 64%, p = 0.02) and ACEi/ARB/ARNi (54% vs 68%, p = 0.01).",2025-08-18,,abstract,8,1,0.7621882000406616,other,1.0,0.7621882000406616,0.7621882000406616,"['vs', 'combination']","{""comparative_terms"": [""vs""], ""combination"": [""acei/arb/arni""]}","['comparative_terms', 'relationship:combination']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.7621882000406616, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7621882000406616, 'final_confidence': 0.7621882000406616}"
med:pmid:40873622,med:pmid:40873622:sec:conclusion:sent:11,enalapril,ACEI,sacubitril_valsartan,ARNI,ARNI significantly reduced MEE compared with ACEI/ARB.,2025-08-12,,conclusion,11,1,0.7535529643044551,other,1.0,0.7535529643044551,0.7535529643044551,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,POS,1.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.7535529643044551, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7535529643044551, 'final_confidence': 0.7535529643044551}"
med:pmid:40873622,med:pmid:40873622:sec:methods:sent:4,enalapril,ACEI,sacubitril_valsartan,ARNI,"According to the use of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB)/ARNI, the 210 patients were divided into the ARNI group (107 cases, 51.0%) and the non-ARNI (ACEI/ARB) group (103 cases, 49.0%).",2025-08-12,,methods,4,1,0.7535529643044551,other,1.0,0.7535529643044551,0.7535529643044551,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.7535529643044551, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7535529643044551, 'final_confidence': 0.7535529643044551}"
med:pmid:40873622,med:pmid:40873622:sec:results:sent:6,enalapril,ACEI,sacubitril_valsartan,ARNI,"ARNI significantly reduced MEE after 1 year compared with the ACEI/ARB [(129.61 ± 40.81) kcal/min vs. (154.49 ± 47.58) kcal/min, <i>P</i> < 0.01].",2025-08-12,,results,6,1,0.7535529643044551,other,1.0,0.7535529643044551,0.7535529643044551,"['compared with', 'vs']","{""comparative_terms"": [""compared with"", ""vs""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.39999999999999997,POS,1.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.7535529643044551, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7535529643044551, 'final_confidence': 0.7535529643044551}"
med:pmid:40788620,med:pmid:40788620:sec:results:sent:3,enalapril,ACEI,sacubitril_valsartan,ARNI,CARE-HK in HF was a multinational prospective registry of outpatients with HF (regardless of left ventricular ejection fraction [LVEF]) treated with an angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker/angiotensin receptor-neprilysin inhibitor (ACEI/ARB/ARNI) and either receiving or potential candidate for a mineralocorticoid receptor antagonist (MRA).,2025-08-11,,results,3,1,0.7521232999978928,other,1.0,0.7521232999978928,0.7521232999978928,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7521232999978928, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7521232999978928, 'final_confidence': 0.7521232999978928}"
med:pmid:40788620,med:pmid:40788620:sec:results:sent:5,enalapril,ACEI,sacubitril_valsartan,ARNI,"included frequency of hyperkalaemic events (defined by clinician report with associated potassium value), achievement of renin-angiotensin system inhibitor (RASi) optimization (defined as ≥50% target doses for ACEI/ARB/ARNI and MRA), medication changes following hyperkalaemic episodes, and clinical events.",2025-08-11,,results,5,1,0.7521232999978928,other,1.0,0.7521232999978928,0.7521232999978928,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7521232999978928, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7521232999978928, 'final_confidence': 0.7521232999978928}"
med:pmid:40769236,med:pmid:40769236:sec:conclusion:sent:10,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"Despite robust evidence supporting their efficacy, the use of statins, ACEIs, and ARNIs remains suboptimal in Colombia.",2025-08-05,,conclusion,10,1,0.7436020948705648,other,1.0,0.7436020948705648,0.7436020948705648,[],,[],[],,,,[],evidence,real_world,0.7,POS,1.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.7436020948705648, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7436020948705648, 'final_confidence': 0.7436020948705648}"
med:pmid:40769236,med:pmid:40769236:sec:introduction:sent:2,enalapril,ACE inhibitors,sacubitril_valsartan,ARNIs,"Effective metabolic control and risk factor management, including evidence-based pharmacological therapies such as statins, ACE inhibitors (ACEIs), and angiotensin receptor-neprilysin inhibitors (ARNIs), are essential for reducing adverse outcomes.",2025-08-05,,introduction,2,1,0.7436020948705648,other,1.0,0.7436020948705648,0.7436020948705648,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7436020948705648, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7436020948705648, 'final_confidence': 0.7436020948705648}"
med:pmid:40397431,med:pmid:40397431:sec:results:sent:3,enalapril,ACEIs,sacubitril_valsartan,sacubitril/valsartan,Patients diagnosed with HF and prescribed either sacubitril/valsartan or angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) within 90 days of their first HF diagnosis between October 2017 and December 2020 were included.,2025-08-01,,results,3,1,0.7379749932627773,other,1.0,0.7379749932627773,0.7379749932627773,[],,[],[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.7379749932627773, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7379749932627773, 'final_confidence': 0.7379749932627773}"
med:pmid:40397431,med:pmid:40397431:sec:results:sent:7,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"Among 7085 sacubitril/valsartan users and 359 153 ACEI/ARB users, 6930 sacubitril/valsartan users [mean (SD) age, 61.7 (14.6) years; 70.9% male] were matched on propensity score to 27 720 ACEI/ARB users [mean (SD) age, 61.7 (15.8) years; 71.1% male].",2025-08-01,,results,7,1,0.7379749932627773,other,1.0,0.7379749932627773,0.7379749932627773,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7379749932627773, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7379749932627773, 'final_confidence': 0.7379749932627773}"
med:pmid:40397431,med:pmid:40397431:sec:results:sent:8,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"During a mean follow-up of 2.2 and 2.3 years, dementia occurred in 200 (2.9%) sacubitril/valsartan users and 980 (3.5%) ACEI/ARB users, respectively.",2025-08-01,,results,8,1,0.7379749932627773,other,1.0,0.7379749932627773,0.7379749932627773,[],,[],[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.7379749932627773, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7379749932627773, 'final_confidence': 0.7379749932627773}"
med:pmid:40397431,med:pmid:40397431:sec:results:sent:9,enalapril,ACEI,sacubitril_valsartan,Sacubitril/valsartan,Sacubitril/valsartan showed a 16% lower risk of dementia compared with ACEI/ARB (HR 0.84; 95% CI 0.72-0.98).,2025-08-01,,results,9,1,0.7379749932627773,other,1.0,0.7379749932627773,0.7379749932627773,"['compared with', 'risk']","{""comparative_terms"": [""compared with""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.7379749932627773, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7379749932627773, 'final_confidence': 0.7379749932627773}"
ppr:doi:10.21203/rs.3.rs-7118793/v1,ppr:doi:10.21203/rs.3.rs-7118793/v1:sec:results:sent:10,enalapril,ACEI,sacubitril_valsartan,ARNI,"Target dose attainment varied by drug class: 46% for beta-blockers, 41% for ACEI/ARB/ARNI, 96% for MRAs, and 100% for ivabradine.",2025-08-01,,results,10,1,0.7379749932627773,other,1.0,0.7379749932627773,0.7379749932627773,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7379749932627773, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7379749932627773, 'final_confidence': 0.7379749932627773}"
med:pmid:41126807,med:pmid:41126807:sec:conclusion:sent:15,enalapril,ACEI,sacubitril_valsartan,ARNI,"Among patients with HFrEF seen at the outpatient, there is good physician adherence to betablockers, ACEI/ARNI/ARBs, and diuretics.",2025-07-31,,conclusion,15,1,0.7365748839712198,other,1.0,0.7365748839712198,0.7365748839712198,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.7365748839712198, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7365748839712198, 'final_confidence': 0.7365748839712198}"
med:pmid:41126807,med:pmid:41126807:sec:results:sent:11,enalapril,ACEI,sacubitril_valsartan,ARNI,"Over three months of follow-up, improvement in the quality of care was demonstrated with ACEI/ARNI/ARBs (81.8% to 90.9%), MRA (68.7 to 81.2%), and SGLT2i (58% to 67.7%).",2025-07-31,,results,11,1,0.7365748839712198,other,1.0,0.7365748839712198,0.7365748839712198,[],,[],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.7365748839712198, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7365748839712198, 'final_confidence': 0.7365748839712198}"
med:pmid:41126807,med:pmid:41126807:sec:results:sent:13,enalapril,ACEI,sacubitril_valsartan,ARNI,"In the 3<sup>rd</sup> month post-discharge, titration to optimal doses was achieved in only 26.4%, 15%, and 6.25% for those on beta-blockers, ACEI/ARNI/ARB, and MRA, respectively.",2025-07-31,,results,13,1,0.7365748839712198,other,1.0,0.7365748839712198,0.7365748839712198,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7365748839712198, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7365748839712198, 'final_confidence': 0.7365748839712198}"
med:pmid:41126807,med:pmid:41126807:sec:results:sent:9,enalapril,ACEI,sacubitril_valsartan,ARNI,"Overall, adherence to prescription of beta-blockers (94.8%), ACEI/ARNI/ARBs (88.5%), and diuretics (100%) were high.",2025-07-31,,results,9,1,0.7365748839712198,other,1.0,0.7365748839712198,0.7365748839712198,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.7365748839712198, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7365748839712198, 'final_confidence': 0.7365748839712198}"
med:pmid:40791946,med:pmid:40791946:sec:results:sent:14,enalapril,ACE inhibitors,sacubitril_valsartan,ARNI,"RAAS inhibitors including ACE inhibitors (18.1%), ARBs (25.2%), and ARNI (10.8%), were also frequently used.",2025-07-28,,results,14,1,0.7323904739348444,other,1.0,0.7323904739348444,0.7323904739348444,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7323904739348444, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7323904739348444, 'final_confidence': 0.7323904739348444}"
med:pmid:40727001,med:pmid:40727001:sec:results:sent:9,enalapril,ACEI,sacubitril_valsartan,ARNI,"LASSO regression showed that the key predictors included age, BNP, New York Heart Association (NYHA) class, LVEF, PLR, MLR, AF history, and ACEI/ARB/ARNI usage.",2025-07-24,,results,9,1,0.7268482146515048,other,1.0,0.7268482146515048,0.7268482146515048,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7268482146515048, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7268482146515048, 'final_confidence': 0.7268482146515048}"
med:pmid:40689605,med:pmid:40689605:sec:conclusion:sent:9,enalapril,ACEIs,sacubitril_valsartan,ARNI,"initiation of ARNI after ADHF stabilization is more effective than ACEIs/ARBs for cardiovascular and renal outcomes, albeit with higher symptomatic hypotension risk.",2025-07-21,,conclusion,9,1,0.722719060874347,review,0.9,0.6504471547869123,0.6504471547869123,['risk'],"{""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""albeit with"", ""higher symptomatic""]}}","['risk_terms', 'risk_posture:acknowledgment']",[],alternative,disfavored,favored,['preferred_over'],comparative,comparative_efficacy,0.8,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.722719060874347, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.6504471547869123, 'final_confidence': 0.6504471547869123}"
med:pmid:40689605,med:pmid:40689605:sec:introduction:sent:3,enalapril,ACEIs,sacubitril_valsartan,ARNI,This meta-analysis evaluates ARNI versus angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) post-ADHF.,2025-07-21,,introduction,3,1,0.722719060874347,review,0.9,0.6504471547869123,0.6504471547869123,"['versus', 'meta-analysis']","{""comparative_terms"": [""versus""], ""study_context"": [""meta-analysis""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.722719060874347, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.6504471547869123, 'final_confidence': 0.6504471547869123}"
med:pmid:40679772,med:pmid:40679772:sec:results:sent:11,enalapril,ACEI,sacubitril_valsartan,ARNI,"Among all patients in our study, 61.6% received either an angiotensin-converting enzyme inhibitor, angiotensin-II receptor blocker, or angiotensin receptor-neprilysin inhibitor (ACEI/ARB/ARNI); 57.0% were prescribed β-blockers; and 32.6% used a sodium-glucose cotransporter 2 inhibitor.",2025-07-18,,results,11,1,0.7186133644168492,other,1.0,0.7186133644168492,0.7186133644168492,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7186133644168492, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7186133644168492, 'final_confidence': 0.7186133644168492}"
med:pmid:40660106,med:pmid:40660106:sec:results:sent:8,enalapril,ACE inhibitors,sacubitril_valsartan,ARNI,"Notably, 82% of patients were initiated on three or four drug classes concurrently at the start of treatment, most commonly including RAS inhibitors, MRAs, and beta-blockers, with a preference for ARNI over ACE inhibitors or ARBs.",2025-07-14,,results,8,1,0.7131753614227996,other,1.0,0.7131753614227996,0.7131753614227996,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.7131753614227996, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7131753614227996, 'final_confidence': 0.7131753614227996}"
med:pmid:40755965,med:pmid:40755965:sec:title:sent:0,enalapril,ACEi,sacubitril_valsartan,angiotensin receptor neprilysin inhibitors,Comparative renal effects of angiotensin receptor neprilysin inhibitors and ACEi/ARB: a systematic review and meta-analysis.,2025-07-11,,title,0,1,0.7091238817905536,other,1.0,0.7091238817905536,0.7091238817905536,"['meta-analysis', 'review', 'systematic review']","{""study_context"": [""meta-analysis"", ""review"", ""systematic review""]}",['study_context'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.7091238817905536, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7091238817905536, 'final_confidence': 0.7091238817905536}"
ppr:doi:10.21203/rs.3.rs-6768681/v1,ppr:doi:10.21203/rs.3.rs-6768681/v1:sec:results:sent:10,enalapril,ACEI,sacubitril_valsartan,ARNI,"While therapy with beta blockers and ACEI/ARB/ARNI was common within the cohort, only a third of the cohort was treated with SGLT2 inhibitors or mineralocorticoid receptor antagonists.",2025-06-25,,results,10,1,0.6879015314631135,other,1.0,0.6879015314631135,0.6879015314631135,"['combination', 'cohort']","{""combination"": [""acei/arb/arni""], ""study_context"": [""cohort""]}","['relationship:combination', 'study_context']",[],,,,[],evidence,clinical_context,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 0.6879015314631135, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6879015314631135, 'final_confidence': 0.6879015314631135}"
med:pmid:40542996,med:pmid:40542996:sec:results:sent:13,enalapril,angiotensin converting enzyme inhibitor,sacubitril_valsartan,ARNi,"The highest incidence of HK was observed with the combination of angiotensin converting enzyme inhibitor (ACEi)/angiotensin ii receptor blockers (ARBs)/angiotensin receptor-neprilysin inhibitor (ARNi)+ mineralocorticoid receptor antagonists (MRAs) (24.4%), followed by the triple therapy ACEi/ARB/ARNi+ sodium glucose cotransporter-2 inhibitor (SGLT2i)+MRA (10.9%), and ACEi/ARB/ARNi + SGLT2i (2.2%).",2025-06-21,,results,13,1,0.6826959358355629,review,0.9,0.6144263422520067,0.6144263422520067,['combination'],"{""combination"": [""acei/arb/arni"", ""triple therapy""]}",['relationship:combination'],[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.6826959358355629, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.6144263422520067, 'final_confidence': 0.6144263422520067}"
med:pmid:40540017,med:pmid:40540017:sec:abstract:sent:4,enalapril,ACEi,sacubitril_valsartan,ARNI,CDMT was defined as concurrent use of angiotensin-converting-enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB) /angiotensin receptor-neprilysin inhibitor (ARNI) plus beta-blocker (BB) plus mineralocorticoid receptor antagonist (MRA).,2025-06-20,,abstract,4,1,0.6814007037046668,other,1.0,0.6814007037046668,0.6814007037046668,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6814007037046668, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6814007037046668, 'final_confidence': 0.6814007037046668}"
med:pmid:40540017,med:pmid:40540017:sec:abstract:sent:8,enalapril,ACEi,sacubitril_valsartan,ARNI,"Target doses of CDMT were achieved for 27% of males on ACEi/ARB/ARNI, 28% on BB, and 23% on MRA.",2025-06-20,,abstract,8,1,0.6814007037046668,other,1.0,0.6814007037046668,0.6814007037046668,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.6814007037046668, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6814007037046668, 'final_confidence': 0.6814007037046668}"
med:pmid:40543460,med:pmid:40543460:sec:methods:sent:5,enalapril,ACEI,sacubitril_valsartan,ARNI,"Quality metrics included antiplatelet and statin or proprotein convertase subtilisin/kexin type 9 inhibitor therapy for atherosclerotic cardiovascular disease prevention, blood pressure control, and GDMT for heart failure with reduced ejection fraction (HFrEF; specified beta blockers; ACEI, ARB, or ARNI; mineralocorticoid receptor antagonist).",2025-06-20,,methods,5,1,0.6814007037046668,other,1.0,0.6814007037046668,0.6814007037046668,[],,[],['cardiovascular disease'],,,,[],,,,,,,,"{'recency_weight': 0.6814007037046668, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6814007037046668, 'final_confidence': 0.6814007037046668}"
med:pmid:40575771,med:pmid:40575771:sec:results:sent:11,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"Currently, GDMT recommendations mainly include five types of drugs: diuretics, angiotensin receptor-neprilysin inhibitors (ARNIs), renin-angiotensin system inhibitors (ACEIs/ARBs), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 inhibitors (SGLT-2i).",2025-06-12,,results,11,1,0.6711269209276027,other,1.0,0.6711269209276027,0.6711269209276027,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6711269209276027, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6711269209276027, 'final_confidence': 0.6711269209276027}"
med:pmid:40470816,med:pmid:40470816:sec:results:sent:5,enalapril,ACEi,sacubitril_valsartan,ARNi,"At baseline, beta-blockers, angiotensin-converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB) or angiotensin receptor-neprilysin inhibitor (ARNi), mineralocorticoid receptor antagonist (MRA) and loop diuretic use was 84% versus 86%, 89% versus 88%, 57% versus 46% and 62% versus 59% in patients receiving versus not receiving CRT, respectively.",2025-06-05,,results,5,1,0.6622645095510069,other,1.0,0.6622645095510069,0.6622645095510069,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6622645095510069, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6622645095510069, 'final_confidence': 0.6622645095510069}"
med:pmid:40470816,med:pmid:40470816:sec:results:sent:8,enalapril,ACEi,sacubitril_valsartan,ARNi,"A significant association between CRT and the likelihood of ACEi/ARB/ARNi and MRA optimization (OR 1.22, 95% CI 1.04-1.44, and OR 1.25, 95% CI 1.05-1.50, respectively) was observed in the per-protocol analysis.",2025-06-05,,results,8,1,0.6622645095510069,other,1.0,0.6622645095510069,0.6622645095510069,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.6622645095510069, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6622645095510069, 'final_confidence': 0.6622645095510069}"
med:pmid:40448468,med:pmid:40448468:sec:introduction:sent:3,enalapril,ACEi,sacubitril_valsartan,ARNi,The purpose of this study was to compare the efficacy and safety of triple GDMT with a sodium-glucose cotransporter inhibitor (SGLTi) vs mineralocorticoid receptor antagonist (MRA) added to beta blocker and angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB)/angiotensin receptor-neprilysin inhibitor (ARNi).,2025-05-31,,introduction,3,1,0.6560059575487075,other,1.0,0.6560059575487075,0.6560059575487075,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6560059575487075, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6560059575487075, 'final_confidence': 0.6560059575487075}"
med:pmid:40448468,med:pmid:40448468:sec:methods:sent:5,enalapril,ACEi,sacubitril_valsartan,ARNi,Patients who received triple GDMT therapy with a SGLTi or MRA added to beta blocker and ACEi/ARB/ARNi therapy at discharge were compared.,2025-05-31,,methods,5,1,0.6560059575487075,other,1.0,0.6560059575487075,0.6560059575487075,"['add-on therapy', 'combination']","{""combination"": [""acei/arb/arni"", ""gdmt""], ""add-on therapy"": [""added to""]}","['relationship:add-on therapy', 'relationship:combination']",[],add_on,backbone,add_on,['add_on_to'],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.6560059575487075, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6560059575487075, 'final_confidence': 0.6560059575487075}"
med:pmid:40450497,med:pmid:40450497:sec:introduction:sent:1,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,We systematically evaluated sacubitril/valsartan (S/V) effects on the renal outcomes of patients with acute or chronic heart failure (HF) receiving angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB).,2025-05-30,,introduction,1,1,0.6547613624813055,review,0.9,0.5892852262331749,0.5892852262331749,[],,[],[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.6547613624813055, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.5892852262331749, 'final_confidence': 0.5892852262331749}"
med:pmid:40418165,med:pmid:40418165:sec:introduction:sent:2,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"Although the use of angiotensin-converting enzyme inhibitors (ACEIs) remains the cornerstone treatment for patients with STEMI, the use of angiotensin-receptor neprilysin inhibitors (ARNIs) may offer better outcomes than ACEIs.",2025-05-26,,introduction,2,1,0.6498065503029224,review,0.9,0.5848258952726302,0.5848258952726302,[],,[],[],,,,[],,,,NEU,0.5,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.6498065503029224, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.5848258952726302, 'final_confidence': 0.5848258952726302}"
med:pmid:40418165,med:pmid:40418165:sec:introduction:sent:3,enalapril,ACEIs,sacubitril_valsartan,ARNIs,This meta-analysis compares the efficacy and safety of ARNIs versus ACEIs in patients with STEMI.,2025-05-26,,introduction,3,1,0.6498065503029224,review,0.9,0.5848258952726302,0.5848258952726302,"['versus', 'safety', 'meta-analysis']","{""comparative_terms"": [""versus""], ""risk_terms"": [""safety""], ""study_context"": [""meta-analysis""]}","['comparative_terms', 'risk_terms', 'study_context']",[],,,,[],,,,POS,2.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.6498065503029224, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.5848258952726302, 'final_confidence': 0.5848258952726302}"
med:pmid:40389107,med:pmid:40389107:sec:introduction:sent:1,enalapril,ACEIs,sacubitril_valsartan,sacubitril/valsartan,This study investigated the effect of uptitration of sacubitril/valsartan (Sac/Val) compared with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEIs/ARBs) on N-terminal pro-B-type natriuretic peptide (NT-proBNP) level within current guideline-directed medical therapy in acute heart failure (AHF).,2025-05-17,,introduction,1,1,0.6387948813107176,other,1.0,0.6387948813107176,0.6387948813107176,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6387948813107176, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6387948813107176, 'final_confidence': 0.6387948813107176}"
med:pmid:40353367,med:pmid:40353367:sec:discussion:sent:10,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Reductions were comparable between sacubitril/valsartan and enalapril, with a numerically greater reduction observed in adult patients versus children.",2025-05-12,,discussion,10,1,0.6327581226956497,randomized controlled trial,1.6,1.0124129963130395,1.0124129963130395,['versus'],"{""comparative_terms"": [""versus""], ""claim_strength_terms"": {""suggestive"": [""greater reduction""]}}","['comparative_terms', 'claim_strength:suggestive']",[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.6327581226956497, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.0124129963130395, 'final_confidence': 1.0124129963130395}"
med:pmid:40353367,med:pmid:40353367:sec:discussion:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"of 361 paediatric patients (sacubitril/valsartan, n = 179; enalapril, n = 182) demonstrated overall higher baseline NT-proBNP levels in younger AGs.",2025-05-12,,discussion,8,1,0.6327581226956497,randomized controlled trial,1.6,1.0124129963130395,1.0124129963130395,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6327581226956497, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.0124129963130395, 'final_confidence': 1.0124129963130395}"
med:pmid:40353367,med:pmid:40353367:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,The PANORAMA-HF trial demonstrated significant N-terminal pro-B-type natriuretic peptide (NT-proBNP) reductions in paediatric patients with left ventricular systolic dysfunction with sacubitril/valsartan or enalapril treatment over 52 weeks.,2025-05-12,,introduction,1,1,0.6327581226956497,randomized controlled trial,1.6,1.0124129963130395,1.0124129963130395,['trial'],"{""study_context"": [""trial""]}",['study_context'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.6327581226956497, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.0124129963130395, 'final_confidence': 1.0124129963130395}"
med:pmid:40353367,med:pmid:40353367:sec:introduction:sent:2,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,This post hoc analysis aims to correlate changes in NT-proBNP levels with clinical outcomes in PANORAMA-HF patients receiving either sacubitril/valsartan or enalapril.,2025-05-12,,introduction,2,1,0.6327581226956497,randomized controlled trial,1.6,1.0124129963130395,1.0124129963130395,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6327581226956497, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.0124129963130395, 'final_confidence': 1.0124129963130395}"
med:pmid:40353367,med:pmid:40353367:sec:results:sent:5,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Associations between baseline NT-proBNP levels, changes post-baseline and the risk of HF clinical events in paediatric patients on sacubitril/valsartan or enalapril were assessed.",2025-05-12,,results,5,1,0.6327581226956497,randomized controlled trial,1.6,1.0124129963130395,1.0124129963130395,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6327581226956497, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.0124129963130395, 'final_confidence': 1.0124129963130395}"
med:pmid:40319618,med:pmid:40319618:sec:conclusion:sent:13,enalapril,ACEI,sacubitril_valsartan,ARNI,"At the cost-effectiveness threshold of RM55 426 per QALY, ARNI is cost-effective compared with ACEI for the heart failure with reduced ejection fraction population.",2025-05-03,,conclusion,13,1,0.6220353575957823,other,1.0,0.6220353575957823,0.6220353575957823,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.6220353575957823, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6220353575957823, 'final_confidence': 0.6220353575957823}"
med:pmid:40319618,med:pmid:40319618:sec:introduction:sent:1,enalapril,ACEI,sacubitril_valsartan,angiotensin receptor neprilysin inhibitor,This study compared the costs and effectiveness of angiotensin receptor neprilysin inhibitor (ARNI) with angiotensin-converting enzyme inhibitor (ACEI) for the heart failure with reduced ejection fraction population from the Malaysian Ministry of Health's perspective.,2025-05-03,,introduction,1,1,0.6220353575957823,other,1.0,0.6220353575957823,0.6220353575957823,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6220353575957823, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6220353575957823, 'final_confidence': 0.6220353575957823}"
med:pmid:40319618,med:pmid:40319618:sec:methods:sent:2,enalapril,ACEI,sacubitril_valsartan,ARNI,"A 3-state Markov model, with a monthly cycle, was constructed to estimate the lifetime healthcare costs, quality-adjusted life year (QALY), and incremental cost-effectiveness ratio (ICER) of ARNI and ACEI.",2025-05-03,,methods,2,1,0.6220353575957823,other,1.0,0.6220353575957823,0.6220353575957823,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.6220353575957823, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6220353575957823, 'final_confidence': 0.6220353575957823}"
med:pmid:40319618,med:pmid:40319618:sec:results:sent:8,enalapril,ACEI,sacubitril_valsartan,ARNI,"Despite ARNI being more expensive compared with ACEI, it gained more QALYs, resulting in an ICER of RM46 498 per QALY.",2025-05-03,,results,8,1,0.6220353575957823,other,1.0,0.6220353575957823,0.6220353575957823,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.6220353575957823, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6220353575957823, 'final_confidence': 0.6220353575957823}"
med:pmid:40332281,med:pmid:40332281:sec:conclusion:sent:12,enalapril,ACEi,sacubitril_valsartan,ARNi,"We found high frequencies of prescription of GDMT for HFrEF, considering the therapeutic goals recommended by cardiology guidelines, but, prescription of target doses were low in ACEi, ARB or ARNi and beta-blockers.",2025-05-02,,conclusion,12,1,0.620855212615535,observational study,1.2,0.745026255138642,0.745026255138642,['combination'],"{""combination"": [""gdmt""]}",['relationship:combination'],[],,,,[],evidence,real_world,0.7,POS,1.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.620855212615535, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.745026255138642, 'final_confidence': 0.745026255138642}"
med:pmid:40332281,med:pmid:40332281:sec:results:sent:10,enalapril,enalapril,sacubitril_valsartan,ARNi,"Only 21,2% were prescribed GDMT target doses of enalapril, losartan or ARNi and 52,3% of beta-blockers.",2025-05-02,,results,10,1,0.620855212615535,observational study,1.2,0.745026255138642,0.745026255138642,['combination'],"{""combination"": [""gdmt""]}",['relationship:combination'],[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.620855212615535, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.745026255138642, 'final_confidence': 0.745026255138642}"
med:pmid:40332281,med:pmid:40332281:sec:results:sent:8,enalapril,ACEi,sacubitril_valsartan,ARNi,"93.1% were prescribed ACEi, ARB or ARNi, 95.8% betablockers, 69.2% spironolactone and 8% the combination hydralazine/isosorbide-dinitrate.",2025-05-02,,results,8,1,0.620855212615535,observational study,1.2,0.745026255138642,0.745026255138642,[],,[],[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.620855212615535, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.745026255138642, 'final_confidence': 0.745026255138642}"
med:pmid:40332281,med:pmid:40332281:sec:results:sent:9,enalapril,enalapril,sacubitril_valsartan,ARNi,"71,7% were using enalapril, losartan or ARNi above 50% of GDMT target doses; 81,2% were using beta-blockers and 100% were using spironolactone.",2025-05-02,,results,9,1,0.620855212615535,observational study,1.2,0.745026255138642,0.745026255138642,['combination'],"{""combination"": [""gdmt""]}",['relationship:combination'],[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.620855212615535, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.745026255138642, 'final_confidence': 0.745026255138642}"
med:pmid:40302030,med:pmid:40302030:sec:introduction:sent:1,enalapril,ACEI,sacubitril_valsartan,ARNI,The 2021 European heart failure (HF) guidelines recommend the combination of four drugs as a standard therapy (angiotensin-converting enzyme inhibitor [ACEI]/angiotensin receptor blocker [ARB]/angiotensin receptor-neprilysin inhibitor [ARNI]; beta-blocker (BB); mineralocorticoid receptor antagonist [MRA]; sodium-glucose co-transporter 2 inhibitor [SGLT2i]) in patients with heart failure and reduced ejection fraction (HFrEF).,2025-04-29,,introduction,1,1,0.6173281947395006,other,1.0,0.6173281947395006,0.6173281947395006,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6173281947395006, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6173281947395006, 'final_confidence': 0.6173281947395006}"
med:pmid:40302030,med:pmid:40302030:sec:results:sent:6,enalapril,ACEI,sacubitril_valsartan,ARNI,"HF drug prescription rates were as follows: ACEI 46.3%, ARB 31.8%, ARNI 12.1%, BB 80.9%, MRA 35.6%, SGLT2i 7.3%.",2025-04-29,,results,6,1,0.6173281947395006,other,1.0,0.6173281947395006,0.6173281947395006,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6173281947395006, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6173281947395006, 'final_confidence': 0.6173281947395006}"
med:pmid:40295134,med:pmid:40295134:sec:introduction:sent:4,enalapril,ACE inhibitor,sacubitril_valsartan,ARNI,"In the ARNI group, if a patient was on an ACE inhibitor or angiotensin II receptor blocker before TAVI, it will be switched to ARNI 100 mg/day (50 mg two times per day) on the first postoperative day.",2025-04-28,,introduction,4,1,0.6161569803361864,other,1.0,0.6161569803361864,0.6161569803361864,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6161569803361864, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6161569803361864, 'final_confidence': 0.6161569803361864}"
med:pmid:40268473,med:pmid:40268473:sec:results:sent:2,enalapril,ACEi,sacubitril_valsartan,ARNI,Sixty-four HF outpatients with LVEF <50% were randomized to ARNI (switching from an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker [ACEi/ARB] to ARNI) or control (continuing with ACEi/ARB).,2025-04-24,,results,2,1,0.6114943012520145,randomized controlled trial,1.6,0.9783908820032233,0.9783908820032233,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6114943012520145, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.9783908820032233, 'final_confidence': 0.9783908820032233}"
med:pmid:40265590,med:pmid:40265590:sec:conclusion:sent:12,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In PARADIGM-HF, sacubitril/valsartan, compared with enalapril, reduced the risk of HF hospitalizations, death from cardiovascular causes, and death from any cause similarly in women and men with HF with reduced ejection fraction.",2025-04-23,,conclusion,12,1,0.610334155094308,randomized controlled trial,1.6,0.9765346481508929,0.9765346481508929,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.610334155094308, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.9765346481508929, 'final_confidence': 0.9765346481508929}"
med:pmid:40265590,med:pmid:40265590:sec:introduction:sent:2,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,Sex-specific efficacy and safety of sacubitril/valsartan in PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) remain unreported.,2025-04-23,,introduction,2,1,0.610334155094308,randomized controlled trial,1.6,0.9765346481508929,0.9765346481508929,['safety'],"{""risk_terms"": [""safety""]}",['risk_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.610334155094308, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.9765346481508929, 'final_confidence': 0.9765346481508929}"
med:pmid:40265590,med:pmid:40265590:sec:results:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,This post hoc analysis of PARADIGM-HF examined sex-based outcomes in patients with HF and reduced ejection fraction randomized to sacubitril/valsartan or enalapril.,2025-04-23,,results,3,1,0.610334155094308,randomized controlled trial,1.6,0.9765346481508929,0.9765346481508929,['randomized'],"{""study_context"": [""randomized""], ""claim_strength_terms"": {""suggestive"": [""post hoc""]}}","['study_context', 'claim_strength:suggestive']",[],,,,[],evidence,clinical_trial,0.7,POS,1.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.610334155094308, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.9765346481508929, 'final_confidence': 0.9765346481508929}"
med:pmid:40265590,med:pmid:40265590:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Compared with enalapril, sacubitril/valsartan reduced the risk of the primary end point to a similar extent in both sexes: hazard ratios, 0.76 (95% CI, 0.62-0.94) in women and 0.80 (95% CI, 0.73-0.89) in men (<i>P</i>-interaction=0.62).",2025-04-23,,results,8,1,0.610334155094308,randomized controlled trial,1.6,0.9765346481508929,0.9765346481508929,"['compared with', 'risk']","{""comparative_terms"": [""compared with""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.610334155094308, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.9765346481508929, 'final_confidence': 0.9765346481508929}"
med:pmid:40266448,med:pmid:40266448:sec:conclusion:sent:15,enalapril,ACEi,sacubitril_valsartan,ARNi,"In HF patients with AKD, ARNi was associated with reduced all-cause mortality, MAKE, and readmission risks compared to ACEi, particularly with concurrent mineralocorticoids, diuretics, or beta-blockers.",2025-04-23,,conclusion,15,1,0.610334155094308,other,1.0,0.610334155094308,0.610334155094308,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,POS,1.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.610334155094308, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.610334155094308, 'final_confidence': 0.610334155094308}"
med:pmid:40266448,med:pmid:40266448:sec:introduction:sent:3,enalapril,ACEi,sacubitril_valsartan,ARNi,This study investigated the outcomes of ARNi compared to angiotensin-converting enzyme inhibitors (ACEi) in HF patients with AKD.,2025-04-23,,introduction,3,1,0.610334155094308,other,1.0,0.610334155094308,0.610334155094308,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.610334155094308, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.610334155094308, 'final_confidence': 0.610334155094308}"
med:pmid:40266448,med:pmid:40266448:sec:methods:sent:5,enalapril,ACEi,sacubitril_valsartan,ARNi,Propensity score matching (1:1) was applied to balance ARNi and ACEi groups.,2025-04-23,,methods,5,1,0.610334155094308,other,1.0,0.610334155094308,0.610334155094308,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.610334155094308, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.610334155094308, 'final_confidence': 0.610334155094308}"
med:pmid:40385266,med:pmid:40385266:sec:introduction:sent:1,enalapril,ACEi,sacubitril_valsartan,ARNis,"The combination therapy of angiotensin-converting enzyme inhibitors (ACEi) or alternatively angiotensin receptor-neprilysin inhibitors (ARNis), beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs), and recently sodium-glucose co-transporter 2 inhibitors (SGLT2is) has been hailed as a breakthrough in heart failure treatment for patients with structurally normal hearts, with international guidelines recommending these as first-line therapies (""fantastic four"").",2025-04-23,,introduction,1,1,0.610334155094308,other,1.0,0.610334155094308,0.610334155094308,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.610334155094308, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.610334155094308, 'final_confidence': 0.610334155094308}"
med:pmid:41080832,med:pmid:41080832:sec:abstract:sent:6,enalapril,ACEi,sacubitril_valsartan,ARNI,"Six secondary endpoints, including dose conversion from ACEi or ARB to ARNI therapy, were assessed.",2025-04-23,,abstract,6,1,0.610334155094308,other,1.0,0.610334155094308,0.610334155094308,[],"{""claim_strength_terms"": {""suggestive"": [""secondary endpoints""]}}",['claim_strength:suggestive'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.610334155094308, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.610334155094308, 'final_confidence': 0.610334155094308}"
med:pmid:40261428,med:pmid:40261428:sec:results:sent:8,enalapril,ACEi,sacubitril_valsartan,ARNI,"Prior to the index admission, chronic HF cases were receiving diuretics, beta blockers, ACEi/ARBs, ARNI, MRAs, and SGLT2i at 79.8%, 74.4%, 43.3%, 10.8%, 40.7%, and 14%, respectively.",2025-04-22,,results,8,1,0.6091762100022605,other,1.0,0.6091762100022605,0.6091762100022605,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6091762100022605, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6091762100022605, 'final_confidence': 0.6091762100022605}"
med:pmid:40232857,med:pmid:40232857:sec:results:sent:4,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"Early quadruple therapy was defined as the prescription of beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs)/angiotensin receptor-neprilysin inhibitors (ARNIs), mineralocorticoid receptor antagonists (MRAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) within 48 h of admission.",2025-04-15,,results,4,1,0.6011318744145693,observational study,1.2,0.7213582492974832,0.7213582492974832,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6011318744145693, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.7213582492974832, 'final_confidence': 0.7213582492974832}"
med:pmid:40255655,med:pmid:40255655:sec:results:sent:12,enalapril,ACEI,sacubitril_valsartan,ARNI,"Key predictors of one-year mortality risk included Beta blockers, ACEI/ARB/ARNI, BNP, CRP, NLR, AF, MI, NYHA class, and age.",2025-04-14,,results,12,1,0.5999913881779043,other,1.0,0.5999913881779043,0.5999913881779043,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5999913881779043, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5999913881779043, 'final_confidence': 0.5999913881779043}"
med:pmid:40255655,med:pmid:40255655:sec:results:sent:13,enalapril,ACEI,sacubitril_valsartan,ARNI,"SHAP analysis revealed that elevated CRP, NLR, and age were associated with increased risk, while Beta blockers, ACEI/ARB/ARNI, and lower BNP values were associated with reduced risk.",2025-04-14,,results,13,1,0.5999913881779043,other,1.0,0.5999913881779043,0.5999913881779043,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5999913881779043, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5999913881779043, 'final_confidence': 0.5999913881779043}"
med:pmid:40283370,med:pmid:40283370:sec:introduction:sent:2,enalapril,ACEIs,sacubitril_valsartan,angiotensin receptor neprilysin inhibitor,The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan (S/V) has been shown to reduce heart failure (HF) hospitalizations and mortality when compared to conventionally administered HF medications (i.e. angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs)).,2025-04-08,,introduction,2,1,0.593193766440473,other,1.0,0.593193766440473,0.593193766440473,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.593193766440473, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.593193766440473, 'final_confidence': 0.593193766440473}"
med:pmid:40188960,med:pmid:40188960:sec:conclusion:sent:9,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"ACEI/ARB, sacubitril/valsartan, and trimetazidine might improve CMD in patients with DbCM.",2025-04-04,,conclusion,9,1,0.5887048581656142,other,1.0,0.5887048581656142,0.5887048581656142,[],"{""claim_strength_terms"": {""exploratory"": [""might improve""]}}",['claim_strength:exploratory'],[],,,,[],,,,NEU,0.5,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.5887048581656142, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5887048581656142, 'final_confidence': 0.5887048581656142}"
med:pmid:40188960,med:pmid:40188960:sec:results:sent:7,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"Patients with elevated NT-pro-BNP had high AMR, and those grouped by medication indicated that ACEI/ARB, sacubitril/valsartan, and trimetazidine might lower AMR in patients with elevated NT-pro-BNP.",2025-04-04,,results,7,1,0.5887048581656142,other,1.0,0.5887048581656142,0.5887048581656142,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.5887048581656142, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5887048581656142, 'final_confidence': 0.5887048581656142}"
med:pmid:40718065,med:pmid:40718065:sec:conclusion:sent:13,enalapril,ACEI,sacubitril_valsartan,ARNI,A high rate of ACEI/ARB/ARNI and BB use was observed.,2025-04-01,,conclusion,13,1,0.5853604833157824,other,1.0,0.5853604833157824,0.5853604833157824,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.5853604833157824, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5853604833157824, 'final_confidence': 0.5853604833157824}"
med:pmid:40718065,med:pmid:40718065:sec:results:sent:8,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"Among them, 82.7% (n=588) received angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), or angiotensin receptor-neprilysin inhibitors (ARNIs); 82.3% (n=585) received beta-blockers (BBs); and 51.3% (n=365) were treated with mineralocorticoid receptor antagonists (MRAs).",2025-04-01,,results,8,1,0.5853604833157824,other,1.0,0.5853604833157824,0.5853604833157824,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5853604833157824, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5853604833157824, 'final_confidence': 0.5853604833157824}"
med:pmid:40718065,med:pmid:40718065:sec:results:sent:9,enalapril,ACEI,sacubitril_valsartan,ARNI,"Among patients with HFrEF, those receiving triple therapy (ACEI/ARB/ARNI + BB + MRA) had lower all-cause mortality compared to other groups (38.8%, log-rank p=0.014).",2025-04-01,,results,9,1,0.5853604833157824,other,1.0,0.5853604833157824,0.5853604833157824,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5853604833157824, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5853604833157824, 'final_confidence': 0.5853604833157824}"
med:pmid:40105368,med:pmid:40105368:sec:methods:sent:5,enalapril,ACEi,sacubitril_valsartan,ARNI,"OMT was defined as receiving an angiotensin-converting-enzyme-inhibitor (ACEi), angiotensin-receptor blocker (ARB) or angiotensin-II-receptor blocker and nephrylisin-inhibitor (ARNI) AND a betablocker (BB) both in doses ≥ 50% of target doses.",2025-03-31,,methods,5,1,0.584249919056718,other,1.0,0.584249919056718,0.584249919056718,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.584249919056718, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.584249919056718, 'final_confidence': 0.584249919056718}"
med:pmid:40101251,med:pmid:40101251:sec:results:sent:10,enalapril,ACEI,sacubitril_valsartan,ARNI,"Of these, 95% reached titration to either guideline-recommended target doses or maximum tolerated doses for both angiotensin-converting enzyme inhibitor/angiotensin receptor blockers/angiotensin and angiotensin receptor-neprilysin inhibitor (ACEI/ARB/ARNI) and beta-blockers combined.",2025-03-18,,results,10,1,0.5700028729326381,observational study,1.2,0.6840034475191656,0.6840034475191656,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5700028729326381, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.6840034475191656, 'final_confidence': 0.6840034475191656}"
med:pmid:40101251,med:pmid:40101251:sec:results:sent:11,enalapril,ACEI,sacubitril_valsartan,ARNI,"The mean number of days to achieve titration ranged from 20.2 days for mineralocorticoid receptor antagonist drugs, between 27.5 to 32.3 days for ACEI/ARB/ARNI drugs and 41.0 days for beta-blockers; 70 (79%) patients completed the satisfaction survey at least once, with more than 98% of survey questions receiving a positive response.",2025-03-18,,results,11,1,0.5700028729326381,observational study,1.2,0.6840034475191656,0.6840034475191656,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.5700028729326381, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.6840034475191656, 'final_confidence': 0.6840034475191656}"
med:pmid:40091512,med:pmid:40091512:sec:results:sent:4,enalapril,ACEi,sacubitril_valsartan,ARNI,"The GDMT score (0-8) factored in doses of beta-blocker (BB), angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB), mineralocorticoid receptor antagonist (MRA), sodium-glucose cotransporter 2 inhibitor (SGLT2i), angiotensin receptor-neprilysin inhibitor (ARNI), isosorbide dinitrate/hydralazine (ISDN/HYD).",2025-03-17,,results,4,1,0.5689214456134292,other,1.0,0.5689214456134292,0.5689214456134292,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5689214456134292, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5689214456134292, 'final_confidence': 0.5689214456134292}"
med:pmid:40091512,med:pmid:40091512:sec:results:sent:7,enalapril,ACEi,sacubitril_valsartan,ARNI,"Prescription rates were 50% for BB, 74.1% for ACEi/ARB/ARNI, 14.8% for SGLT2i, 47% for MRA, and 19.6% for ISDN/HYD.",2025-03-17,,results,7,1,0.5689214456134292,other,1.0,0.5689214456134292,0.5689214456134292,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.5689214456134292, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5689214456134292, 'final_confidence': 0.5689214456134292}"
ppr:doi:10.1101/2025.03.12.25323680,ppr:doi:10.1101/2025.03.12.25323680:sec:results:sent:7,enalapril,ACEi,sacubitril_valsartan,ARNi,"The combinations which resulted in the greatest improvement of quality of life were ARNi + BB + MRA + SGLT2i [MD 7.11 (95% CI -0.99-15.22)], which did not have a statistically significant effect, followed by ARNi + BB + SGLT2i [MD 5.33 (95% CI 0.40-10.25)], ACEi + BB + MRA+ SGLT2i [MD 5.32 (95% CI -2.63-13.26)], ACEi + BB + MRA + ivabradine [MD 5.24 (95% CI -3.07-13.55)].",2025-03-14,,results,7,1,0.5656894583997203,other,1.0,0.5656894583997203,0.5656894583997203,[],"{""claim_strength_terms"": {""confirmatory"": [""statistically significant""]}}",['claim_strength:confirmatory'],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 0.5656894583997203, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5656894583997203, 'final_confidence': 0.5656894583997203}"
med:pmid:40063170,med:pmid:40063170:sec:results:sent:15,enalapril,ACE inhibitors,sacubitril_valsartan,ARNI,"The prescription rates for key medications were as follows: β-blockers 76.4%, ACE inhibitors/ARBs 71.6%, MRA 63.3%, SGLT2I 33.5%, and ARNI 0%.",2025-03-10,,results,15,1,0.5614086850091832,other,1.0,0.5614086850091832,0.5614086850091832,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5614086850091832, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5614086850091832, 'final_confidence': 0.5614086850091832}"
med:pmid:40063170,med:pmid:40063170:sec:results:sent:7,enalapril,ACE inhibitors,sacubitril_valsartan,ARNI,"Medications were classified according to the four-pillar therapy recommended by the AHA, including β-blockers, ARNI, ACE inhibitors/ARBs, SGLT2, and MRAs.",2025-03-10,,results,7,1,0.5614086850091832,other,1.0,0.5614086850091832,0.5614086850091832,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5614086850091832, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5614086850091832, 'final_confidence': 0.5614086850091832}"
med:pmid:39661383,med:pmid:39661383:sec:conclusion:sent:12,enalapril,ACEI,sacubitril_valsartan,ARNI,"Results of this cross-sectional study reveal that in the 7 years after FDA drug approval of sacubitril-valsartan, rates of ARNI or ACEI, ARB, or ARNI prescription at discharge increased, and rates of ACEI or ARB prescription decreased.",2025-03-01,,results,12,1,0.5518950126619467,other,1.0,0.5518950126619467,0.5518950126619467,[],,[],[],,,,[],evidence,real_world,0.7,POS,1.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.5518950126619467, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5518950126619467, 'final_confidence': 0.5518950126619467}"
med:pmid:39661383,med:pmid:39661383:sec:introduction:sent:4,enalapril,angiotensin converting enzyme inhibitor,sacubitril_valsartan,ARNI,"Rates of ARNI, angiotensin converting enzyme inhibitor (ACEI), and angiotensin II receptor blocker (ARB) prescription at discharge were evaluated across 3 time periods.",2025-03-01,,introduction,4,1,0.5518950126619467,other,1.0,0.5518950126619467,0.5518950126619467,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5518950126619467, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5518950126619467, 'final_confidence': 0.5518950126619467}"
med:pmid:39661383,med:pmid:39661383:sec:introduction:sent:7,enalapril,ACEI,sacubitril_valsartan,ARNI,"<h4>Main outcomes and measures</h4> Rates of ARNI, ACEI, and ARB prescription at discharge were evaluated across 3 time periods as follows: (1) period 1 included the US Food and Drug Administration (FDA) approval of sacubitril-valsartan to the day before the PIONEER-HF (Comparison of Sacubitril-Valsartan vs Enalapril on Effect on N-Terminal Pro-Brain Natriuretic Peptide in Patients Stabilized From an Acute Heart Failure Episode) trial publication (July 7, 2015-November 10, 2018); (2) period 2 included the day of the PIONEER-HF trial publication to the day before publication of the 2021 Update to the 2017 Consensus for Optimization of Heart Failure Treatment (November 11, 2018-January 10, 2021); and (3) period 3 included the day of the 2021 update publication to the last available data at the time of analysis (January 11, 2021-December 31, 2022).",2025-03-01,,introduction,7,1,0.5518950126619467,other,1.0,0.5518950126619467,0.5518950126619467,"['vs', 'trial']","{""comparative_terms"": [""vs""], ""study_context"": [""trial""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEG,-2.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.5518950126619467, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5518950126619467, 'final_confidence': 0.5518950126619467}"
med:pmid:39661383,med:pmid:39661383:sec:results:sent:10,enalapril,ACEI,sacubitril_valsartan,ARNI,"ACEI or ARB prescription at discharge fell from 88.3% (2612 of 2957) to 45.9% (2033 of 4434) over the same period, whereas ACEI, ARB, or ARNI prescription increased from 71.1% (2639 of 3713) to 84.7% (3990 of 4711).",2025-03-01,,results,10,1,0.5518950126619467,other,1.0,0.5518950126619467,0.5518950126619467,[],,[],[],,,,[],evidence,real_world,0.7,POS,1.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.5518950126619467, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5518950126619467, 'final_confidence': 0.5518950126619467}"
med:pmid:39661383,med:pmid:39661383:sec:results:sent:11,enalapril,ACEI,sacubitril_valsartan,ARNI,"In adjusted logistic regression models, compared with period 1, patients discharged during period 2 and period 3 were found to have a 3.81-fold (95% CI, 3.65-3.98) and 9.15-fold (95% CI, 8.79-9.52) increased odds of ARNI prescription at discharge, and a 0.46 (95% CI, 0.45-0.48) and 0.25 (95% CI, 0.24-0.26) decreased odds of ACEI or ARB prescription at discharge.",2025-03-01,,results,11,1,0.5518950126619467,other,1.0,0.5518950126619467,0.5518950126619467,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],evidence,real_world,0.7,POS,1.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.5518950126619467, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5518950126619467, 'final_confidence': 0.5518950126619467}"
med:pmid:40115097,med:pmid:40115097:sec:methods:sent:6,enalapril,ACEI,sacubitril_valsartan,angiotensin receptor neprilysin inhibitor,"Statistical comparison between two groups was performed, which focused on indicators of standardized management [proportion of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and echocardiography performed in the diagnosis of HF, application ratio of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB)/angiotensin receptor neprilysin inhibitor (ARNI), β-blockers in heart failure with reduced ejection fraction (HFrEF) patients, 1 week, 1 month, 3 months and 1 year follow-up rate] and clinical prognosis indicators (NT-proBNP level, 6-minute walking distance test, heart function grading, shorter average duration in hospital) at discharge, review of relevant indicators after 1 year, readmission rate and incidence of main adverse cardiovascular and cerebrovascular events (MACCEs) in 1 year.",2025-02-21,,methods,6,1,0.5435738450361919,other,1.0,0.5435738450361919,0.5435738450361919,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5435738450361919, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5435738450361919, 'final_confidence': 0.5435738450361919}"
med:pmid:40115097,med:pmid:40115097:sec:results:sent:7,enalapril,ACEI,sacubitril_valsartan,ARNI,"Compared to the control group, the proportion of patients using NT-proBNP (94.7% <i>vs.</i> 87.3%, P=0.03), echocardiography (88.7% <i>vs.</i> 78.7%, P=0.02), the ratio of patients using ACEI/ARB/ARNI (87.0% <i>vs.</i> 72.2%, P=0.03) and β-blocker (82.7% <i>vs.</i> 66.7%, P=0.03) before discharge, and the follow-up rate of each period after discharge (1 week, 90.7% <i>vs.</i> 80.0%, P=0.01; 1 month, 84.7% <i>vs.</i> 72.0%, P=0.01; 3 months, 76.7% <i>vs.</i> 64.0%, P=0.02; 1 year, 88.0% <i>vs.</i> 79.3%, P=0.04) was higher in the center group.",2025-02-21,,results,7,1,0.5435738450361919,other,1.0,0.5435738450361919,0.5435738450361919,"['compared to', 'vs', 'combination']","{""comparative_terms"": [""compared to"", ""vs""], ""combination"": [""acei/arb/arni""], ""claim_strength_terms"": {""confirmatory"": [""p=""]}}","['comparative_terms', 'relationship:combination', 'claim_strength:confirmatory']",[],,,,[],evidence,real_world,0.49999999999999994,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.5435738450361919, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5435738450361919, 'final_confidence': 0.5435738450361919}"
med:pmid:39983618,med:pmid:39983618:sec:conclusion:sent:11,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Treatment with sacubitril/valsartan or enalapril prevented deterioration of myocardial function at 6 months in patients with hematologic malignancies treated with BMT.,2025-02-20,,conclusion,11,1,0.542542559697216,other,1.0,0.542542559697216,0.542542559697216,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.542542559697216, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.542542559697216, 'final_confidence': 0.542542559697216}"
med:pmid:39983618,med:pmid:39983618:sec:introduction:sent:2,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,The authors investigated whether early initiation of sacubitril/valsartan or enalapril could be helpful to prevent CTRCD in patients undergoing BMT.,2025-02-20,,introduction,2,1,0.542542559697216,other,1.0,0.542542559697216,0.542542559697216,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.542542559697216, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.542542559697216, 'final_confidence': 0.542542559697216}"
med:pmid:39983618,med:pmid:39983618:sec:methods:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"We randomized 90 patients with preserved left ventricular ejection fraction (LVEF) after BMT to sacubitril/valsartan, enalapril, or no cardioprotective medication (controls).",2025-02-20,,methods,3,1,0.542542559697216,other,1.0,0.542542559697216,0.542542559697216,['randomized'],"{""study_context"": [""randomized""]}",['study_context'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.542542559697216, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.542542559697216, 'final_confidence': 0.542542559697216}"
med:pmid:39983618,med:pmid:39983618:sec:results:sent:6,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Patients treated with sacubitril/valsartan or enalapril for 6 months did not show a deterioration of LV GLS or LVEF (P > 0.05).,2025-02-20,,results,6,1,0.542542559697216,other,1.0,0.542542559697216,0.542542559697216,[],,[],[],,,,[],comparative,comparative_efficacy,0.8,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.542542559697216, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.542542559697216, 'final_confidence': 0.542542559697216}"
med:pmid:39983618,med:pmid:39983618:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The percent improvement of GWW and GWE was greater in the sacubitril/valsartan compared to enalapril or control group (P = 0.044 and P = 0.011, respectively) at 6 months.",2025-02-20,,results,8,1,0.542542559697216,other,1.0,0.542542559697216,0.542542559697216,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,POS,1.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.542542559697216, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.542542559697216, 'final_confidence': 0.542542559697216}"
med:pmid:39983618,med:pmid:39983618:sec:title:sent:0,enalapril,Enalapril,sacubitril_valsartan,Sacubitril/Valsartan,Effect of Sacubitril/Valsartan or Enalapril on Left Ventricular Function in Patients With Hematologic Malignancies Treated With Bone Marrow Transplantation: A Randomized Controlled Trial.,2025-02-20,,results,0,1,0.542542559697216,other,1.0,0.542542559697216,0.542542559697216,"['randomized', 'randomized controlled trial', 'trial']","{""study_context"": [""randomized"", ""randomized controlled trial"", ""trial""]}",['study_context'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.542542559697216, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.542542559697216, 'final_confidence': 0.542542559697216}"
med:pmid:39970741,med:pmid:39970741:sec:title:sent:0,enalapril,ACE Inhibitors,sacubitril_valsartan,Sacubitril/Valsartan,Sacubitril/Valsartan vs ACE Inhibitors or ARBs: A Systematic Review and Meta-Analysis of Randomized Trials.,2025-02-18,,title,0,1,0.5404858550677889,other,1.0,0.5404858550677889,0.5404858550677889,"['vs', 'meta-analysis', 'randomized', 'review', 'systematic review']","{""comparative_terms"": [""vs""], ""study_context"": [""meta-analysis"", ""randomized"", ""review"", ""systematic review""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.5404858550677889, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5404858550677889, 'final_confidence': 0.5404858550677889}"
med:pmid:40486108,med:pmid:40486108:sec:introduction:sent:2,enalapril,ACEIs,sacubitril_valsartan,ARNIs,Angiotensin receptor-neprilysin inhibitors (ARNIs) have emerged as a promising alternative to angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in HF management.,2025-02-18,,introduction,2,1,0.5404858550677889,other,1.0,0.5404858550677889,0.5404858550677889,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5404858550677889, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5404858550677889, 'final_confidence': 0.5404858550677889}"
med:pmid:40486108,med:pmid:40486108:sec:methods:sent:5,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"We conducted a systematic review and meta-analysis of published studies assessing the use of ARNIs in ACHD patients with HF, comparing them to ACEIs/ARBs.",2025-02-18,,methods,5,1,0.5404858550677889,other,1.0,0.5404858550677889,0.5404858550677889,"['meta-analysis', 'review', 'systematic review']","{""study_context"": [""meta-analysis"", ""review"", ""systematic review""]}",['study_context'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.5404858550677889, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5404858550677889, 'final_confidence': 0.5404858550677889}"
med:pmid:40486108,med:pmid:40486108:sec:results:sent:9,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"Substituting ACEIs/ARBs with ARNIs significantly improved the NYHA functional class (log odds ratio [log OR] 0.67, 95% CI 0.15-1.19; <i>p</i> = 0.01).",2025-02-18,,results,9,1,0.5404858550677889,other,1.0,0.5404858550677889,0.5404858550677889,[],,[],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.609948+00:00,"{'recency_weight': 0.5404858550677889, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5404858550677889, 'final_confidence': 0.5404858550677889}"
med:pmid:39939202,med:pmid:39939202:sec:results:sent:11,enalapril,ACEIs,sacubitril_valsartan,ARNIs,Increased age was associated with less likelihood of the prescription of ACEIs/ARBs/ARNIs and mineralocorticoid receptor antagonists at any dose and ≥50% target dose.,2025-02-11,,results,11,1,0.5333485940796269,other,1.0,0.5333485940796269,0.5333485940796269,[],,[],[],,,,[],evidence,real_world,0.7,POS,1.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.5333485940796269, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5333485940796269, 'final_confidence': 0.5333485940796269}"
med:pmid:39939202,med:pmid:39939202:sec:results:sent:12,enalapril,ACEIs,sacubitril_valsartan,ARNIs,Better renal function was a predictor for ACEIs/ARBs/ARNIs at any dose and ≥50% target dose.,2025-02-11,,results,12,1,0.5333485940796269,other,1.0,0.5333485940796269,0.5333485940796269,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5333485940796269, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5333485940796269, 'final_confidence': 0.5333485940796269}"
med:pmid:39939202,med:pmid:39939202:sec:results:sent:9,enalapril,ACEIs,sacubitril_valsartan,angiotensin receptor neprilysin inhibitors,"The prescription of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs)/angiotensin receptor neprilysin inhibitors (ARNIs) and mineralocorticoid receptor antagonists at any dose (52% vs 80%; p<0.01, 25% vs 52%; p<0.01, respectively) were lower in non-cardiology than in cardiology wards, but there was no difference between wards for beta blockers.",2025-02-11,,results,9,1,0.5333485940796269,other,1.0,0.5333485940796269,0.5333485940796269,['vs'],"{""comparative_terms"": [""vs""], ""claim_strength_terms"": {""confirmatory"": [""p<""]}}","['comparative_terms', 'claim_strength:confirmatory']",[],,,,[],evidence,real_world,0.49999999999999994,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.5333485940796269, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5333485940796269, 'final_confidence': 0.5333485940796269}"
med:pmid:39922597,med:pmid:39922597:sec:conclusion:sent:11,enalapril,ACEi,sacubitril_valsartan,ARNi,"In our study, early adoption of guideline-recommended medical therapy is still limited, with a significant rise in SGLT2i prescriptions after January 2022 and a lower risk of the composite of all-cause death and urgent readmissions at 30 days restricted to the use of ACEi/ARB/ARNi.",2025-02-08,,conclusion,11,1,0.530318692764066,observational study,1.2,0.6363824313168791,0.6363824313168791,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.530318692764066, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.6363824313168791, 'final_confidence': 0.6363824313168791}"
med:pmid:39922597,med:pmid:39922597:sec:results:sent:7,enalapril,ACE inhibitor,sacubitril_valsartan,ARNi,"Among the 999 included patients, β-blockers were prescribed in 93% of patients, ACE inhibitor (ACEi)/angiotensin receptor blocker (ARB)/angiotensin-neprilysin receptor inhibitor (ARNi) in 73%, mineralocorticoid receptor antagonist in 30% and SGLT2 inhibitors in 18%.",2025-02-08,,results,7,1,0.530318692764066,observational study,1.2,0.6363824313168791,0.6363824313168791,[],,[],[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.530318692764066, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.6363824313168791, 'final_confidence': 0.6363824313168791}"
med:pmid:39922597,med:pmid:39922597:sec:results:sent:9,enalapril,ACEi,sacubitril_valsartan,ARNi,"In multivariate analysis, the use of ACEi/ARB/ARNi was associated with a lower risk of 30-day all-cause death and urgent rehospitalisation (adjusted OR 0.38; 95% CI 0.24 to 0.59; p<0.01).",2025-02-08,,results,9,1,0.530318692764066,observational study,1.2,0.6363824313168791,0.6363824313168791,"['combination', 'risk']","{""combination"": [""acei/arb/arni""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}, ""claim_strength_terms"": {""confirmatory"": [""p<""]}}","['relationship:combination', 'risk_terms', 'risk_posture:acknowledgment', 'claim_strength:confirmatory']",[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.530318692764066, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.6363824313168791, 'final_confidence': 0.6363824313168791}"
med:pmid:39888167,med:pmid:39888167:sec:conclusion:sent:9,enalapril,ACEi,sacubitril_valsartan,sacubitril/valsartan,"Among patients with de novo HFrEF, sacubitril/valsartan (compared with that of ACEi/ARB) was associated with fewer all-cause, CV and HF hospitalizations.",2025-01-30,,conclusion,9,1,0.5213318736832575,other,1.0,0.5213318736832575,0.5213318736832575,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.5213318736832575, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5213318736832575, 'final_confidence': 0.5213318736832575}"
med:pmid:39888167,med:pmid:39888167:sec:introduction:sent:2,enalapril,ACEi,sacubitril_valsartan,sacubitril/valsartan,We examined the effectiveness of sacubitril/valsartan versus angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) on all-cause and cause-specific hospitalizations among patients with de novo HFrEF from the Optum® dataset in the United States.,2025-01-30,,introduction,2,1,0.5213318736832575,other,1.0,0.5213318736832575,0.5213318736832575,['versus'],"{""comparative_terms"": [""versus""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.5213318736832575, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5213318736832575, 'final_confidence': 0.5213318736832575}"
med:pmid:39888167,med:pmid:39888167:sec:methods:sent:3,enalapril,ACEi,sacubitril_valsartan,sacubitril/valsartan,This retrospective cohort study included adult patients with de novo HFrEF (diagnosed ≤30 days) with left ventricular ejection fraction (LVEF) ≤40% who were first prescribed with sacubitril/valsartan or ACEi/ARB from 1 January 2016 to 31 March 2020.,2025-01-30,,methods,3,1,0.5213318736832575,other,1.0,0.5213318736832575,0.5213318736832575,"['cohort', 'retrospective']","{""study_context"": [""cohort"", ""retrospective""], ""real_world_terms"": [""retrospective""]}","['study_context', 'real_world_terms']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.5213318736832575, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5213318736832575, 'final_confidence': 0.5213318736832575}"
med:pmid:39888167,med:pmid:39888167:sec:results:sent:5,enalapril,ACEi,sacubitril_valsartan,sacubitril/valsartan,A cohort of 3290 patients with de novo HFrEF who were prescribed with sacubitril/valsartan and a propensity-matched cohort of 6580 patients who were prescribed with ACEi/ARB were analysed.,2025-01-30,,results,5,1,0.5213318736832575,other,1.0,0.5213318736832575,0.5213318736832575,['cohort'],"{""study_context"": [""cohort""]}",['study_context'],[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.5213318736832575, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5213318736832575, 'final_confidence': 0.5213318736832575}"
med:pmid:39888167,med:pmid:39888167:sec:results:sent:8,enalapril,ACEi,sacubitril_valsartan,sacubitril/valsartan,"Patients in the sacubitril/valsartan cohort when compared with the ACEi/ARB cohort had lower annual rates of all-cause hospitalizations [incidence rate ratio (IRR): 0.81, 95% confidence interval (CI): 0.75-0.89, P < 0.001], cardiovascular (CV) hospitalizations (IRR: 0.80, 95% CI: 0.73-0.87, P < 0.001) and HF hospitalizations (IRR: 0.86, 95% CI: 0.78-0.95, P = 0.002).",2025-01-30,,results,8,1,0.5213318736832575,other,1.0,0.5213318736832575,0.5213318736832575,"['compared with', 'cohort']","{""comparative_terms"": [""compared with""], ""study_context"": [""cohort""]}","['comparative_terms', 'study_context']",[],,,,[],comparative,comparative_efficacy,0.39999999999999997,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.5213318736832575, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5213318736832575, 'final_confidence': 0.5213318736832575}"
med:pmid:39864551,med:pmid:39864551:sec:conclusion:sent:12,enalapril,ACEi,sacubitril_valsartan,Sacubitril/valsartan,"Sacubitril/valsartan is a promising alternative to ARB or ACEi in managing RH, offering superior blood pressure reductions and potential benefits in reversing cardiac remodeling, while maintaining a favorable safety profile with minimal risk of serious adverse events.",2025-01-27,,conclusion,12,1,0.5183702381836035,other,1.0,0.5183702381836035,0.5183702381836035,"['superior', 'adverse events', 'risk', 'safety', 'safety profile', 'serious', 'serious adverse events']","{""comparative_terms"": [""superior""], ""risk_terms"": [""adverse events"", ""risk"", ""safety"", ""safety profile"", ""serious"", ""serious adverse events""], ""endpoint_terms"": [""blood pressure""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""], ""minimization"": [""minimal risk""], ""reassurance"": [""favorable safety profile""]}, ""claim_strength_terms"": {""exploratory"": [""promising""]}}","['comparative_terms', 'risk_terms', 'endpoint_terms', 'risk_posture:acknowledgment', 'risk_posture:minimization', 'risk_posture:reassurance', 'claim_strength:exploratory']",[],,,,[],comparative,comparative_safety,0.9,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.5183702381836035, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5183702381836035, 'final_confidence': 0.5183702381836035}"
med:pmid:39829077,med:pmid:39829077:sec:methods:sent:6,enalapril,ACEis,sacubitril_valsartan,ARNis,"GDMT was defined by five medication classes-angiotensin-converting enzyme (ACE) inhibitors (ACEis)/angiotensin receptor blockers (ARBs)/angiotensin receptor-neprilysin inhibitors (ARNis), beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs), sodium-glucose cotransporter 2 inhibitors (SGLT2is) and vasodilators (Black patients only).",2025-01-19,,methods,6,1,0.5105545385574677,other,1.0,0.5105545385574677,0.5105545385574677,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5105545385574677, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5105545385574677, 'final_confidence': 0.5105545385574677}"
med:pmid:39829077,med:pmid:39829077:sec:results:sent:10,enalapril,ACEis,sacubitril_valsartan,ARNis,"Among the 93.8% on some form of GDMT, 82.8%, 81.4%, 23.5%, 3.6% and 13.4% were on ACEis/ARBs/ARNis, BBs, MRAs, SGLT2is and vasodilators (Black patients only), respectively.",2025-01-19,,results,10,1,0.5105545385574677,other,1.0,0.5105545385574677,0.5105545385574677,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5105545385574677, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5105545385574677, 'final_confidence': 0.5105545385574677}"
med:pmid:39829077,med:pmid:39829077:sec:results:sent:11,enalapril,ACEis,sacubitril_valsartan,ARNis,"Among treated patients, 45.8%, 21.4%, 77.6%, 100% and 14.7% were treated at ≥80% of the target dose for ACEis/ARBs/ARNis, BBs, MRAs, SGLT2is and vasodilators, respectively.",2025-01-19,,results,11,1,0.5105545385574677,other,1.0,0.5105545385574677,0.5105545385574677,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5105545385574677, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5105545385574677, 'final_confidence': 0.5105545385574677}"
ppr:doi:10.1101/2025.01.10.25320367,ppr:doi:10.1101/2025.01.10.25320367:sec:results:sent:8,enalapril,ACEi,sacubitril_valsartan,sacubitril/valsartan,"The groups were well matched for age: 52.9±11.3 (IVB) vs. 53.5±11.8, gender: 57% male, HFrEF diagnosis: 66.4%, co-morbidities: hypertension 81.3% and coronary artery disease event 38.3%, and goal-directed medical therapy: ß-adrenergic blockers 89.7%, ACEi/ARB/sacubitril/valsartan 79.4%, mineral corticoid antagonists 39.3%.",2025-01-12,,results,8,1,0.5038125286487749,other,1.0,0.5038125286487749,0.5038125286487749,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5038125286487749, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5038125286487749, 'final_confidence': 0.5038125286487749}"
med:pmid:39792134,med:pmid:39792134:sec:introduction:sent:1,enalapril,ACEi,sacubitril_valsartan,sacubitril/valsartan,"Whether prior treatment with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) modifies efficacy and safety of sacubitril/valsartan (Sac/Val) in patients with heart failure (HF) and ejection fraction (EF) >40% is unclear, thus Sac/Val according to ACEi/ARB status at baseline was assessed.",2025-01-10,,introduction,1,1,0.5019026442691725,randomized controlled trial,1.6,0.8030442308306761,0.8030442308306761,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5019026442691725, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.8030442308306761, 'final_confidence': 0.8030442308306761}"
med:pmid:39792134,med:pmid:39792134:sec:results:sent:2,enalapril,ACEi,sacubitril_valsartan,ARNI,"This was a pre-specified analysis of Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF (PARAGLIDE-HF), a double-blind, randomized controlled trial of Sac/Val versus valsartan, categorizing patients according to baseline ACEi/ARB status.",2025-01-10,,results,2,1,0.5019026442691725,randomized controlled trial,1.6,0.8030442308306761,0.8030442308306761,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5019026442691725, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.8030442308306761, 'final_confidence': 0.8030442308306761}"
med:pmid:40463763,med:pmid:40463763:sec:introduction:sent:2,enalapril,ACEI,sacubitril_valsartan,ARNI,Angiotensin receptor-neprilysin inhibitor (ARNI) has superior beneficial effects on mortality and quality of life compared to angiotensin-converting enzyme inhibitor (ACEI).,2025-01-01,,introduction,2,1,0.4933973656098115,other,1.0,0.4933973656098115,0.4933973656098115,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.4933973656098115, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.4933973656098115, 'final_confidence': 0.4933973656098115}"
med:pmid:40463763,med:pmid:40463763:sec:introduction:sent:4,enalapril,ACEI,sacubitril_valsartan,ARNI,"The study was conducted to evaluate the possible impact of ARNI therapy compared to ACEI on cardiac remodeling using echocardiographic parameters, including global longitudinal strain (GLS) in heart failure with reduced left ventricular ejection fraction (HFrEF) patients.",2025-01-01,,introduction,4,1,0.4933973656098115,other,1.0,0.4933973656098115,0.4933973656098115,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.4933973656098115, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.4933973656098115, 'final_confidence': 0.4933973656098115}"
med:pmid:40463763,med:pmid:40463763:sec:methods:sent:6,enalapril,ACEI,sacubitril_valsartan,ARNI,"The study included two groups: the ARNI group included forty patients prescribed ARNI, and the ACEI group included forty patients prescribed ACEI.",2025-01-01,,methods,6,1,0.4933973656098115,other,1.0,0.4933973656098115,0.4933973656098115,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.4933973656098115, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.4933973656098115, 'final_confidence': 0.4933973656098115}"
med:pmid:40463763,med:pmid:40463763:sec:results:sent:10,enalapril,ACEI,sacubitril_valsartan,ARNI,"There was a significant improvement in the ARNI group regarding LVEF (<i>P</i> = 0.011), 2D GLS (<i>P</i> < 0.001), and 3D GLS compared to the ACEI group, but no significant change in the LV mass index.",2025-01-01,,results,10,1,0.4933973656098115,other,1.0,0.4933973656098115,0.4933973656098115,['compared to'],"{""comparative_terms"": [""compared to""], ""claim_strength_terms"": {""confirmatory"": [""significant improvement""]}}","['comparative_terms', 'claim_strength:confirmatory']",[],,,,[],comparative,comparative_efficacy,0.6,POS,1.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.4933973656098115, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.4933973656098115, 'final_confidence': 0.4933973656098115}"
med:pmid:40463763,med:pmid:40463763:sec:results:sent:9,enalapril,ACEI,sacubitril_valsartan,ARNI,"After a 6-month follow-up period, there was a significant reduction in LV-indexed volumes in the ARNI group (<i>P</i> < 0.001) and indexed left atrial volumes (<i>P</i> = 0.013) compared to the ACEI group.",2025-01-01,,results,9,1,0.4933973656098115,other,1.0,0.4933973656098115,0.4933973656098115,['compared to'],"{""comparative_terms"": [""compared to""], ""claim_strength_terms"": {""confirmatory"": [""significant reduction""]}}","['comparative_terms', 'claim_strength:confirmatory']",[],,,,[],comparative,comparative_efficacy,0.6,POS,1.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.4933973656098115, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.4933973656098115, 'final_confidence': 0.4933973656098115}"
med:pmid:39719408,med:pmid:39719408:sec:results:sent:4,enalapril,ACEI,sacubitril_valsartan,ARNI,Individual patient data from the PARAGON-HF (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ARB [Angiotensin Receptor Blocker] Global Outcomes in HFpEF) and PARADIGM-HF (Prospective Comparison of ARNI With ACEI [Angiotensin-Converting Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in HF) trials were used to examine patient characteristics and outcomes according to quartiles of PNI.,2024-12-24,,results,4,1,0.48595819313832567,other,1.0,0.48595819313832567,0.48595819313832567,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.48595819313832567, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.48595819313832567, 'final_confidence': 0.48595819313832567}"
med:pmid:39687932,med:pmid:39687932:sec:results:sent:8,enalapril,ACEI,sacubitril_valsartan,ARNI,"The proportion of patients who halted GDMT was 70.4%, 53.2%, 59.8% and 63.8% for MRA, beta-blockers, ACEI/ARB/ARNI and SGLT-2 inhibitors.",2024-12-17,,results,8,1,0.4795409845819077,other,1.0,0.4795409845819077,0.4795409845819077,['combination'],"{""combination"": [""acei/arb/arni"", ""gdmt""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4795409845819077, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.4795409845819077, 'final_confidence': 0.4795409845819077}"
med:pmid:39816068,med:pmid:39816068:sec:abstract:sent:1,enalapril,ACEI,sacubitril_valsartan,ARNI,Previous studies have reported that angiotensin receptor-neprilysin inhibitors (ARNI) are superior to angiotensin-converting enzyme inhibitors (ACEI) in treating heart failure with reduced ejection fraction (HFrEF).,2024-12-07,,abstract,1,1,0.47052026558285104,other,1.0,0.47052026558285104,0.47052026558285104,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.47052026558285104, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.47052026558285104, 'final_confidence': 0.47052026558285104}"
med:pmid:39816068,med:pmid:39816068:sec:abstract:sent:10,enalapril,ACEI,sacubitril_valsartan,ARNI,A higher KCCQ overall score was observed in the ARNI group in contrast to the ACEI group (<i>p</i>=0.01).,2024-12-07,,abstract,10,1,0.47052026558285104,other,1.0,0.47052026558285104,0.47052026558285104,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.47052026558285104, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.47052026558285104, 'final_confidence': 0.47052026558285104}"
med:pmid:39816068,med:pmid:39816068:sec:abstract:sent:11,enalapril,ACEI,sacubitril_valsartan,ARNI,ARNI demonstrated superior results in improving the ejection fraction as compared with ACEI (<i>p</i>=0.001).,2024-12-07,,abstract,11,1,0.47052026558285104,other,1.0,0.47052026558285104,0.47052026558285104,"['compared with', 'superior']","{""comparative_terms"": [""compared with"", ""superior""]}",['comparative_terms'],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.47052026558285104, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.47052026558285104, 'final_confidence': 0.47052026558285104}"
med:pmid:39816068,med:pmid:39816068:sec:abstract:sent:14,enalapril,ACEI,sacubitril_valsartan,ARNI,"In conclusion, ARNI was more efficacious than ACEI in improving the quality of life and left ventricular ejection fraction of patients with HFrEF.",2024-12-07,,abstract,14,1,0.47052026558285104,other,1.0,0.47052026558285104,0.47052026558285104,[],,[],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.47052026558285104, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.47052026558285104, 'final_confidence': 0.47052026558285104}"
med:pmid:39816068,med:pmid:39816068:sec:abstract:sent:3,enalapril,ACEI,sacubitril_valsartan,ARNI,The aim of this study was to compare the efficacies of ARNI and ACEI on patients with HFrEF in Indonesia.,2024-12-07,,abstract,3,1,0.47052026558285104,other,1.0,0.47052026558285104,0.47052026558285104,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.47052026558285104, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.47052026558285104, 'final_confidence': 0.47052026558285104}"
med:pmid:39816068,med:pmid:39816068:sec:abstract:sent:5,enalapril,ACEI,sacubitril_valsartan,ARNI,Both ACEI and ARNI each consisted of 40 subjects receiving standard treatment for heart failure.,2024-12-07,,abstract,5,1,0.47052026558285104,other,1.0,0.47052026558285104,0.47052026558285104,[],,[],[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.47052026558285104, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.47052026558285104, 'final_confidence': 0.47052026558285104}"
med:pmid:39816068,med:pmid:39816068:sec:abstract:sent:8,enalapril,ACEI,sacubitril_valsartan,ARNI,Paired <i>t</i>-test was used to compare the outcomes of ACEI and ARNI.,2024-12-07,,abstract,8,1,0.47052026558285104,other,1.0,0.47052026558285104,0.47052026558285104,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.47052026558285104, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.47052026558285104, 'final_confidence': 0.47052026558285104}"
med:pmid:39816068,med:pmid:39816068:sec:abstract:sent:9,enalapril,ACEI,sacubitril_valsartan,ARNI,The results revealed that KKCQ score and LVEF were improved in both ARNI and ACEI groups (each with <i>p</i><0.001).,2024-12-07,,abstract,9,1,0.47052026558285104,other,1.0,0.47052026558285104,0.47052026558285104,[],,[],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.594300+00:00,"{'recency_weight': 0.47052026558285104, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.47052026558285104, 'final_confidence': 0.47052026558285104}"
med:pmid:39622578,med:pmid:39622578:sec:methods:sent:3,enalapril,ACE inhibitor,sacubitril_valsartan,sacubitril/valsartan,"HFrEF patients with symptomatic LVEF≤35% despite ACE inhibitor/beta blocker/mineralocorticoid receptor antagonist therapy, and qualified for sacubitril/valsartan switchover were recruited to this single centre prospective study.",2024-12-02,,methods,3,1,0.466073740806395,observational study,1.2,0.559288488967674,0.559288488967674,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.466073740806395, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.559288488967674, 'final_confidence': 0.559288488967674}"
med:pmid:39620289,med:pmid:39620289:sec:results:sent:10,enalapril,ACEi,sacubitril_valsartan,ARNi,"Although 69.5% of the study participants indicated prescribing all four classes of HF medications during the initial hospitalization is feasible, most cardiologists preferred a sequential approach starting with ACEi/ARNi, followed by beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter 2 inhibitors (SGLT2i).",2024-12-01,,results,10,1,0.4651894910946686,other,1.0,0.4651894910946686,0.4651894910946686,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4651894910946686, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.4651894910946686, 'final_confidence': 0.4651894910946686}"
med:pmid:39620289,med:pmid:39620289:sec:results:sent:8,enalapril,ACEi,sacubitril_valsartan,ARNi,"While 52.6% of physicians considered angiotensin receptor-neprilysin inhibitor (ARNi) treatment the most effective medication for HF, 62.7% would initiate HF treatment with an angiotensin-converting enzyme inhibitor (ACEi) instead of ARNi due to reimbursement and cost issues.",2024-12-01,,results,8,1,0.4651894910946686,other,1.0,0.4651894910946686,0.4651894910946686,[],"{""access_terms"": [""reimbursement""]}",['access_terms'],[],,,,[],access,coverage_access,0.65,POS,1.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4651894910946686, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.4651894910946686, 'final_confidence': 0.4651894910946686}"
med:pmid:39720381,med:pmid:39720381:sec:abstract:sent:6,enalapril,ACE inhibitors,sacubitril_valsartan,ARNIs,"Combining beta-blockers and ACE inhibitors, or integrating them with newer agents such as angiotensin receptor-neprilysin inhibitors (ARNIs) and mineralocorticoid receptor antagonists (MRAs), provides an additive benefit, improving long-term survival and reducing heart failure-related hospitalizations.",2024-11-23,,abstract,6,1,0.4581756213471096,review,0.9,0.41235805921239865,0.41235805921239865,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4581756213471096, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.41235805921239865, 'final_confidence': 0.41235805921239865}"
med:pmid:39563094,med:pmid:39563094:sec:conclusion:sent:11,enalapril,enalapril,sacubitril_valsartan,Sacubitril/valsartan,"Sacubitril/valsartan may be more effective than enalapril in reducing the risk of death in patients not treated with a beta-blocker compared to those treated with a beta-blocker, but is effective regardless of beta-blocker use.",2024-11-19,,conclusion,11,1,0.4547084434124103,randomized controlled trial,1.6,0.7275335094598565,0.7275335094598565,"['compared to', 'risk']","{""comparative_terms"": [""compared to""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment']",[],alternative,disfavored,favored,['preferred_over'],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4547084434124103, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.7275335094598565, 'final_confidence': 0.7275335094598565}"
med:pmid:39563094,med:pmid:39563094:sec:results:sent:10,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Safety outcomes related to sacubitril/valsartan versus enalapril did not differ according to background beta-blocker use.,2024-11-19,,results,10,1,0.4547084434124103,randomized controlled trial,1.6,0.7275335094598565,0.7275335094598565,"['versus', 'safety']","{""comparative_terms"": [""versus""], ""risk_terms"": [""safety""]}","['comparative_terms', 'risk_terms']",[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4547084434124103, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.7275335094598565, 'final_confidence': 0.7275335094598565}"
med:pmid:39563094,med:pmid:39563094:sec:results:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,We examined the effect of sacubitril/valsartan compared to enalapril on outcomes according to background beta-blocker treatment in the 8399 patients with heart failure with reduced ejection fraction enrolled in PARADIGM-HF.,2024-11-19,,results,3,1,0.4547084434124103,randomized controlled trial,1.6,0.7275335094598565,0.7275335094598565,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4547084434124103, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.7275335094598565, 'final_confidence': 0.7275335094598565}"
med:pmid:39571389,med:pmid:39571389:sec:results:sent:9,enalapril,ACEI,sacubitril_valsartan,ARNI,"Key predictors included the E/e' ratio, NYHA classification, LVEF, age, BNP levels, MLR, history of atrial fibrillation (AF), use of ACEI/ARB/ARNI, and history of myocardial infarction (MI).",2024-11-14,,results,9,1,0.45041134399376476,other,1.0,0.45041134399376476,0.45041134399376476,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.45041134399376476, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.45041134399376476, 'final_confidence': 0.45041134399376476}"
med:pmid:39497472,med:pmid:39497472:sec:conclusion:sent:12,enalapril,ACEi,sacubitril_valsartan,ARNI,This is the first study to our knowledge to describe real-world prescribing practices when transitioning patients from ACEi to ARNI for the treatment of HFrEF.,2024-11-04,,conclusion,12,1,0.441938587130871,other,1.0,0.441938587130871,0.441938587130871,['real-world'],"{""study_context"": [""real-world""], ""real_world_terms"": [""real-world""]}","['study_context', 'real_world_terms']",[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.441938587130871, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.441938587130871, 'final_confidence': 0.441938587130871}"
med:pmid:39497472,med:pmid:39497472:sec:introduction:sent:1,enalapril,ACEi,sacubitril_valsartan,ARNI,The 2022 AHA-ACC HFSA Guideline for Management of Heart Failure recommend initiating an angiotensin receptor/neprilysin inhibitor (ARNI) in patients with heart failure with reduced ejection fraction (HFrEF) who can tolerate an angiotensin-converting enzyme inhibitor (ACEi).,2024-11-04,,introduction,1,1,0.441938587130871,other,1.0,0.441938587130871,0.441938587130871,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.441938587130871, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.441938587130871, 'final_confidence': 0.441938587130871}"
med:pmid:39497472,med:pmid:39497472:sec:introduction:sent:2,enalapril,ACEi,sacubitril_valsartan,ARNI,"The manufacturer recommends initiating a 36-hour washout period when switching from ACEi to ARNI due to an increased risk of adverse effects, including angioedema.",2024-11-04,,introduction,2,1,0.441938587130871,other,1.0,0.441938587130871,0.441938587130871,"['switching', 'adverse effects', 'risk']","{""switching"": [""switching from""], ""risk_terms"": [""adverse effects"", ""risk""], ""risk_posture_terms"": {""acknowledgment"": [""increased risk"", ""risk of""]}}","['relationship:switching', 'risk_terms', 'risk_posture:acknowledgment']",[],switch,switch_destination,switch_source,['switch_from'],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.441938587130871, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.441938587130871, 'final_confidence': 0.441938587130871}"
med:pmid:39497472,med:pmid:39497472:sec:introduction:sent:3,enalapril,ACEi,sacubitril_valsartan,ARNI,This study investigated the adherence to the washout period when transitioning from ACEi to ARNI at a community hospital.,2024-11-04,,introduction,3,1,0.441938587130871,other,1.0,0.441938587130871,0.441938587130871,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.441938587130871, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.441938587130871, 'final_confidence': 0.441938587130871}"
med:pmid:39497472,med:pmid:39497472:sec:introduction:sent:4,enalapril,ACEi,sacubitril_valsartan,ARNI,The primary objective was to assess the rate of adherence to the 36-hour washout when transitioning patients from ACEi to ARNI.,2024-11-04,,introduction,4,1,0.441938587130871,other,1.0,0.441938587130871,0.441938587130871,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.441938587130871, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.441938587130871, 'final_confidence': 0.441938587130871}"
med:pmid:39497472,med:pmid:39497472:sec:methods:sent:6,enalapril,ACEi,sacubitril_valsartan,ARNI,"This was a retrospective cohort study including patients with HFrEF who were transitioned from ACEi to ARNI during their hospital stay between March 1, 2016 and December 31, 2022.",2024-11-04,,methods,6,1,0.441938587130871,other,1.0,0.441938587130871,0.441938587130871,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.441938587130871, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.441938587130871, 'final_confidence': 0.441938587130871}"
med:pmid:39497472,med:pmid:39497472:sec:methods:sent:7,enalapril,ACEi,sacubitril_valsartan,ARNI,Patients were excluded if they did not receive an ACEi or ARNI during their admission or if they had an ejection fraction >40%.,2024-11-04,,methods,7,1,0.441938587130871,other,1.0,0.441938587130871,0.441938587130871,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.441938587130871, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.441938587130871, 'final_confidence': 0.441938587130871}"
med:pmid:39497472,med:pmid:39497472:sec:results:sent:9,enalapril,ACEi,sacubitril_valsartan,ARNI,"Of 33 patients included in this study, 67% received the full 36-hour washout period when transitioning from ACEi to ARNI.",2024-11-04,,results,9,1,0.441938587130871,other,1.0,0.441938587130871,0.441938587130871,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.441938587130871, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.441938587130871, 'final_confidence': 0.441938587130871}"
med:pmid:39602121,med:pmid:39602121:sec:results:sent:13,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"Not filling a cardiovascular medication after hospitalization was associated with not filling that medication at the time of discharge (adjusted risk ratio, 0.27 [95% CI, 0.27-0.28] for ACEIs, ARBs, or ARNIs; 0.24 [0.24-0.25] for β-blockers; 0.20 [0.19-0.20] for P2Y12Is; 0.31 [0.31-0.32] for statins or PCSK9Is; and 0.27 [0.26-0.28] for SGLT2Is or GLP-1RAs).",2024-11-04,,results,13,1,0.441938587130871,other,1.0,0.441938587130871,0.441938587130871,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.441938587130871, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.441938587130871, 'final_confidence': 0.441938587130871}"
med:pmid:39602121,med:pmid:39602121:sec:results:sent:9,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"<h4>Main outcome and measures</h4> Medicare Part D prescription fill records were examined for the following agents: (1) angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), or angiotensin receptor-neprilysin inhibitors (ARNIs); (2) β-blockers; (3) platelet adenosine diphosphate receptor inhibitors (P2Y12Is); (4) statins or proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9Is); and (5) glucagon-like peptide 1 receptor agonists (GLP-1RAs) or sodium glucose cotransporter 2 inhibitors (SGLT2Is).",2024-11-04,,results,9,1,0.441938587130871,other,1.0,0.441938587130871,0.441938587130871,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.441938587130871, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.441938587130871, 'final_confidence': 0.441938587130871}"
med:pmid:39210725,med:pmid:39210725:sec:introduction:sent:5,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Participants with chronic HF, New York Heart Association classes II through IV symptoms, and elevated natriuretic peptides were randomized to treatment with either sacubitril/valsartan or a renin-angiotensin system inhibitor (RASi)-enalapril in the PARADIGM-HF trial or valsartan in the PARAGON-HF trial.",2024-11-01,,introduction,5,1,0.4394279771444405,randomized controlled trial,1.6,0.7030847634311048,0.7030847634311048,"['randomized', 'trial']","{""study_context"": [""randomized"", ""trial""]}",['study_context'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.4394279771444405, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.7030847634311048, 'final_confidence': 0.7030847634311048}"
med:pmid:39210725,med:pmid:39210725:sec:methods:sent:6,enalapril,enalapril,sacubitril_valsartan,Sacubitril/valsartan,Sacubitril/valsartan vs RASi (enalapril or valsartan).,2024-11-01,,methods,6,1,0.4394279771444405,randomized controlled trial,1.6,0.7030847634311048,0.7030847634311048,['vs'],"{""comparative_terms"": [""vs""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.4394279771444405, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.7030847634311048, 'final_confidence': 0.7030847634311048}"
med:pmid:39455534,med:pmid:39455534:sec:results:sent:11,enalapril,ACEis,sacubitril_valsartan,ARNIs,"Angiotensin receptor/neprilysin inhibitors (ARNIs) are the first choice for patients with HF and reduced ejection fraction, with ACEis being the second choice in this group.",2024-10-25,,results,11,1,0.4336252125966307,other,1.0,0.4336252125966307,0.4336252125966307,[],,[],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4336252125966307, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.4336252125966307, 'final_confidence': 0.4336252125966307}"
med:pmid:39439294,med:pmid:39439294:sec:results:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"PARADIGM-HF and PARAGON-HF were randomized trials testing sacubitril/valsartan versus enalapril or valsartan, respectively, in patients with HF and LVEF ≤40% (PARADIGM-HF) or LVEF ≥45% (PARAGON-HF).",2024-10-22,,results,3,1,0.4311618300796596,randomized controlled trial,1.6,0.6898589281274554,0.6898589281274554,"['versus', 'randomized']","{""comparative_terms"": [""versus""], ""study_context"": [""randomized""]}","['comparative_terms', 'study_context']",[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4311618300796596, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6898589281274554, 'final_confidence': 0.6898589281274554}"
med:pmid:39412629,med:pmid:39412629:sec:methods:sent:3,enalapril,ACEIs,sacubitril_valsartan,angiotensin receptor neprilysin inhibitor,"Screening criteria included hypertension (mild or moderate); first-line treatment and washout periods; studies (monotherapy) with AZL-M, angiotensin type II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor neprilysin inhibitor (ARNIs), beta-blockers, calcium channel blockers (CCBs), and diuretics, either as intervention or comparator; and antihypertension efficacy as an outcome measure.",2024-10-16,,methods,3,1,0.42627696825289096,review,0.9,0.38364927142760186,0.38364927142760186,[],"{""line_of_therapy_terms"": [""first-line""]}",['line_of_therapy_terms'],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.42627696825289096, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.38364927142760186, 'final_confidence': 0.38364927142760186}"
med:pmid:39544776,med:pmid:39544776:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,To evaluate the therapeutic effect of sacubitril/valsartan compared to enalapril in managing heart failure (HF) after percutaneous coronary intervention (PCI).,2024-10-15,,introduction,1,1,0.42546822222561836,other,1.0,0.42546822222561836,0.42546822222561836,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.42546822222561836, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.42546822222561836, 'final_confidence': 0.42546822222561836}"
med:pmid:39544776,med:pmid:39544776:sec:methods:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The observation group was comprised of 31 patients treated with sacubitril/valsartan (LCZ696) sodium tablets, while the control group, including 32 patients, received enalapril maleate tablets.",2024-10-15,,methods,3,1,0.42546822222561836,other,1.0,0.42546822222561836,0.42546822222561836,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.42546822222561836, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.42546822222561836, 'final_confidence': 0.42546822222561836}"
med:pmid:38330576,med:pmid:38330576:sec:conclusion:sent:18,enalapril,enalapril,sacubitril_valsartan,Sacubitril valsartan,The main findings of the study showed that Sacubitril valsartan sodium showed better clinical efficacy than enalapril in patients with heart failure and non-valvular reduced ejection fraction.,2024-10-01,,conclusion,18,1,0.4143055705373166,observational study,1.2,0.49716668464477987,0.49716668464477987,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.4143055705373166, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.49716668464477987, 'final_confidence': 0.49716668464477987}"
med:pmid:38330576,med:pmid:38330576:sec:introduction:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril valsartan,This study aimed to explore the clinical efficacy of sacubitril valsartan sodium and enalapril in such patients.,2024-10-01,,introduction,3,1,0.4143055705373166,observational study,1.2,0.49716668464477987,0.49716668464477987,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.4143055705373166, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.49716668464477987, 'final_confidence': 0.49716668464477987}"
med:pmid:38330576,med:pmid:38330576:sec:title:sent:0,enalapril,Enalapril,sacubitril_valsartan,Sacubitril Valsartan,A Comparative Analysis of the Clinical Efficacy of Sacubitril Valsartan Sodium and Enalapril in Patients with Non-Valvular Ejection Fraction Reduction in Heart Failure.,2024-10-01,,introduction,0,1,0.4143055705373166,observational study,1.2,0.49716668464477987,0.49716668464477987,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.4143055705373166, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.49716668464477987, 'final_confidence': 0.49716668464477987}"
med:pmid:39110471,med:pmid:39110471:sec:abstract:sent:2,enalapril,ACE Inhibitor,sacubitril_valsartan,ARNi,The Prospective ARNi vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI (PARADISE-MI) and Valsartan in Acute Myocardial Infarction (VALIANT) trials enrolled patients with pulmonary congestion and/or left ventricular dysfunction after AMI.,2024-10-01,,abstract,2,1,0.4143055705373166,randomized controlled trial,1.6,0.6628889128597066,0.6628889128597066,"['vs', 'trial']","{""comparative_terms"": [""vs""], ""study_context"": [""trial""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.4143055705373166, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6628889128597066, 'final_confidence': 0.6628889128597066}"
med:pmid:39352849,med:pmid:39352849:sec:abstract:sent:4,enalapril,ACEI,sacubitril_valsartan,angiotensin receptor neprilysin inhibitor,"Owing to its particular pathophysiology unlike another etiologies of heart failure, in CCM angiotensin-converting enzyme inhibitors (ACEI), angiotensin II type I receptor blockers (ARB), and angiotensin receptor neprilysin inhibitor (ARNI) are not recommended.",2024-09-27,,abstract,4,1,0.4111703728850134,review,0.9,0.37005333559651205,0.37005333559651205,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.4111703728850134, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.37005333559651205, 'final_confidence': 0.37005333559651205}"
med:pmid:39327768,med:pmid:39327768:sec:results:sent:10,enalapril,ACEis,sacubitril_valsartan,ARNIs,"At discharge, the proportions of patients on beta-blockers, angiotensin-converting enzyme inhibitors (ACEis)/angiotensin receptor blockers (ARBs)/angiotensin receptor/neprilysin inhibitors (ARNIs) and mineralocorticoid receptor antagonists (MRAs) were 78% (n = 144), 58% (n = 107) and 55% (n = 101), respectively.",2024-09-26,,results,10,1,0.41039028756404045,other,1.0,0.41039028756404045,0.41039028756404045,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.41039028756404045, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.41039028756404045, 'final_confidence': 0.41039028756404045}"
med:pmid:39319469,med:pmid:39319469:sec:conclusion:sent:11,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In this study, sacubitril/valsartan did not show superiority over enalapril in the treatment of children with HF attributable to systemic LVSD using the prespecified global rank end point.",2024-09-25,,conclusion,11,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39319469,med:pmid:39319469:sec:introduction:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"PANORAMA-HF (Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor for the Medical Treatment of Pediatric HF) is a randomized, double-blind trial that evaluated the pharmacokinetics and pharmacodynamics (PK/PD), safety, and efficacy of sacubitril/valsartan versus enalapril in children 1 month to <18 years of age with HF attributable to systemic left ventricular systolic dysfunction (LVSD).",2024-09-25,,introduction,3,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,"['versus', 'safety', 'double-blind', 'randomized', 'trial']","{""comparative_terms"": [""versus""], ""risk_terms"": [""safety""], ""study_context"": [""double-blind"", ""randomized"", ""trial""]}","['comparative_terms', 'risk_terms', 'study_context']",[],,,,[],,,,POS,2.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39319469,med:pmid:39319469:sec:methods:sent:4,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Children with HF attributable to LVSD were randomized to sacubitril/valsartan versus enalapril to assess the efficacy and safety of sacubitril/valsartan at 52 weeks of follow-up.,2024-09-25,,methods,4,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,"['versus', 'safety', 'randomized']","{""comparative_terms"": [""versus""], ""risk_terms"": [""safety""], ""study_context"": [""randomized""]}","['comparative_terms', 'risk_terms', 'study_context']",[],,,,[],,,,POS,2.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39319469,med:pmid:39319469:sec:methods:sent:5,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The primary end point of the study was to determine whether sacubitril/valsartan was superior to enalapril for the treatment of pediatric patients with HF attributable to systemic LVSD, assessed using a primary global rank end point consisting of ranking patients from worst to best on the basis of clinical events such as death, listing for urgent heart transplant, mechanical life support requirement, worsening HF, New York Heart Association (NYHA)/Ross class, Patient Global Impression of Severity (PGIS), and Pediatric Quality of Life Inventory physical functioning domain.",2024-09-25,,methods,5,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39319469,med:pmid:39319469:sec:results:sent:10,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Adverse events were similar between treatment arms (incidence: sacubitril/valsartan, 88.8%; enalapril, 87.8%), and the safety profile of sacubitril/valsartan was acceptable in children.",2024-09-25,,results,10,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,"['adverse events', 'safety', 'safety profile']","{""risk_terms"": [""adverse events"", ""safety"", ""safety profile""]}",['risk_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39319469,med:pmid:39319469:sec:results:sent:7,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"A total of 375 children (mean age, 8.1±5.6 years; 52% female) were randomized to sacubitril/valsartan (N=187) or enalapril (N=188).",2024-09-25,,results,7,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,['randomized'],"{""study_context"": [""randomized""]}",['study_context'],[],,,,[],evidence,clinical_trial,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39320292,med:pmid:39320292:sec:conclusion:sent:12,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Although both asymptomatic and symptomatic hypotension during treatment with sacubitril/valsartan or enalapril were associated with worse outcomes, the benefits of sacubitril/valsartan were maintained (or even enhanced) in patients experiencing hypotension.",2024-09-25,,conclusion,12,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39320292,med:pmid:39320292:sec:introduction:sent:2,enalapril,ACEI,sacubitril_valsartan,ARNI,This study sought to examine the association between asymptomatic vs symptomatic hypotension and outcomes in PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure).,2024-09-25,,introduction,2,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39320292,med:pmid:39320292:sec:methods:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In a post hoc analysis of PARADIGM-HF, the efficacy and safety of sacubitril/valsartan compared to enalapril were estimated using time-updated Cox proportional hazards models.",2024-09-25,,methods,3,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39320292,med:pmid:39320292:sec:results:sent:10,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,The safety of sacubitril/valsartan vs enalapril was also maintained regardless of the occurrence of hypotension.,2024-09-25,,results,10,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,"['vs', 'safety']","{""comparative_terms"": [""vs""], ""risk_terms"": [""safety""]}","['comparative_terms', 'risk_terms']",[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39320292,med:pmid:39320292:sec:results:sent:11,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Discontinuation of randomized treatment was less common with sacubitril/valsartan vs enalapril in patients experiencing asymptomatic and symptomatic hypotension.,2024-09-25,,results,11,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,"['vs', 'randomized']","{""comparative_terms"": [""vs""], ""study_context"": [""randomized""]}","['comparative_terms', 'study_context']",[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39320292,med:pmid:39320292:sec:results:sent:9,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"However, the effect of sacubitril/valsartan on the primary outcome was not diminished in patients experiencing hypotension compared to those who did not: the HR for sacubitril/valsartan vs enalapril was 0.80 (95% CI: 0.72-0.89) for no hypotension, 0.87 (95% CI: 0.70-1.08) for asymptomatic hypotension, and 0.51 (95% CI: 0.38-0.69) for symptomatic hypotension (P<sub>interaction</sub> = 0.01), and this was also true for cardiovascular and all-cause deaths.",2024-09-25,,results,9,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,"['compared to', 'vs']","{""comparative_terms"": [""compared to"", ""vs""], ""claim_strength_terms"": {""confirmatory"": [""p<""]}}","['comparative_terms', 'claim_strength:confirmatory']",[],,,,[],comparative,comparative_efficacy,0.39999999999999997,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39318024,med:pmid:39318024:sec:results:sent:7,enalapril,ACEi,sacubitril_valsartan,ARNi,"The first drug class initiated in HFrEF was angiotensin-converting enzyme inhibitors/angiotensin receptor-neprilysin inhibitor (ACEi/ARNi) (91.2%), beta-blockers (BB) (73.8%), mineralocorticoid receptor antagonists (MRAs) (53.4%), and sodium-glucose cotransporter 2 (SGLT2) inhibitors (48.1%).",2024-09-24,,results,7,1,0.4088345541211638,other,1.0,0.4088345541211638,0.4088345541211638,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.4088345541211638, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.4088345541211638, 'final_confidence': 0.4088345541211638}"
med:pmid:39318024,med:pmid:39318024:sec:results:sent:8,enalapril,ACEi,sacubitril_valsartan,ARNi,"The combination ACEi/ARNi + MRA+ BB was preferred by 39.3% of physicians, ACEi/ARNi + SGLT2 inhibitors + BB by 33.3%, and ACEi/ARNi + BB by 22.2%.",2024-09-24,,results,8,1,0.4088345541211638,other,1.0,0.4088345541211638,0.4088345541211638,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4088345541211638, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.4088345541211638, 'final_confidence': 0.4088345541211638}"
med:pmid:39284545,med:pmid:39284545:sec:conclusion:sent:9,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Incidence of hypotension-related AEs was higher in the sacubitril/valsartan versus enalapril group but did not affect risk of cardiovascular death or HF hospitalization, which was similar between treatment groups.",2024-09-14,,conclusion,9,1,0.4011439046284056,randomized controlled trial,1.6,0.641830247405449,0.641830247405449,"['versus', 'aes', 'risk']","{""comparative_terms"": [""versus""], ""risk_terms"": [""aes"", ""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],comparative,comparative_safety,0.9,POS,1.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4011439046284056, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.641830247405449, 'final_confidence': 0.641830247405449}"
med:pmid:39284545,med:pmid:39284545:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The PARALLEL-HF trial showed that treatment with sacubitril/valsartan resulted in more symptomatic hypotension versus enalapril in Japanese patients with heart failure (HF) and reduced ejection fraction, similar to PARADIGM-HF.",2024-09-14,,introduction,1,1,0.4011439046284056,randomized controlled trial,1.6,0.641830247405449,0.641830247405449,"['similar to', 'versus', 'trial']","{""comparative_terms"": [""similar to"", ""versus""], ""study_context"": [""trial""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4011439046284056, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.641830247405449, 'final_confidence': 0.641830247405449}"
med:pmid:39284545,med:pmid:39284545:sec:methods:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"This post-hoc analysis characterized hypotension-related adverse events (AEs) and their effects on efficacy using data from PARALLEL-HF, in which patients received sacubitril/valsartan 200 mg twice daily or enalapril 10 mg twice daily.",2024-09-14,,methods,3,1,0.4011439046284056,randomized controlled trial,1.6,0.641830247405449,0.641830247405449,"['adverse events', 'aes']","{""risk_terms"": [""adverse events"", ""aes""], ""claim_strength_terms"": {""suggestive"": [""post-hoc""]}}","['risk_terms', 'claim_strength:suggestive']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4011439046284056, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.641830247405449, 'final_confidence': 0.641830247405449}"
med:pmid:39284545,med:pmid:39284545:sec:results:sent:4,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Of 223 patients, 28.2 % experienced hypotension-related AEs and incidence was higher with sacubitril/valsartan versus enalapril (hazard ratio, 2.2; 95 % CI, 1.3-3.8; p = 0.0027).",2024-09-14,,results,4,1,0.4011439046284056,randomized controlled trial,1.6,0.641830247405449,0.641830247405449,"['versus', 'aes']","{""comparative_terms"": [""versus""], ""risk_terms"": [""aes""]}","['comparative_terms', 'risk_terms']",[],,,,[],comparative,comparative_safety,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4011439046284056, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.641830247405449, 'final_confidence': 0.641830247405449}"
med:pmid:39284545,med:pmid:39284545:sec:results:sent:5,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"However, reduction in mean systolic blood pressure from baseline to study end did not significantly differ (sacubitril/valsartan: -2.2 mmHg vs enalapril: -1.3 mmHg; p = 0.6895).",2024-09-14,,results,5,1,0.4011439046284056,randomized controlled trial,1.6,0.641830247405449,0.641830247405449,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.4011439046284056, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.641830247405449, 'final_confidence': 0.641830247405449}"
med:pmid:39284545,med:pmid:39284545:sec:results:sent:7,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Hypotension-related AEs leading to treatment discontinuation were not significantly different for sacubitril/valsartan versus enalapril (3.4 % vs 6.9 %, p = 0.5957).",2024-09-14,,results,7,1,0.4011439046284056,randomized controlled trial,1.6,0.641830247405449,0.641830247405449,"['versus', 'vs', 'aes']","{""comparative_terms"": [""versus"", ""vs""], ""risk_terms"": [""aes""]}","['comparative_terms', 'risk_terms']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4011439046284056, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.641830247405449, 'final_confidence': 0.641830247405449}"
med:pmid:39284545,med:pmid:39284545:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Reduction in risk of cardiovascular death or HF hospitalization was similar with sacubitril/valsartan versus enalapril in patients with or without hypotension-related AEs.,2024-09-14,,results,8,1,0.4011439046284056,randomized controlled trial,1.6,0.641830247405449,0.641830247405449,"['versus', 'aes', 'risk']","{""comparative_terms"": [""versus""], ""risk_terms"": [""aes"", ""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],comparative,comparative_safety,0.9,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4011439046284056, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.641830247405449, 'final_confidence': 0.641830247405449}"
med:pmid:39284545,med:pmid:39284545:sec:title:sent:0,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Incidence and risk factors of hypotension-related adverse events among Japanese patients with heart failure receiving sacubitril/valsartan or enalapril: Results from the PARALLEL-HF study.,2024-09-14,,results,0,1,0.4011439046284056,randomized controlled trial,1.6,0.641830247405449,0.641830247405449,"['adverse events', 'risk']","{""risk_terms"": [""adverse events"", ""risk""]}",['risk_terms'],[],,,,[],,,,NEG,-3.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.4011439046284056, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.641830247405449, 'final_confidence': 0.641830247405449}"
med:pmid:39404722,med:pmid:39404722:sec:results:sent:4,enalapril,ACEi,sacubitril_valsartan,ARNI,"The present study demonstrates that the addition of dapagliflozin is beneficial in terms of clinical and cost-effectiveness, regardless of the initial regimen (angiotensin receptor-neprilysin inhibitors [ARNI] or angiotensin-converting enzyme inhibitors [ACEi]/angiotensin II receptor blockers [ARB]) of standard drug therapy for HFrEF and in all cases leads to an increase in life expectancy, a decrease in the number of hospitalizations and emergency visits due to CHF, as well as cardiovascular mortality.",2024-09-14,,results,4,1,0.4011439046284056,other,1.0,0.4011439046284056,0.4011439046284056,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.4011439046284056, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.4011439046284056, 'final_confidence': 0.4011439046284056}"
med:pmid:39404722,med:pmid:39404722:sec:results:sent:6,enalapril,ACEi,sacubitril_valsartan,ARNI,"In the case of adding dapagliflozin the values of the additional cost of an added year of life in the 3 considered standard therapy options (ARNI or ACEi/ARB, only ACEi/ARB and only ARNI) were 291,256, 279,571 and 338,374 rubles respectively.",2024-09-14,,results,6,1,0.4011439046284056,other,1.0,0.4011439046284056,0.4011439046284056,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.4011439046284056, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.4011439046284056, 'final_confidence': 0.4011439046284056}"
med:pmid:39260836,med:pmid:39260836:sec:introduction:sent:2,enalapril,ACE inhibitors,sacubitril_valsartan,Sacubitril/valsartan,"Sacubitril/valsartan, a combination drug consisting of a neprilysin inhibitor and an angiotensin receptor blocker (ARB), has shown a greater improvement in the prognosis of HF than ACE inhibitors (ACEI) or ARB.",2024-09-10,,introduction,2,1,0.3981083059846422,other,1.0,0.3981083059846422,0.3981083059846422,[],"{""claim_strength_terms"": {""suggestive"": [""greater improvement""]}}",['claim_strength:suggestive'],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.3981083059846422, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3981083059846422, 'final_confidence': 0.3981083059846422}"
med:pmid:39260836,med:pmid:39260836:sec:introduction:sent:3,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"Recent studies have found that ACEI/ARB or sacubitril/valsartan can increase flow-mediated dilation (FMD) and reduce pulse wave velocity (PWV), which are independent predictors of cardiovascular events and HF prognosis.",2024-09-10,,introduction,3,1,0.3981083059846422,other,1.0,0.3981083059846422,0.3981083059846422,[],,[],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.3981083059846422, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3981083059846422, 'final_confidence': 0.3981083059846422}"
med:pmid:39260836,med:pmid:39260836:sec:introduction:sent:4,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,The purpose of this study is to assess and compare the effect of sacubitril/valsartan and ACEI/ARB on FMD and PWV using meta-analysis and further provide a reference for the role of sacubitril/valsartan in the treatment of HF.,2024-09-10,,introduction,4,1,0.3981083059846422,other,1.0,0.3981083059846422,0.3981083059846422,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.3981083059846422, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3981083059846422, 'final_confidence': 0.3981083059846422}"
med:pmid:39260836,med:pmid:39260836:sec:introduction:sent:5,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"<h4>Methods and analysis</h4> Clinical randomised controlled trials investigating the effect of sacubitril/valsartan and/or ACEI/ARB on FMD and PWV in patients with HF will be searched in the relevant database, including PubMed, Web of Science, Embase, Cochrane Library and China's National Knowledge Infrastructure up to January 2024.",2024-09-10,,introduction,5,1,0.3981083059846422,other,1.0,0.3981083059846422,0.3981083059846422,['randomised'],"{""study_context"": [""randomised""]}",['study_context'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.3981083059846422, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3981083059846422, 'final_confidence': 0.3981083059846422}"
med:pmid:39260836,med:pmid:39260836:sec:title:sent:0,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,Comparative effects of sacubitril/valsartan and ACEI/ARB on endothelial function and arterial stiffness in patients with heart failure: a protocol for systematic review and meta-analysis.,2024-09-10,,introduction,0,1,0.3981083059846422,other,1.0,0.3981083059846422,0.3981083059846422,"['meta-analysis', 'review', 'systematic review']","{""study_context"": [""meta-analysis"", ""review"", ""systematic review""]}",['study_context'],[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.3981083059846422, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3981083059846422, 'final_confidence': 0.3981083059846422}"
med:pmid:39264627,med:pmid:39264627:sec:conclusion:sent:14,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"In this cohort study, sacubitril/valsartan treatment was associated with a potential kidney function benefit in patients with mHTN-associated TMA compared with ACEI/ARB treatment.",2024-09-03,,conclusion,14,1,0.3928511788004144,other,1.0,0.3928511788004144,0.3928511788004144,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.3928511788004144, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3928511788004144, 'final_confidence': 0.3928511788004144}"
med:pmid:39264627,med:pmid:39264627:sec:introduction:sent:2,enalapril,ACEI,sacubitril_valsartan,ARNI,"To evaluate the kidney outcomes of angiotensin receptor-neprilysin inhibitor (ARNI), specifically sacubitril/valsartan, vs angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy for patients with mHTN-associated TMA.",2024-09-03,,introduction,2,1,0.3928511788004144,other,1.0,0.3928511788004144,0.3928511788004144,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.3928511788004144, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3928511788004144, 'final_confidence': 0.3928511788004144}"
med:pmid:39264627,med:pmid:39264627:sec:results:sent:10,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"Among the 217 patients (mean [SD] age, 35.9 [8.8] years; 188 men [86.6%]) included in the study, 66 (30.4%) received sacubitril/valsartan and 151 (69.6%) received ACEI/ARBs at baseline.",2024-09-03,,results,10,1,0.3928511788004144,other,1.0,0.3928511788004144,0.3928511788004144,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.3928511788004144, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3928511788004144, 'final_confidence': 0.3928511788004144}"
med:pmid:39264627,med:pmid:39264627:sec:results:sent:11,enalapril,ACEI,sacubitril_valsartan,Sacubitril/valsartan,"Sacubitril/valsartan treatment was associated with shorter time to the primary outcome compared with ACEI/ARB treatment (20 of 63 [31.7%] vs 38 of 117 [32.5%]; adjusted hazard ratio [aHR], 1.85; 95% CI, 1.05-3.23).",2024-09-03,,results,11,1,0.3928511788004144,other,1.0,0.3928511788004144,0.3928511788004144,"['compared with', 'vs']","{""comparative_terms"": [""compared with"", ""vs""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.39999999999999997,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.3928511788004144, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3928511788004144, 'final_confidence': 0.3928511788004144}"
med:pmid:39264627,med:pmid:39264627:sec:results:sent:12,enalapril,ACEI,sacubitril_valsartan,Sacubitril/valsartan,"Sacubitril/valsartan treatment was independently associated with shorter time to a 15% increase in eGFR (15 of 46 [32.6%] vs 46 of 83 [55.4%]; aHR, 2.13; 95% CI, 1.09-4.17) and kidney survival free from dialysis (11 of 23 [47.8%] vs 16 of 57 [28.1%]; aHR, 2.63; 95% CI, 1.15-5.88) compared with ACEI/ARB treatment.",2024-09-03,,results,12,1,0.3928511788004144,other,1.0,0.3928511788004144,0.3928511788004144,"['compared with', 'vs']","{""comparative_terms"": [""compared with"", ""vs""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.39999999999999997,POS,1.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.3928511788004144, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3928511788004144, 'final_confidence': 0.3928511788004144}"
med:pmid:39264627,med:pmid:39264627:sec:results:sent:6,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,<h4>Exposures</h4> Treatment with sacubitril/valsartan or ACEI/ARBs during hospitalization and after discharge.,2024-09-03,,results,6,1,0.3928511788004144,other,1.0,0.3928511788004144,0.3928511788004144,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.3928511788004144, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3928511788004144, 'final_confidence': 0.3928511788004144}"
med:pmid:39264627,med:pmid:39264627:sec:results:sent:9,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,Propensity score matching (PSM) and Cox proportional hazards regression analysis were used to evaluate the association between sacubitril/valsartan and ACEI/ARB therapy with kidney recovery outcomes.,2024-09-03,,results,9,1,0.3928511788004144,other,1.0,0.3928511788004144,0.3928511788004144,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.3928511788004144, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3928511788004144, 'final_confidence': 0.3928511788004144}"
med:pmid:39387766,med:pmid:39387766:sec:conclusion:sent:13,enalapril,ACEI,sacubitril_valsartan,ARNI,Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF]; NCT01035255; Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711).,2024-08-31,,conclusion,13,1,0.39061942959046086,randomized controlled trial,1.6,0.6249910873447374,0.6249910873447374,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.39061942959046086, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6249910873447374, 'final_confidence': 0.6249910873447374}"
med:pmid:39387766,med:pmid:39387766:sec:methods:sent:3,enalapril,ACEI,sacubitril_valsartan,ARNI,"PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) and PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction) were global, randomized clinical trials testing sacubitril/valsartan against a renin-angiotensin system inhibitor (RASi) (enalapril or valsartan, respectively) in patients with HF and left ventricular ejection fraction ≤40% (PARADIGM-HF) or left ventricular ejection fraction ≥45% (PARAGON-HF).",2024-08-31,,methods,3,1,0.39061942959046086,randomized controlled trial,1.6,0.6249910873447374,0.6249910873447374,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.39061942959046086, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6249910873447374, 'final_confidence': 0.6249910873447374}"
med:pmid:39262640,med:pmid:39262640:sec:introduction:sent:2,enalapril,ACEi,sacubitril_valsartan,ARNI,This study aimed to investigate the prevalence of influenza vaccination among Japanese patients with HF enrolled in the PARALLEL-HF (Prospective comparison of ARNI with ACEi to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) trial and the association between receiving influenza vaccination and cardiovascular events including death or HF hospitalization.,2024-08-29,,introduction,2,1,0.38913864476570686,other,1.0,0.38913864476570686,0.38913864476570686,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.38913864476570686, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.38913864476570686, 'final_confidence': 0.38913864476570686}"
med:pmid:39262640,med:pmid:39262640:sec:results:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In PARALLEL-HF, in which 223 patients with HF and reduced ejection fraction (HFrEF) were randomized to the angiotensin-receptor neprilysin inhibitor (sacubitril/valsartan) or enalapril, 97 (43%) received influenza vaccination.",2024-08-29,,results,3,1,0.38913864476570686,other,1.0,0.38913864476570686,0.38913864476570686,['randomized'],"{""study_context"": [""randomized""]}",['study_context'],[],,,,[],evidence,clinical_trial,0.7,POS,1.0,lexicon_v1,2026-01-08T18:51:51.578298+00:00,"{'recency_weight': 0.38913864476570686, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.38913864476570686, 'final_confidence': 0.38913864476570686}"
med:pmid:39186181,med:pmid:39186181:sec:introduction:sent:2,enalapril,ACEi,sacubitril_valsartan,ARNI,"Since ARNI and SGLT2i were introduced to treat heart failure (HF), its therapeutic regimen has modernized from previous treatment with beta-blocker (BB) and angiotensin-converting enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB) with mineralocorticoid receptor antagonist (MRA) as added-on in HF with reduced ejection fraction (HFrEF).",2024-08-26,,introduction,2,1,0.3869279860993128,observational study,1.2,0.4643135833191753,0.4643135833191753,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.3869279860993128, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.4643135833191753, 'final_confidence': 0.4643135833191753}"
med:pmid:39186181,med:pmid:39186181:sec:methods:sent:5,enalapril,ACEi,sacubitril_valsartan,ARNI,"Patients received either conventional (BB, ACEi/ARB, with/without MRA, n = 20,140) or modern (BB, ACEi/ARB, MRA, SGLT2i or BB, ARNI, MRA with/without SGLT2i, n = 709) treatment at the index visit.",2024-08-26,,methods,5,1,0.3869279860993128,observational study,1.2,0.4643135833191753,0.4643135833191753,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.3869279860993128, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.4643135833191753, 'final_confidence': 0.4643135833191753}"
med:pmid:39156077,med:pmid:39156077:sec:results:sent:9,enalapril,ACEI,sacubitril_valsartan,ARNI,"The optimal independent predictors for all-cause mortality (<i>APSELNH: A: angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitor (ACEI/ARB/ARNI), P: percutaneous coronary intervention/coronary artery bypass graft (PCI/CABG), S: stroke, E: eGFR, L: lg of NT-proBNP</i>, <i>N: NYHA, H: healthcare</i>) were incorporated into the dynamic nomogram.",2024-08-13,,results,9,1,0.3774926730853985,other,1.0,0.3774926730853985,0.3774926730853985,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.3774926730853985, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3774926730853985, 'final_confidence': 0.3774926730853985}"
med:pmid:39220717,med:pmid:39220717:sec:results:sent:5,enalapril,ACEI,sacubitril_valsartan,ARNI,"In this overall cohort, prior to admission ACEI/ARB/ARNI (45.6 % vs 48.1 %, p < 0.0001) and BB (56.9 % vs 62.4 %, p < 0.0001) use was lower among admitted HFrEF patients during the pandemic when compared to the year prior.",2024-08-02,,results,5,1,0.3696888819674141,other,1.0,0.3696888819674141,0.3696888819674141,"['compared to', 'vs', 'combination', 'cohort']","{""comparative_terms"": [""compared to"", ""vs""], ""combination"": [""acei/arb/arni""], ""study_context"": [""cohort""]}","['comparative_terms', 'relationship:combination', 'study_context']",[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.3696888819674141, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3696888819674141, 'final_confidence': 0.3696888819674141}"
med:pmid:39220717,med:pmid:39220717:sec:results:sent:6,enalapril,ACEI,sacubitril_valsartan,ARNI,"Rates of ACEI/ARB/ARNI, MRA, and triple therapy (ACE/ARB/ARNI + BB + MRA) prescription at discharge were higher during the pandemic compared to the year prior.",2024-08-02,,results,6,1,0.3696888819674141,other,1.0,0.3696888819674141,0.3696888819674141,"['compared to', 'combination']","{""comparative_terms"": [""compared to""], ""combination"": [""acei/arb/arni"", ""triple therapy""]}","['comparative_terms', 'relationship:combination']",[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.3696888819674141, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3696888819674141, 'final_confidence': 0.3696888819674141}"
med:pmid:38513366,med:pmid:38513366:sec:conclusion:sent:10,enalapril,ACEi,sacubitril_valsartan,ARNI,"Beta-blockers, ACEi/ARB/ARNI, and SGLT2i were independently associated with a lower risk of all-cause mortality in patients with HFmrEF, specifically when applied as combined 'HF triple therapy'.",2024-08-01,,conclusion,10,1,0.36898749663138863,other,1.0,0.36898749663138863,0.36898749663138863,"['combination', 'risk']","{""combination"": [""acei/arb/arni"", ""triple therapy""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['relationship:combination', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],positioning,combination,0.85,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.36898749663138863, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.36898749663138863, 'final_confidence': 0.36898749663138863}"
med:pmid:38513366,med:pmid:38513366:sec:results:sent:4,enalapril,ACEi,sacubitril_valsartan,ARNI,"The prognostic value of treatment with beta-blockers (BB), angiotensin-converting enzyme inhibitors, receptor blockers, or receptor-neprilysin inhibitor (ACEi/ARB/ARNI), mineralocorticoid receptor antagonists (MRA), and sodium-glucose-linked transport protein 2 inhibitors (SGLT2i) was investigated for all-cause mortality at 30 months (a median follow-up) and HF-related rehospitalization.",2024-08-01,,results,4,1,0.36898749663138863,other,1.0,0.36898749663138863,0.36898749663138863,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.36898749663138863, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.36898749663138863, 'final_confidence': 0.36898749663138863}"
med:pmid:38513366,med:pmid:38513366:sec:results:sent:6,enalapril,ACEi,sacubitril_valsartan,ARNI,"Treatment with BB [27.0 vs. 35.0%; hazard ratio (HR) = 0.737; 95% confidence interval (CI) 0.617-0.881; P = 0.001], ACEi/ARB/ARNI (25.9 vs. 37.6%; HR = 0.612; 95% CI 0.517-0.725; P = 0.001), and SGLT2i (11.9 vs. 29.5%; HR = 0.441; 95% CI 0.236-0.824; P = 0.010) was associated with a lower risk of 30-month all-cause mortality, which was still demonstrated after multivariable adjustment and propensity score matching.",2024-08-01,,results,6,1,0.36898749663138863,other,1.0,0.36898749663138863,0.36898749663138863,"['vs', 'combination', 'risk']","{""comparative_terms"": [""vs""], ""combination"": [""acei/arb/arni""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'relationship:combination', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],comparative,comparative_safety,0.7,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.36898749663138863, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.36898749663138863, 'final_confidence': 0.36898749663138863}"
med:pmid:38513366,med:pmid:38513366:sec:results:sent:9,enalapril,ACEi,sacubitril_valsartan,ARNI,"Finally, the lowest risk of long-term all-cause mortality was observed in patients with combined use of BB, ACEi/ARB/ARNI, and SGLT2i (HR = 0.456; 95% CI 0.227-0.916; P = 0.027).",2024-08-01,,results,9,1,0.36898749663138863,other,1.0,0.36898749663138863,0.36898749663138863,"['combination', 'risk']","{""combination"": [""acei/arb/arni""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['relationship:combination', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],comparative,comparative_efficacy,0.6000000000000001,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.36898749663138863, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.36898749663138863, 'final_confidence': 0.36898749663138863}"
med:pmid:39111953,med:pmid:39111953:sec:abstract:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"PARACHUTE-HF (Prevention And Reduction of Adverse outcomes in Chagasic Heart failUre Trial Evaluation) is an active-controlled, randomized, phase IV trial designed to evaluate the effect of sacubitril/valsartan 200 mg twice daily vs enalapril 10 mg twice daily added to standard of care treatment for HF.",2024-08-01,,abstract,3,1,0.36898749663138863,other,1.0,0.36898749663138863,0.36898749663138863,"['vs', 'add-on therapy', 'phase', 'phase iv', 'randomized', 'trial']","{""comparative_terms"": [""vs""], ""add-on therapy"": [""added to""], ""study_context"": [""phase"", ""phase iv"", ""randomized"", ""trial""], ""trial_phase_terms"": [""phase iv""]}","['comparative_terms', 'relationship:add-on therapy', 'study_context', 'trial_phase_terms']",[],add_on,add_on,backbone,['add_on_to'],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.36898749663138863, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.36898749663138863, 'final_confidence': 0.36898749663138863}"
med:pmid:39111953,med:pmid:39111953:sec:abstract:sent:7,enalapril,Enalapril,sacubitril_valsartan,Sacubitril/Valsartan,"Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC [PARACHUTE-HF]; NCT04023227).",2024-08-01,,abstract,7,1,0.36898749663138863,other,1.0,0.36898749663138863,0.36898749663138863,"['compared with', 'safety']","{""comparative_terms"": [""compared with""], ""risk_terms"": [""safety""]}","['comparative_terms', 'risk_terms']",[],,,,[],,,,POS,2.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.36898749663138863, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.36898749663138863, 'final_confidence': 0.36898749663138863}"
med:pmid:39111953,med:pmid:39111953:sec:title:sent:0,enalapril,Enalapril,sacubitril_valsartan,Sacubitril/Valsartan,Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy: Rationale and Design of the PARACHUTE-HF Trial.,2024-08-01,,title,0,1,0.36898749663138863,other,1.0,0.36898749663138863,0.36898749663138863,"['versus', 'trial']","{""comparative_terms"": [""versus""], ""study_context"": [""trial""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.36898749663138863, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.36898749663138863, 'final_confidence': 0.36898749663138863}"
med:pmid:39106509,med:pmid:39106509:sec:discussion:sent:9,enalapril,ACE inhibitors,sacubitril_valsartan,ARNI,"of prescribed pathogenetic therapy showed that in patients with HFrEF, the frequency of prescription of ACE inhibitors, â-blockers and MRA decreased (<i>p</i>=0.023, 006 and 0.01, respectively), and ARNI, on the contrary, increased with a decrease in GFR (<i>p</i>=0.026).",2024-07-30,,discussion,9,1,0.3675887155054508,other,1.0,0.3675887155054508,0.3675887155054508,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.3675887155054508, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3675887155054508, 'final_confidence': 0.3675887155054508}"
med:pmid:39105079,med:pmid:39105079:sec:conclusion:sent:12,enalapril,ACEI,sacubitril_valsartan,ARNI,"ARNI has proven effective in treating HFrEF patients; however, significant benefits were not observed in these patients with ESRD undergoing dialysis compared with ACEI/ARB in this real-world cohort.",2024-07-22,,conclusion,12,1,0.3620464162476564,other,1.0,0.3620464162476564,0.3620464162476564,"['compared with', 'cohort', 'real-world']","{""comparative_terms"": [""compared with""], ""study_context"": [""cohort"", ""real-world""], ""real_world_terms"": [""real-world""]}","['comparative_terms', 'study_context', 'real_world_terms']",[],,,,[],evidence,real_world,0.72,POS,2.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.3620464162476564, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3620464162476564, 'final_confidence': 0.3620464162476564}"
med:pmid:39105079,med:pmid:39105079:sec:introduction:sent:2,enalapril,ACEI,sacubitril_valsartan,ARNI,This study aimed to examine the real-world effects of ARNI vs. angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) in this subpopulation.,2024-07-22,,introduction,2,1,0.3620464162476564,other,1.0,0.3620464162476564,0.3620464162476564,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.3620464162476564, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3620464162476564, 'final_confidence': 0.3620464162476564}"
med:pmid:39105079,med:pmid:39105079:sec:methods:sent:3,enalapril,ACEI,sacubitril_valsartan,ARNI,"This multi-institutional, retrospective study identified 349 HFrEF patients with ESRD on dialysis, who initiated either ARNI or ACEI/ARB therapy.",2024-07-22,,methods,3,1,0.3620464162476564,other,1.0,0.3620464162476564,0.3620464162476564,['retrospective'],"{""study_context"": [""retrospective""], ""real_world_terms"": [""retrospective"", ""retrospective study""]}","['study_context', 'real_world_terms']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.3620464162476564, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3620464162476564, 'final_confidence': 0.3620464162476564}"
med:pmid:39105079,med:pmid:39105079:sec:results:sent:7,enalapril,ACEI,sacubitril_valsartan,ARNI,"Out of 349 patients screened, 89 were included in the final analysis (42 in the ARNI group and 47 in the ACEI/ARB group).",2024-07-22,,results,7,1,0.3620464162476564,other,1.0,0.3620464162476564,0.3620464162476564,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.3620464162476564, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3620464162476564, 'final_confidence': 0.3620464162476564}"
med:pmid:39105079,med:pmid:39105079:sec:results:sent:9,enalapril,ACEI,sacubitril_valsartan,ARNI,"The primary composite rate of HHF or mortality was 20.6 events per 100 patient-years in the ARNI group and 26.1 in the ACEI/ARB group; the adjusted hazard ratio was 0.98 (95% CI: 0.28-3.43, <i>P</i> = 0.97).",2024-07-22,,results,9,1,0.3620464162476564,other,1.0,0.3620464162476564,0.3620464162476564,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.3620464162476564, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3620464162476564, 'final_confidence': 0.3620464162476564}"
med:pmid:39020009,med:pmid:39020009:sec:abstract:sent:2,enalapril,ACE inhibitors,sacubitril_valsartan,angiotensin receptor neprilysin inhibitors,"To investigate the effect of angiotensin receptor neprilysin inhibitors (ARNIs) on the blood ketone body levels, 46 stable pre-heart failure (HF)/HF patients were studied, including 23 who switched from angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) to ARNIs (ARNI group) and 23 who continued treatment with ACE inhibitors or ARBs (control group).",2024-07-17,,abstract,2,1,0.35862499430724726,other,1.0,0.35862499430724726,0.35862499430724726,[],,[],[],switch,switch_destination,switch_source,['switch_from'],,,,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.35862499430724726, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.35862499430724726, 'final_confidence': 0.35862499430724726}"
med:pmid:39058824,med:pmid:39058824:sec:abstract:sent:14,enalapril,ACEI,sacubitril_valsartan,Sacubitril/valsartan,Sacubitril/valsartan for the treatment of HFrEF is associated with a significantly lower rate of all-cause readmission as well as HF readmissions compared to ACEI/ARB.,2024-07-01,,abstract,14,1,0.3478922218526699,other,1.0,0.3478922218526699,0.3478922218526699,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.3478922218526699, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3478922218526699, 'final_confidence': 0.3478922218526699}"
med:pmid:39058824,med:pmid:39058824:sec:abstract:sent:5,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,Eligible patients were adults (≥18 years old) with a confirmed diagnosis of HFrEF who were discharged on either sacubitril/valsartan or angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) in addition to the other recommended therapy for HFrEF.,2024-07-01,,abstract,5,1,0.3478922218526699,other,1.0,0.3478922218526699,0.3478922218526699,[],,[],[],add_on,add_on,backbone,['add_on_to'],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.3478922218526699, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3478922218526699, 'final_confidence': 0.3478922218526699}"
med:pmid:39058824,med:pmid:39058824:sec:abstract:sent:9,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"A total of 398 patients were included in our analysis; 199 (50.0%) received sacubitril/valsartan (group 1), and 199 (50.0%) received ACEI/ARB (group 2).",2024-07-01,,abstract,9,1,0.3478922218526699,other,1.0,0.3478922218526699,0.3478922218526699,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.3478922218526699, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.3478922218526699, 'final_confidence': 0.3478922218526699}"
med:pmid:38904251,med:pmid:38904251:sec:results:sent:3,enalapril,ACEI,sacubitril_valsartan,ARNI,"Baseline circulating protein concentrations significantly associated with the primary end point and the timing and occurrence of total heart failure hospitalization and cardiovascular death were identified by recurrent events regression, accounting for multiple testing, adjusted for age, sex, treatment, and anticoagulant use, and compared with published analyses in 2515 patients with heart failure with reduced ejection fraction from the PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) and ATMOSPHERE (Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-Mortality in Patients With Chronic Heart Failure) clinical trials.",2024-06-21,,results,3,1,0.3413479679177815,randomized controlled trial,1.6,0.5461567486684504,0.5461567486684504,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.3413479679177815, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.5461567486684504, 'final_confidence': 0.5461567486684504}"
med:pmid:38930091,med:pmid:38930091:sec:introduction:sent:8,enalapril,ACEI,sacubitril_valsartan,Sacubitril/Valsartan,"After adjusting for age, gender, smoking, hemoglobin (Hgb), use of SGLT2is at admission, use of Angiotensin-Converting Enzyme Inhibitors (ACEI-Is)/Angiotensin Receptor Blockers (ARBs) at discharge and Sacubitril/Valsartan at discharge, the aforementioned result remained significant (HR = 0.38; 95% CI: 0.19-0.73; <i>p</i> = 0.004).",2024-06-18,,introduction,8,1,0.339408803422855,other,1.0,0.339408803422855,0.339408803422855,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.339408803422855, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.339408803422855, 'final_confidence': 0.339408803422855}"
med:pmid:38842957,med:pmid:38842957:sec:conclusion:sent:11,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"These data support continuation of sacubitril/valsartan for heart failure treatment even when eGFR declines below this threshold (PARADIGM-HF [Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure], NCT01035255; and PARAGON-HF [Prospective Comparison of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction], NCT01920711).",2024-06-05,,conclusion,11,1,0.33113225477550345,randomized controlled trial,1.6,0.5298116076408056,0.5298116076408056,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.33113225477550345, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.5298116076408056, 'final_confidence': 0.5298116076408056}"
med:pmid:38811344,med:pmid:38811344:sec:conclusion:sent:14,enalapril,ACEI,sacubitril_valsartan,ARNI,Adding SGLT-2i to ARNI/ACEI + BB + MRA is beneficial for reversing cardiac remodeling.,2024-05-28,,conclusion,14,1,0.3261396258604658,review,0.9,0.2935256632744192,0.2935256632744192,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.3261396258604658, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.2935256632744192, 'final_confidence': 0.2935256632744192}"
med:pmid:38811344,med:pmid:38811344:sec:conclusion:sent:15,enalapril,ACEI,sacubitril_valsartan,ARNI,"The new quadruple drug ""ARNI + BB + MRA + SGLT-2i"" is superior to the golden triangle ""ACEI + BB + MRA"" in improving LVEF.",2024-05-28,,conclusion,15,1,0.3261396258604658,review,0.9,0.2935256632744192,0.2935256632744192,['superior'],"{""comparative_terms"": [""superior""]}",['comparative_terms'],[],alternative,disfavored,favored,['preferred_over'],comparative,comparative_efficacy,0.6,POS,1.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.3261396258604658, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.2935256632744192, 'final_confidence': 0.2935256632744192}"
med:pmid:38811344,med:pmid:38811344:sec:introduction:sent:1,enalapril,ACEIs,sacubitril_valsartan,Angiotensin receptor neprilysin inhibitors,"Angiotensin receptor neprilysin inhibitors (ARNIs), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers (BBs), and mineralocorticoid receptor antagonists (MRAs) are the cornerstones in treating heart failure with reduced ejection fraction (HFrEF).",2024-05-28,,introduction,1,1,0.3261396258604658,review,0.9,0.2935256632744192,0.2935256632744192,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.3261396258604658, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.2935256632744192, 'final_confidence': 0.2935256632744192}"
med:pmid:38811344,med:pmid:38811344:sec:results:sent:11,enalapril,ACEI,sacubitril_valsartan,ARNI,"ARNI + BB + MRA + SGLT-2i (5.83%, 95% CI: 0.53% to 11.14%) and ARNI + BB + MRA (3.83%, 95% CI: 0.72% to 6.90%) were superior to the traditional golden triangle ACEI + BB + MRA in improving LVEF.",2024-05-28,,results,11,1,0.3261396258604658,review,0.9,0.2935256632744192,0.2935256632744192,['superior'],"{""comparative_terms"": [""superior""]}",['comparative_terms'],[],alternative,disfavored,favored,['preferred_over'],comparative,comparative_efficacy,0.39999999999999997,POS,1.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.3261396258604658, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.2935256632744192, 'final_confidence': 0.2935256632744192}"
med:pmid:38783593,med:pmid:38783593:sec:conclusion:sent:17,enalapril,ACEis,sacubitril_valsartan,ARNis,"Beyond the well-established risk for hyperkalaemia, our preliminary results suggest a potentially negative impact of saltSubs on GDMT use, especially for ACEis/ARBs/ARNis in CHF management.",2024-05-23,,conclusion,17,1,0.32305753135136694,other,1.0,0.32305753135136694,0.32305753135136694,"['combination', 'risk']","{""combination"": [""gdmt""], ""risk_terms"": [""risk""], ""claim_strength_terms"": {""exploratory"": [""preliminary""]}}","['relationship:combination', 'risk_terms', 'claim_strength:exploratory']",[],,,,[],positioning,combination,0.85,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.32305753135136694, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.32305753135136694, 'final_confidence': 0.32305753135136694}"
med:pmid:38783593,med:pmid:38783593:sec:results:sent:12,enalapril,ACEi,sacubitril_valsartan,ARNi,"In the overall population, ACEi/ARB/ARNi use was less frequent in case of saltSub recommendations (74% vs. 82%, P = 0.012).",2024-05-23,,results,12,1,0.32305753135136694,other,1.0,0.32305753135136694,0.32305753135136694,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.32305753135136694, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.32305753135136694, 'final_confidence': 0.32305753135136694}"
med:pmid:38783593,med:pmid:38783593:sec:results:sent:15,enalapril,ACEi,sacubitril_valsartan,ARNi,The under-prescription of ACEi/ARB/ARNi was found when patients had EF < 40% (P = 0.029) and/or EF ≥ 40% (P = 0.043).,2024-05-23,,results,15,1,0.32305753135136694,other,1.0,0.32305753135136694,0.32305753135136694,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.32305753135136694, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.32305753135136694, 'final_confidence': 0.32305753135136694}"
med:pmid:38783593,med:pmid:38783593:sec:results:sent:8,enalapril,ACEis,sacubitril_valsartan,ARNis,"collection included baseline characteristics, the use and recommendations of saltSubs, and the use of GDMTs, which included (i) angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) or angiotensin receptor-neprilysin inhibitors (ARNis), (ii) mineralocorticoid receptor antagonists (MRAs), and/or (iii) beta-blockers (BBs).",2024-05-23,,results,8,1,0.32305753135136694,other,1.0,0.32305753135136694,0.32305753135136694,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.32305753135136694, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.32305753135136694, 'final_confidence': 0.32305753135136694}"
med:pmid:38792317,med:pmid:38792317:sec:abstract:sent:4,enalapril,ACEis,sacubitril_valsartan,ARNis,"Patients were classified into two groups according to a scoring scale determined by combination and doses of four types of HF agents (ACEis/ARBs/ARNis, BBs, MRAs, and SGLT2is) at discharge.",2024-05-08,,abstract,4,1,0.31398490843047655,other,1.0,0.31398490843047655,0.31398490843047655,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.31398490843047655, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.31398490843047655, 'final_confidence': 0.31398490843047655}"
med:pmid:38663899,med:pmid:38663899:sec:abstract:sent:2,enalapril,enalapril,sacubitril_valsartan,sacubitril valsartan,We report a case in which bilateral renal artery revascularisation allowed the safe reintroduction of enalapril (and subsequently sacubitril valsartan) in a patient with severe left ventricular systolic dysfunction.,2024-04-24,,abstract,2,1,0.30574715062600727,case report,0.7,0.21402300543820507,0.21402300543820507,[],,[],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.30574715062600727, 'study_type': 'case report', 'study_type_weight': 0.7, 'mention_count': 1, 'combined_weight': 0.21402300543820507, 'final_confidence': 0.21402300543820507}"
med:pmid:38639469,med:pmid:38639469:sec:results:sent:6,enalapril,ACEI,sacubitril_valsartan,ARNI,"In the nationwide panel, the proportion of patients with versus without WHFE receiving ≥50% of guideline-recommended dose on index visit was 35% versus 40% for beta blocker, 74% versus 83% for ACEI/ARB/ARNI, and 48% versus 49% for MRA.",2024-04-19,,results,6,1,0.3028577697001819,observational study,1.2,0.3634293236402183,0.3634293236402183,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.3028577697001819, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.3634293236402183, 'final_confidence': 0.3634293236402183}"
med:pmid:38639469,med:pmid:38639469:sec:results:sent:7,enalapril,ACEI,sacubitril_valsartan,ARNI,"The proportion of patients receiving ≥50% of guideline-recommended dose was lower in the GHS: 29% versus 34% for beta-blocker, 16% versus 31% for ACEI/ARB/ARNI, and 18% versus 22% for MRA.",2024-04-19,,results,7,1,0.3028577697001819,observational study,1.2,0.3634293236402183,0.3634293236402183,"['versus', 'combination']","{""comparative_terms"": [""versus""], ""combination"": [""acei/arb/arni""]}","['comparative_terms', 'relationship:combination']",[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.3028577697001819, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.3634293236402183, 'final_confidence': 0.3634293236402183}"
med:pmid:38635062,med:pmid:38635062:sec:abstract:sent:1,enalapril,ACEI,sacubitril_valsartan,ARNI,"Effects of angiotensin receptor/neprilysin inhibitors (ARNI) on ventricular remodeling in patients with heart failure, especially heart failure with reduced ejection fraction (HFrEF), are better than those of angiotensin-converting enzyme inhibitors (ACEI).",2024-04-18,,abstract,1,1,0.30228317844539865,randomized controlled trial,1.6,0.48365308551263786,0.48365308551263786,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.30228317844539865, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.48365308551263786, 'final_confidence': 0.48365308551263786}"
med:pmid:38621576,med:pmid:38621576:sec:methods:sent:3,enalapril,Angiotensin Converting Enzyme Inhibitor,sacubitril_valsartan,Angiotensin Receptor Neprilysin Inhibitor,"We conducted a cross-sectional study of adults with a diagnosis of HF and EF ≤40% with ≥2 outpatient encounters between January 1, 2017 and January 10, 2021, prescribed ≥1 of the following GDMT: 1) Beta Blocker, 2) Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker/Angiotensin Receptor Neprilysin Inhibitor, 3) Mineralocorticoid Receptor Antagonist, 4) Sodium Glucose Cotransporter-2 Inhibitor.",2024-04-14,,methods,3,1,0.29999569408895216,other,1.0,0.29999569408895216,0.29999569408895216,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.29999569408895216, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.29999569408895216, 'final_confidence': 0.29999569408895216}"
med:pmid:39076544,med:pmid:39076544:sec:abstract:sent:2,enalapril,ACEi,sacubitril_valsartan,ARNI,"There has been remarkable progress in the treatment of HF over recent years with the establishment of guideline-directed medical therapies including: (1) Beta-blockers, (2) renal angiotensin aldosterone system (RAAS) inhibition (i.e., angiotensin-converting enzyme inhibitor [ACEi], aldosterone receptor blocker [ARB] or angiotensin receptor-neprilysin inhibitor [ARNI]); (3) mineralocorticoid receptor antagonists (MRA), and (4) sodium-glucose cotransporter-2 inhibitors (SGLT2i).",2024-04-11,,abstract,2,1,0.29829144782624045,review,0.9,0.2684623030436164,0.2684623030436164,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.29829144782624045, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.2684623030436164, 'final_confidence': 0.2684623030436164}"
med:pmid:38597935,med:pmid:38597935:sec:introduction:sent:1,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,The objective of this meta-analysis is to determine how sacubitril/valsartan (SV) compares to equivalent and sub-equivalent angiotensin receptor blockers (ARB) or angiotensin-converting enzyme inhibitors (ACEI) in patients with heart failure with reduced ejection fraction (HFrEF).,2024-04-10,,introduction,1,1,0.2977255199404633,review,0.9,0.267952967946417,0.267952967946417,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.2977255199404633, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.267952967946417, 'final_confidence': 0.267952967946417}"
med:pmid:38588927,med:pmid:38588927:sec:methods:sent:4,enalapril,ACEI,sacubitril_valsartan,ARNI,PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) was a global randomized controlled trial evaluating sacubitril/valsartan vs enalapril in patients with heart failure with reduced ejection fraction (HFrEF).,2024-04-06,,methods,4,1,0.2954725250074299,randomized controlled trial,1.6,0.4727560400118878,0.4727560400118878,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.2954725250074299, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.4727560400118878, 'final_confidence': 0.4727560400118878}"
med:pmid:38573461,med:pmid:38573461:sec:methods:sent:10,enalapril,ACE inhibitor,sacubitril_valsartan,ARNI,"Comparison of patterns pre- and postindex HFH showed some increase in use of mineralocorticoid receptor antagonists (MRAs), angiotensin receptor-neprilysin inhibitor (ARNI), and triple therapy; use of angiotensin-converting enzyme (ACE) inhibitor/ angiotensin receptor blocker (ARB) plus beta-blockers remained constant/slightly declined; < 20% patients received triple therapy (ACE inhibitor/ARB plus beta-blocker plus MRA).",2024-04-04,,methods,10,1,0.2943524290828071,other,1.0,0.2943524290828071,0.2943524290828071,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.2943524290828071, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.2943524290828071, 'final_confidence': 0.2943524290828071}"
med:pmid:37917889,med:pmid:37917889:sec:conclusion:sent:12,enalapril,ACEIs,sacubitril_valsartan,Sacubitril/valsartan,"Sacubitril/valsartan may provide superior benefits in reducing heart failure hospitalization rates, NT-proBNP levels, and improving NYHA classification in patients with HFpEF compared to ACEIs and ARBs.",2024-04-01,,conclusion,12,1,0.29268024165789114,review,0.9,0.26341221749210203,0.26341221749210203,"['compared to', 'superior']","{""comparative_terms"": [""compared to"", ""superior""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.29268024165789114, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.26341221749210203, 'final_confidence': 0.26341221749210203}"
med:pmid:37917889,med:pmid:37917889:sec:introduction:sent:2,enalapril,ACEIs,sacubitril_valsartan,sacubitril/valsartan,"In this context, the objective of this meta-analysis is to evaluate the effectiveness of sacubitril/valsartan compared to angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in managing HFpEF.",2024-04-01,,introduction,2,1,0.29268024165789114,review,0.9,0.26341221749210203,0.26341221749210203,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.29268024165789114, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.26341221749210203, 'final_confidence': 0.26341221749210203}"
med:pmid:37917889,med:pmid:37917889:sec:methods:sent:4,enalapril,ACEIs,sacubitril_valsartan,sacubitril/valsartan,Randomized controlled trials comparing sacubitril/valsartan to ACEIs or ARBs in HFpEF patients were included.,2024-04-01,,methods,4,1,0.29268024165789114,review,0.9,0.26341221749210203,0.26341221749210203,['randomized'],"{""study_context"": [""randomized""]}",['study_context'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.29268024165789114, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.26341221749210203, 'final_confidence': 0.26341221749210203}"
med:pmid:37917889,med:pmid:37917889:sec:results:sent:8,enalapril,ACEIs,sacubitril_valsartan,Sacubitril/valsartan,"Sacubitril/valsartan substantially reduced heart failure hospitalization rates compared to ACEIs and ARBs, according to a total of six studies involving 5,201 participants (Relative Risk, 0.78; 95% CI, 0.65 to 0.85; P = .001).",2024-04-01,,results,8,1,0.29268024165789114,review,0.9,0.26341221749210203,0.26341221749210203,"['compared to', 'risk']","{""comparative_terms"": [""compared to""], ""risk_terms"": [""risk""]}","['comparative_terms', 'risk_terms']",[],,,,[],comparative,comparative_efficacy,0.39999999999999997,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.29268024165789114, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.26341221749210203, 'final_confidence': 0.26341221749210203}"
med:pmid:38644253,med:pmid:38644253:sec:abstract:sent:11,enalapril,ACEI,sacubitril_valsartan,angiotensin receptor neprilysin inhibitor,"Multivariate Cox proportional hazard regression analysis showed that increased left ventricular end-diastolic diameter (<i>HR</i>=1.21, 95%<i>CI</i>: 1.01-1.44, <i>P</i>=0.042), moderate or severe mitral regurgitation (<i>HR</i>=1.71, 95%<i>CI</i>: 1.19-2.47, <i>P</i>=0.004), increased ln (N-terminal pro-B-type natriuretic peptide) (<i>HR</i>=1.30, 95%<i>CI</i>: 1.10-1.54, <i>P</i>=0.002) were independent risk factors for dverse cardiovascular events in DCM patients, and angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB)/angiotensin receptor neprilysin inhibitor (ARNI) treatment (<i>HR</i>=0.45, 95%<i>CI</i>: 0.26-0.78, <i>P</i>=0.004) was independent protective factor.",2024-04-01,,abstract,11,1,0.29268024165789114,other,1.0,0.29268024165789114,0.29268024165789114,['risk'],"{""risk_terms"": [""risk""]}",['risk_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.29268024165789114, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.29268024165789114, 'final_confidence': 0.29268024165789114}"
med:pmid:38644253,med:pmid:38644253:sec:abstract:sent:14,enalapril,ACEI,sacubitril_valsartan,ARNI,"<b>Conclusion:</b> An increase in left ventricular end-diastolic diameter, moderate or severe mitral regurgitation, elevated N-terminal pro-B-type natriuretic peptide, and non use of ACEI/ARB/ARNI are independent predictors of cardiovascular events in DCM patients.",2024-04-01,,abstract,14,1,0.29268024165789114,other,1.0,0.29268024165789114,0.29268024165789114,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.29268024165789114, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.29268024165789114, 'final_confidence': 0.29268024165789114}"
med:pmid:38555468,med:pmid:38555468:sec:results:sent:10,enalapril,ACEI,sacubitril_valsartan,ARNI,"LASSO regression identified five important predictors: age, Killip classification, B-type natriuretic peptide precursor (NTpro-BNP), left ventricular ejection fraction (LVEF), and the usage of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors (ACEI/ARB/ARNI).",2024-03-30,,results,10,1,0.29157073089749014,other,1.0,0.29157073089749014,0.29157073089749014,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.29157073089749014, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.29157073089749014, 'final_confidence': 0.29157073089749014}"
med:pmid:38418004,med:pmid:38418004:sec:conclusion:sent:13,enalapril,ACE Inhibitor,sacubitril_valsartan,ARNI,Prospective ARNI vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI; NCT02924727).,2024-03-01,,conclusion,13,1,0.2759475063309733,randomized controlled trial,1.6,0.4415160101295573,0.4415160101295573,"['vs', 'trial']","{""comparative_terms"": [""vs""], ""study_context"": [""trial""]}","['comparative_terms', 'study_context']",[],,,,[],evidence,clinical_trial,0.7,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.2759475063309733, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.4415160101295573, 'final_confidence': 0.4415160101295573}"
med:pmid:38418004,med:pmid:38418004:sec:methods:sent:4,enalapril,ACE inhibitor,sacubitril_valsartan,ARNI,The PARADISE-MI (Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction) trial enrolled patients with AMI complicated by left ventricular dysfunction and/or pulmonary congestion and at least 1 risk-enhancing factor.,2024-03-01,,methods,4,1,0.2759475063309733,randomized controlled trial,1.6,0.4415160101295573,0.4415160101295573,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.2759475063309733, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.4415160101295573, 'final_confidence': 0.4415160101295573}"
med:pmid:38508844,med:pmid:38508844:sec:conclusion:sent:15,enalapril,Enalapril,sacubitril_valsartan,Sacubitril/Valsartan,"Comparison of Sacubitril/Valsartan Versus Enalapril on Effect of NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode [PIONEER-HF]; NCT02554890; Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event [HFpEF Decompensation] Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation [PARAGLIDE-HF]; NCT03988634).",2024-03-01,,conclusion,15,1,0.2759475063309733,randomized controlled trial,1.6,0.4415160101295573,0.4415160101295573,"['versus', 'safety', 'tolerability']","{""comparative_terms"": [""versus""], ""risk_terms"": [""safety"", ""tolerability""]}","['comparative_terms', 'risk_terms']",[],,,,[],comparative,comparative_efficacy,0.39999999999999997,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.2759475063309733, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.4415160101295573, 'final_confidence': 0.4415160101295573}"
med:pmid:38508844,med:pmid:38508844:sec:introduction:sent:2,enalapril,Enalapril,sacubitril_valsartan,sacubitril/valsartan,Data from randomized trials of sacubitril/valsartan in HF patients with EF ≤40% (PIONEER-HF [Comparison of Sacubitril/Valsartan Versus Enalapril on Effect of NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode] trial) and >40% (PARAGLIDE-HF [Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF] trial) following recent worsening heart failure (WHF) were pooled to examine treatment effect across the EF spectrum.,2024-03-01,,results,2,1,0.2759475063309733,randomized controlled trial,1.6,0.4415160101295573,0.4415160101295573,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.2759475063309733, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.4415160101295573, 'final_confidence': 0.4415160101295573}"
med:pmid:38508844,med:pmid:38508844:sec:methods:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The PIONEER-HF and PARAGLIDE-HF trials were double-blind, randomized trials of sacubitril/valsartan vs control therapy (enalapril or valsartan, respectively).",2024-03-01,,methods,3,1,0.2759475063309733,randomized controlled trial,1.6,0.4415160101295573,0.4415160101295573,"['vs', 'double-blind', 'randomized']","{""comparative_terms"": [""vs""], ""study_context"": [""double-blind"", ""randomized""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.2759475063309733, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.4415160101295573, 'final_confidence': 0.4415160101295573}"
med:pmid:38516430,med:pmid:38516430:sec:abstract:sent:10,enalapril,ACEis,sacubitril_valsartan,sacubitril/valsartan,"sacubitril/valsartan showed notable improvements compared to ACEis and ARBs in the following areas: reduction in NT-proBNP levels, prevention of further deterioration in renal function, and decreased hospitalizations for HF.",2024-02-19,,abstract,10,1,0.2702429275338945,review,0.9,0.24321863478050507,0.24321863478050507,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.2702429275338945, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.24321863478050507, 'final_confidence': 0.24321863478050507}"
med:pmid:38516430,med:pmid:38516430:sec:abstract:sent:4,enalapril,ACE inhibitors,sacubitril_valsartan,ARNIs,The purpose of this research is to present the most recent data regarding the efficacy and renal impact of ARNIs in the treatment of HF in comparison to ACE inhibitors and ARBs.,2024-02-19,,abstract,4,1,0.2702429275338945,review,0.9,0.24321863478050507,0.24321863478050507,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.2702429275338945, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.24321863478050507, 'final_confidence': 0.24321863478050507}"
med:pmid:38359813,med:pmid:38359813:sec:introduction:sent:1,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"Although several guidelines recommend that patients with heart failure with reduced ejection fraction (HFrEF) be treated with angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEIs/ARBs) or angiotensin receptor-neprilysin inhibitors (ARNIs), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 inhibitor (SGLT2i), there are still several gaps in their prescription and dosage in Colombia.",2024-02-15,,introduction,1,1,0.26819790315525294,observational study,1.2,0.3218374837863035,0.3218374837863035,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.26819790315525294, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.3218374837863035, 'final_confidence': 0.3218374837863035}"
med:pmid:38359813,med:pmid:38359813:sec:results:sent:7,enalapril,ACEI,sacubitril_valsartan,ARNIs,"Among those individuals, 88.9% were prescribed beta-blockers, 72.3% with ACEI/ARBs, 67.9% with MRAs, and 13.1% with ARNIs.",2024-02-15,,results,7,1,0.26819790315525294,observational study,1.2,0.3218374837863035,0.3218374837863035,[],,[],[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.26819790315525294, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.3218374837863035, 'final_confidence': 0.3218374837863035}"
med:pmid:38465175,med:pmid:38465175:sec:abstract:sent:2,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"Angiotensin receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin receptor-neprilysin inhibitors (ARNIs) such as sacubitril/valsartan have demonstrated promise in managing acute heart failure (HF).",2024-02-07,,abstract,2,1,0.26415416357104005,review,0.9,0.23773874721393604,0.23773874721393604,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.26415416357104005, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.23773874721393604, 'final_confidence': 0.23773874721393604}"
med:pmid:38465175,med:pmid:38465175:sec:abstract:sent:4,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"Hence, we conducted this review and meta-analysis, by adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines and aligned with European Society of Cardiology recommendations, to compare sacubitril/valsartan with traditional ACEI/ARB treatments for AMI.",2024-02-07,,abstract,4,1,0.26415416357104005,review,0.9,0.23773874721393604,0.23773874721393604,"['meta-analysis', 'review']","{""study_context"": [""meta-analysis"", ""review""]}",['study_context'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.26415416357104005, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.23773874721393604, 'final_confidence': 0.23773874721393604}"
med:pmid:38402552,med:pmid:38402552:sec:introduction:sent:2,enalapril,ACEi,sacubitril_valsartan,ARNI,"<h4>Hypothesis</h4> We aimed to assess the success of optimization, long-term applicability, and adherence of neurohormonal antagonist triple therapy (TT:RASi [ACEi/ARB/ARNI] + βB + MRA) according to the KD after a HF hospitalization and to investigate its impact on prognosis.",2024-02-01,,introduction,2,1,0.261161420475549,other,1.0,0.261161420475549,0.261161420475549,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.261161420475549, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.261161420475549, 'final_confidence': 0.261161420475549}"
med:pmid:38279516,med:pmid:38279516:sec:conclusion:sent:10,enalapril,angiotensin converting enzyme inhibitors,sacubitril_valsartan,ARNI,Increasing the proportion of patients receiving ARNI instead of angiotensin converting enzyme inhibitors as first-line treatment of HFrEF will lead to a considerable number of additional life years gained and prevented hospitalizations but with additional cost in terms of health care expenditure in Sweden and in the United Kingdom.,2024-01-26,,conclusion,10,1,0.25820258375925165,other,1.0,0.25820258375925165,0.25820258375925165,[],"{""line_of_therapy_terms"": [""first-line""]}",['line_of_therapy_terms'],[],,,,[],positioning,line_of_therapy,0.83,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.25820258375925165, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.25820258375925165, 'final_confidence': 0.25820258375925165}"
med:pmid:38356826,med:pmid:38356826:sec:conclusion:sent:6,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In CHF patients, the combination of LBBP with sacubitril/valsartan had a better therapeutic effect compared to LBBP with enalapril, with more effective improvement of the cardiopulmonary function, reduction of myocardial injury, and improvement in quality of life.",2024-01-01,,conclusion,6,1,0.24623063833027797,other,1.0,0.24623063833027797,0.24623063833027797,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,POS,5.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.24623063833027797, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.24623063833027797, 'final_confidence': 0.24623063833027797}"
med:pmid:38356826,med:pmid:38356826:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,To assess the efficacy of left bundle branch pacing (LBBP) combined with either sacubitril/valsartan or enalapril in the treatment of chronic heart failure (CHF).,2024-01-01,,introduction,1,1,0.24623063833027797,other,1.0,0.24623063833027797,0.24623063833027797,['combination'],"{""combination"": [""combined with""]}",['relationship:combination'],[],add_on,add_on,add_on,['combination_with'],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.24623063833027797, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.24623063833027797, 'final_confidence': 0.24623063833027797}"
med:pmid:38356826,med:pmid:38356826:sec:methods:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"We divided the data into two treatment groups for the analysis: 71 patients received LBBP combined with sacubitril/valsartan treatment (sacubitril/valsartan group), and 67 received LBBP combined with enalapril treatment (enalapril group).",2024-01-01,,methods,3,1,0.24623063833027797,other,1.0,0.24623063833027797,0.24623063833027797,['combination'],"{""combination"": [""combined with""]}",['relationship:combination'],[],add_on,add_on,add_on,['combination_with'],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.24623063833027797, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.24623063833027797, 'final_confidence': 0.24623063833027797}"
med:pmid:38356826,med:pmid:38356826:sec:title:sent:0,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Comparison of the efficacy of combining left bundle branch pacing with either sacubitril/valsartan or enalapril in the treatment of chronic heart failure: A retrospective observational analysis.,2024-01-01,,methods,0,1,0.24623063833027797,other,1.0,0.24623063833027797,0.24623063833027797,"['observational', 'retrospective']","{""study_context"": [""observational"", ""retrospective""], ""real_world_terms"": [""observational"", ""retrospective""]}","['study_context', 'real_world_terms']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.24623063833027797, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.24623063833027797, 'final_confidence': 0.24623063833027797}"
med:pmid:39033432,med:pmid:39033432:sec:abstract:sent:10,enalapril,ACEIs,sacubitril_valsartan,ARNI,<b>Conclusion:</b> Our study showed that ARNI resulted in a greater improvement in heart failure than ACEIs/ARBs in patients with HFrEF and moderate-to-severe CKD.,2024-01-01,,abstract,10,1,0.24623063833027797,other,1.0,0.24623063833027797,0.24623063833027797,[],"{""claim_strength_terms"": {""suggestive"": [""greater improvement""]}}",['claim_strength:suggestive'],['chronic kidney disease'],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.24623063833027797, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.24623063833027797, 'final_confidence': 0.24623063833027797}"
med:pmid:39033432,med:pmid:39033432:sec:abstract:sent:2,enalapril,ACEIs,sacubitril_valsartan,ARNI,We performed a retrospective study to compare the efficacy of ARNI with that of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) in patients with HFrEF and moderate-to-severe CKD.,2024-01-01,,abstract,2,1,0.24623063833027797,other,1.0,0.24623063833027797,0.24623063833027797,['retrospective'],"{""study_context"": [""retrospective""], ""real_world_terms"": [""retrospective"", ""retrospective study""]}","['study_context', 'real_world_terms']",['chronic kidney disease'],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.24623063833027797, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.24623063833027797, 'final_confidence': 0.24623063833027797}"
med:pmid:39033432,med:pmid:39033432:sec:abstract:sent:7,enalapril,ACEI,sacubitril_valsartan,ARNI,"<b>Results:</b> Compared with the ACEI/ARB group, the ARNI group, with 90.77% (59/65) in the lower target dose group, showed a lower rate of death due to cardiovascular disease (6.6% vs 0.9% after IPTW) and a lower incidence of rehospitalization (46.5% vs 30.4% after IPTW).",2024-01-01,,abstract,7,1,0.24623063833027797,other,1.0,0.24623063833027797,0.24623063833027797,"['compared with', 'vs']","{""comparative_terms"": [""compared with"", ""vs""]}",['comparative_terms'],['cardiovascular disease'],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.24623063833027797, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.24623063833027797, 'final_confidence': 0.24623063833027797}"
med:pmid:38764991,med:pmid:38764991:sec:abstract:sent:2,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,<b>Background:</b> The PARADIGM HF trial showed sacubitril/valsartan (SV) to be superior to enalapril in patients with reduced ejection fraction (HFrEF).,2023-12-06,,abstract,2,1,0.23436829380924173,review,0.9,0.21093146442831756,0.21093146442831756,"['superior', 'trial']","{""comparative_terms"": [""superior""], ""study_context"": [""trial""]}","['comparative_terms', 'study_context']",[],alternative,disfavored,favored,['preferred_over'],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.23436829380924173, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.21093146442831756, 'final_confidence': 0.21093146442831756}"
med:pmid:38040431,med:pmid:38040431:sec:introduction:sent:11,enalapril,ACEi,sacubitril_valsartan,ARNI,"During the study period, 33 606 (84%) patients had an active prescription of beta blocker, 32 626 (82%) had ACEi/ARB/ARNI, 11 611 (29%) MRA and 7472 (19%) SGLT2i.",2023-12-01,,introduction,11,1,0.23215345950460756,other,1.0,0.23215345950460756,0.23215345950460756,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.23215345950460756, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.23215345950460756, 'final_confidence': 0.23215345950460756}"
med:pmid:38040431,med:pmid:38040431:sec:introduction:sent:7,enalapril,ACEi,sacubitril_valsartan,angiotensin receptor neprilysin inhibitor,"<h4>Participants</h4> Patients seen at a large health system in New York City (NYC), who were >18 years old with diagnosis of HF or reduced ejection fraction (<40%) since 2017, had at least one clinical encounter between 1 April 2021 and 31 October 2022 and active prescriptions for any of the four GDMTs (beta-blocker, ACEi/angiotensin receptor blocker (ARB)/angiotensin receptor neprilysin inhibitor (ARNI), mineralocorticoid receptor antagonist (MRA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i)) during the study period.",2023-12-01,,introduction,7,1,0.23215345950460756,other,1.0,0.23215345950460756,0.23215345950460756,[],,[],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.23215345950460756, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.23215345950460756, 'final_confidence': 0.23215345950460756}"
med:pmid:38032698,med:pmid:38032698:sec:conclusion:sent:12,enalapril,ACEI,sacubitril_valsartan,ARNI,"Regarding optimal medical therapy, approximately a quarter of the patients still need to receive BB and ACEI/ARB/ARNI, less than half do not receive MRA, and more than two-thirds do not receive SGLT2i.",2023-11-30,,conclusion,12,1,0.2317130106835946,other,1.0,0.2317130106835946,0.2317130106835946,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.2317130106835946, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.2317130106835946, 'final_confidence': 0.2317130106835946}"
med:pmid:38032698,med:pmid:38032698:sec:results:sent:9,enalapril,ACEI,sacubitril_valsartan,ARNI,"The percentage of use of the four pharmacological pillars at the time of recruitment was 70.7% for beta-blockers (BB), 77.4% for angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB II)/angiotensin receptor-neprilysin inhibitor (ARNI), 56.8% for mineralocorticoid receptor antagonists (MRA), and 30.7% for sodium-glucose cotransporter type-2 inhibitors (SGLT2i).",2023-11-30,,results,9,1,0.2317130106835946,other,1.0,0.2317130106835946,0.2317130106835946,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.2317130106835946, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.2317130106835946, 'final_confidence': 0.2317130106835946}"
med:pmid:37933184,med:pmid:37933184:sec:results:sent:3,enalapril,ACE Inhibitor,sacubitril_valsartan,ARNI,Patients (n = 5661) included in the PARADISE MI trial (Prospective ARNI vs. ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI) were stratified according to MRA.,2023-11-29,,results,3,1,0.23127339749589232,other,1.0,0.23127339749589232,0.23127339749589232,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.23127339749589232, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.23127339749589232, 'final_confidence': 0.23127339749589232}"
med:pmid:38047039,med:pmid:38047039:sec:results:sent:14,enalapril,ACEI,sacubitril_valsartan,ARNI,"The utilization rate of ACEI/ARB/ARNI, β-blocker were high in management group.",2023-11-27,,results,14,1,0.2303966716818685,other,1.0,0.2303966716818685,0.2303966716818685,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.2303966716818685, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.2303966716818685, 'final_confidence': 0.2303966716818685}"
med:pmid:37933210,med:pmid:37933210:sec:conclusion:sent:11,enalapril,ACEi,sacubitril_valsartan,ARNI,Treatment with BB and ACEi/ARB/ARNI was associated with lower mortality/morbidity.,2023-11-22,,conclusion,11,1,0.22821937012020807,other,1.0,0.22821937012020807,0.22821937012020807,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],positioning,combination,0.85,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.22821937012020807, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.22821937012020807, 'final_confidence': 0.22821937012020807}"
med:pmid:37933210,med:pmid:37933210:sec:results:sent:4,enalapril,ACEi,sacubitril_valsartan,ARNI,"Beta-blockers (BB) were administered to 574 (82%) patients, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers or angiotensin receptor-neprilysin inhibitors (ACEi/ARB/ARNI) were administered to 381 (55%) patients and 416 (60%) received mineralocorticoid receptor antagonists (MRA).",2023-11-22,,results,4,1,0.22821937012020807,other,1.0,0.22821937012020807,0.22821937012020807,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.22821937012020807, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.22821937012020807, 'final_confidence': 0.22821937012020807}"
med:pmid:37933210,med:pmid:37933210:sec:results:sent:5,enalapril,ACEi,sacubitril_valsartan,ARNI,"Overall, ≥50% of target doses were reached in 41%, 22%, and 56% of the patients on BB, ACEi/ARB/ARNI and MRA, respectively.",2023-11-22,,results,5,1,0.22821937012020807,other,1.0,0.22821937012020807,0.22821937012020807,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.22821937012020807, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.22821937012020807, 'final_confidence': 0.22821937012020807}"
med:pmid:37933210,med:pmid:37933210:sec:results:sent:6,enalapril,ACEi,sacubitril_valsartan,ARNI,"Hypotension, bradycardia, kidney dysfunction and hyperkalaemia were the main causes of underprescription and/or underdosing, but up to a half of the patients did not receive target doses for unknown causes (51%, 41%, and 55% for BB, ACEi/ARB/ARNI and MRA, respectively).",2023-11-22,,results,6,1,0.22821937012020807,other,1.0,0.22821937012020807,0.22821937012020807,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.22821937012020807, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.22821937012020807, 'final_confidence': 0.22821937012020807}"
med:pmid:37933210,med:pmid:37933210:sec:results:sent:7,enalapril,ACEi,sacubitril_valsartan,ARNI,The proportions of patients receiving BB and ACEi/ARB/ARNI were lower among those fulfilling the 2018 HFA-ESC criteria for advanced HF.,2023-11-22,,results,7,1,0.22821937012020807,other,1.0,0.22821937012020807,0.22821937012020807,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.22821937012020807, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.22821937012020807, 'final_confidence': 0.22821937012020807}"
med:pmid:37933210,med:pmid:37933210:sec:results:sent:8,enalapril,ACEi,sacubitril_valsartan,ARNI,"Treatment with BB and ACEi/ARB/ARNI were associated with a lower risk of death or HF hospitalizations (adjusted hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.48-0.84, and HR 0.74, 95% CI 0.58-0.95, respectively).",2023-11-22,,results,8,1,0.22821937012020807,other,1.0,0.22821937012020807,0.22821937012020807,"['combination', 'risk']","{""combination"": [""acei/arb/arni""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['relationship:combination', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],comparative,comparative_efficacy,0.6000000000000001,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.22821937012020807, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.22821937012020807, 'final_confidence': 0.22821937012020807}"
med:pmid:37989299,med:pmid:37989299:sec:conclusion:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,The efficacy of sacubitril/valsartan compared with enalapril was consistent across baseline SBP tertiles in Japanese patients from the PARALLEL-HF study.,2023-11-21,,conclusion,8,1,0.2277863851769027,randomized controlled trial,1.6,0.3644582162830443,0.3644582162830443,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.2277863851769027, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.3644582162830443, 'final_confidence': 0.3644582162830443}"
med:pmid:37989299,med:pmid:37989299:sec:results:sent:5,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,No significant difference was observed between sacubitril/valsartan and enalapril for the composite outcome of cardiovascular death and HF hospitalization across SBP tertiles (P-interaction=0.2682).,2023-11-21,,results,5,1,0.2277863851769027,randomized controlled trial,1.6,0.3644582162830443,0.3644582162830443,['no significant difference'],"{""comparative_terms"": [""no significant difference""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.2277863851769027, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.3644582162830443, 'final_confidence': 0.3644582162830443}"
med:pmid:37989299,med:pmid:37989299:sec:results:sent:6,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Although the P-interaction value was not significant (0.2106), a greater reduction in NT-proBNP with sacubitril/valsartan compared with enalapril was observed in patients with SBP >130 mmHg (P=0.0076).",2023-11-21,,results,6,1,0.2277863851769027,randomized controlled trial,1.6,0.3644582162830443,0.3644582162830443,['compared with'],"{""comparative_terms"": [""compared with""], ""claim_strength_terms"": {""confirmatory"": [""p=""], ""suggestive"": [""greater reduction""]}}","['comparative_terms', 'claim_strength:confirmatory', 'claim_strength:suggestive']",[],,,,[],comparative,comparative_efficacy,0.6,POS,1.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.2277863851769027, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.3644582162830443, 'final_confidence': 0.3644582162830443}"
med:pmid:37989299,med:pmid:37989299:sec:results:sent:7,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The incidence of hypotension-related events and reduction or discontinuation of treatment due to hypotension-related events was higher in the lower SBP subgroup, and these events were more frequent in the sacubitril/valsartan than enalapril group.",2023-11-21,,results,7,1,0.2277863851769027,randomized controlled trial,1.6,0.3644582162830443,0.3644582162830443,[],,[],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.2277863851769027, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.3644582162830443, 'final_confidence': 0.3644582162830443}"
med:pmid:38084196,med:pmid:38084196:sec:abstract:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,The objective of this meta-analysis was to compare outcomes between sacubitril/valsartan and enalapril in patients with heart failure.,2023-11-10,,abstract,1,1,0.22307742657669394,review,0.9,0.20076968391902456,0.20076968391902456,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.22307742657669394, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.20076968391902456, 'final_confidence': 0.20076968391902456}"
med:pmid:38084196,med:pmid:38084196:sec:results:sent:6,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Pooled analysis showed that the risk of all-cause mortality was higher in patients receiving enalapril compared to patients receiving sacubitril/valsartan (risk ratio [RR]: 0.57; 95% CI: 0.31 to 1.04).,2023-11-10,,results,6,1,0.22307742657669394,review,0.9,0.20076968391902456,0.20076968391902456,"['compared to', 'risk', 'pooled analysis']","{""comparative_terms"": [""compared to""], ""risk_terms"": [""risk""], ""study_context"": [""pooled analysis""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'study_context', 'risk_posture:acknowledgment']",[],,,,[],comparative,comparative_safety,0.9,NEG,-2.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.22307742657669394, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.20076968391902456, 'final_confidence': 0.20076968391902456}"
med:pmid:38084196,med:pmid:38084196:sec:results:sent:7,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Risk of cardiovascular mortality was significantly higher in the enalapril group compared to the sacubitril/valsartan group (RR: 0.75; 95% CI: 0.62 to 0.91).,2023-11-10,,results,7,1,0.22307742657669394,review,0.9,0.20076968391902456,0.20076968391902456,"['compared to', 'risk']","{""comparative_terms"": [""compared to""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],comparative,comparative_safety,0.9,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.22307742657669394, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.20076968391902456, 'final_confidence': 0.20076968391902456}"
med:pmid:38084196,med:pmid:38084196:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,The risk of cardiovascular hospitalization was significantly higher in the enalapril group compared to the sacubitril/valsartan group (RR: 0.76; 95% CI: 0.66 to 0.86).,2023-11-10,,results,8,1,0.22307742657669394,review,0.9,0.20076968391902456,0.20076968391902456,"['compared to', 'risk']","{""comparative_terms"": [""compared to""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],comparative,comparative_safety,0.9,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.22307742657669394, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.20076968391902456, 'final_confidence': 0.20076968391902456}"
med:pmid:38084196,med:pmid:38084196:sec:results:sent:9,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In conclusion, our meta-analysis of nine studies underscores the superior clinical performance of sacubitril/valsartan compared to enalapril in managing patients with heart failure.",2023-11-10,,results,9,1,0.22307742657669394,review,0.9,0.20076968391902456,0.20076968391902456,"['compared to', 'superior', 'meta-analysis']","{""comparative_terms"": [""compared to"", ""superior""], ""study_context"": [""meta-analysis""]}","['comparative_terms', 'study_context']",[],,,,[],evidence,evidence_review,0.7,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.22307742657669394, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.20076968391902456, 'final_confidence': 0.20076968391902456}"
med:pmid:38084196,med:pmid:38084196:sec:title:sent:0,enalapril,Enalapril,sacubitril_valsartan,Sacubitril/Valsartan,Comparison of Outcomes Between Sacubitril/Valsartan and Enalapril in Patients With Heart Failure: A Systematic Review and Meta-Analysis.,2023-11-10,,results,0,1,0.22307742657669394,review,0.9,0.20076968391902456,0.20076968391902456,"['meta-analysis', 'review', 'systematic review']","{""study_context"": [""meta-analysis"", ""review"", ""systematic review""]}",['study_context'],[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.22307742657669394, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.20076968391902456, 'final_confidence': 0.20076968391902456}"
ppr:doi:10.1101/2023.10.31.23297731,ppr:doi:10.1101/2023.10.31.23297731:sec:conclusion:sent:16,enalapril,ACEI,sacubitril_valsartan,ARNI,"Physicians’ level of adherence to prescription and up-titration of GDMT was satisfactory for ACEI/ARNI/ARBs and B-blockers, however, it was poor for SGLT2is and MRAs.",2023-11-03,,conclusion,16,1,0.22013162919991386,other,1.0,0.22013162919991386,0.22013162919991386,['combination'],"{""combination"": [""gdmt""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.625816+00:00,"{'recency_weight': 0.22013162919991386, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.22013162919991386, 'final_confidence': 0.22013162919991386}"
ppr:doi:10.1101/2023.10.31.23297731,ppr:doi:10.1101/2023.10.31.23297731:sec:results:sent:11,enalapril,ACEI,sacubitril_valsartan,ARNI,"GAI at discharge were 66.2%, 71.7%, and 42.6% for ACEI/ARNI/ARBs, B-blockers, and MRAs, respectively.",2023-11-03,,results,11,1,0.22013162919991386,other,1.0,0.22013162919991386,0.22013162919991386,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.22013162919991386, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.22013162919991386, 'final_confidence': 0.22013162919991386}"
ppr:doi:10.1101/2023.10.31.23297731,ppr:doi:10.1101/2023.10.31.23297731:sec:results:sent:14,enalapril,ACEI,sacubitril_valsartan,ARNI,"The proportions for good QUALIFY scores for ACEI/ARNI/ARBs, B- blockers, and MRAs were 35.8%, 38.5%, and 9.5%, respectively.",2023-11-03,,results,14,1,0.22013162919991386,other,1.0,0.22013162919991386,0.22013162919991386,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.22013162919991386, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.22013162919991386, 'final_confidence': 0.22013162919991386}"
ppr:doi:10.1101/2023.10.31.23297731,ppr:doi:10.1101/2023.10.31.23297731:sec:results:sent:15,enalapril,ACEI,sacubitril_valsartan,ARNI,"Uptitration to ≥ 50% of target dose was done in 51.9%, 48.7%, and 7.9% of patients for ACEI/ARNI/ARBs, B- blockers, and MRAs, respectively.",2023-11-03,,results,15,1,0.22013162919991386,other,1.0,0.22013162919991386,0.22013162919991386,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.22013162919991386, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.22013162919991386, 'final_confidence': 0.22013162919991386}"
med:pmid:37755814,med:pmid:37755814:sec:introduction:sent:4,enalapril,ACEI,sacubitril_valsartan,ARNI,"<h4>Design, setting, and participants</h4> This economic evaluation included participant-level data from the PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) and the PARAGON-HF (Prospective Comparison of ARNi with ARB Global Outcomes in HF With Preserved Ejection Fraction) trials.",2023-11-01,,introduction,4,1,0.21929714030541786,other,1.0,0.21929714030541786,0.21929714030541786,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.21929714030541786, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.21929714030541786, 'final_confidence': 0.21929714030541786}"
med:pmid:37940331,med:pmid:37940331:sec:conclusion:sent:11,enalapril,ACEI,sacubitril_valsartan,ARNI,"This study suggested that SGLT2i, ARNI and IVA in addition to ACEI+BB+MRA may be better in prolonging time to develop PCO in HFrEF patients.",2023-11-01,,conclusion,11,1,0.21929714030541786,other,1.0,0.21929714030541786,0.21929714030541786,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.21929714030541786, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.21929714030541786, 'final_confidence': 0.21929714030541786}"
med:pmid:37940331,med:pmid:37940331:sec:methods:sent:4,enalapril,ACE inhibitors,sacubitril_valsartan,ARNI,"The RCTs were included if comparing any single or combination of drugs, that is, ACE inhibitors (ACEI), angiotensin receptor blockers, beta-blockers (BB), mineralocorticoid receptor antagonists (MRA), ivabradine (IVA), angiotensin receptor blocker/neprilysin inhibitors (ARNI) and sodium-glucose cotransporter-2 inhibitors (SGLT2i), soluble guanylyl cyclase and omecamtiv mecarbil and reporting PCO.",2023-11-01,,methods,4,1,0.21929714030541786,other,1.0,0.21929714030541786,0.21929714030541786,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.21929714030541786, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.21929714030541786, 'final_confidence': 0.21929714030541786}"
med:pmid:37940331,med:pmid:37940331:sec:results:sent:8,enalapril,ACEI,sacubitril_valsartan,ARNI,"Our findings suggested that ACEI+BB+MRA+SGLT2i, BB+MRA+ARNI, and ACEI+BB+MRA+IVA had lower probability of PCOs than the conventional triple therapy (ACEI+BB+MRA).",2023-11-01,,results,8,1,0.21929714030541786,other,1.0,0.21929714030541786,0.21929714030541786,['combination'],"{""combination"": [""triple therapy""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.21929714030541786, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.21929714030541786, 'final_confidence': 0.21929714030541786}"
med:pmid:37861303,med:pmid:37861303:sec:results:sent:9,enalapril,ACE inhibitor,sacubitril_valsartan,ARNI,"At discharge, 92 patients (56%) were prescribed β-blockers, 28 (17%) were prescribed an ACE inhibitor, ARB or ARNI, and 50 (30%) were prescribed loop diuretics.",2023-10-20,,results,9,1,0.2143562208991877,other,1.0,0.2143562208991877,0.2143562208991877,[],,[],[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.2143562208991877, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.2143562208991877, 'final_confidence': 0.2143562208991877}"
med:pmid:37933369,med:pmid:37933369:sec:abstract:sent:11,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"However, the sacubitril/valsartan combination proved to be beneficial in significantly reducing the risk of major adverse cardiac events (MACE) (RR: 0.64 {0.48, 0.84}) and rehospitalizations (RR: 0.53 {0.39, 0.71}) as compared to ACEI post MI.",2023-10-05,,abstract,11,1,0.2083363235922581,review,0.9,0.1875026912330323,0.1875026912330323,"['compared to', 'risk']","{""comparative_terms"": [""compared to""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],,,,NEG,-2.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.2083363235922581, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.1875026912330323, 'final_confidence': 0.1875026912330323}"
med:pmid:37933369,med:pmid:37933369:sec:abstract:sent:15,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"Although the sacubitril/valsartan combination has no difference in mortality and outcomes compared to ACEI, there is evidence that using it proves to be more beneficial post MI compared to ACEI and ARB usage alone.",2023-10-05,,abstract,15,1,0.2083363235922581,review,0.9,0.1875026912330323,0.1875026912330323,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.2083363235922581, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.1875026912330323, 'final_confidence': 0.1875026912330323}"
med:pmid:37933369,med:pmid:37933369:sec:abstract:sent:2,enalapril,ACEIs,sacubitril_valsartan,sacubitril/valsartan,The purpose of this study is to investigate further the efficacy of sacubitril/valsartan over angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in reducing the risk of heart failure (HF) in post-MI patients and providing a clear evidence-based medicine guideline for future use.,2023-10-05,,abstract,2,1,0.2083363235922581,review,0.9,0.1875026912330323,0.1875026912330323,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.2083363235922581, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.1875026912330323, 'final_confidence': 0.1875026912330323}"
med:pmid:37933369,med:pmid:37933369:sec:abstract:sent:7,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,Six studies analyzed the sacubitril/valsartan and ACEI combination.,2023-10-05,,abstract,7,1,0.2083363235922581,review,0.9,0.1875026912330323,0.1875026912330323,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.2083363235922581, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.1875026912330323, 'final_confidence': 0.1875026912330323}"
med:pmid:37933369,med:pmid:37933369:sec:abstract:sent:8,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"The pooled analysis reported a significant increase in the risk of hypotension (relative risk {RR}: 1.29 {1.18, 1.41}) in the sacubitril/valsartan compared to the ACEI alone group.",2023-10-05,,abstract,8,1,0.2083363235922581,review,0.9,0.1875026912330323,0.1875026912330323,"['compared to', 'risk', 'pooled analysis']","{""comparative_terms"": [""compared to""], ""risk_terms"": [""risk""], ""study_context"": [""pooled analysis""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'study_context', 'risk_posture:acknowledgment']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.2083363235922581, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.1875026912330323, 'final_confidence': 0.1875026912330323}"
med:pmid:37933369,med:pmid:37933369:sec:abstract:sent:9,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"In addition, a significant increase was observed in the left ventricle ejection fraction (LVEF) after using the sacubitril/valsartan combination compared to using ACEI alone (RR: 3.08 {2.68, 4.48}).",2023-10-05,,abstract,9,1,0.2083363235922581,review,0.9,0.1875026912330323,0.1875026912330323,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.2083363235922581, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.1875026912330323, 'final_confidence': 0.1875026912330323}"
med:pmid:37759279,med:pmid:37759279:sec:results:sent:7,enalapril,ACEi,sacubitril_valsartan,ARNI,"We reviewed 464 articles, including 144 articles that had information about beta-blockers (BB), 179 articles about angiotensin-converting enzyme inhibitors (ACEi), 75 articles about angiotensin receptor blockers (ARB), 80 articles about diuretics, 37 articles about mineralocorticoid receptor antagonists (MRA), and 33 articles about angiotensin receptor-neprilysin inhibitor (ARNI).",2023-09-27,,results,7,1,0.20519514378202022,other,1.0,0.20519514378202022,0.20519514378202022,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.20519514378202022, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.20519514378202022, 'final_confidence': 0.20519514378202022}"
med:pmid:37941691,med:pmid:37941691:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,Sacubitril/valsartan,"Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is superior to enalapril for chronic heart failure (CHF) with reduced ejection fraction (EF).",2023-09-27,,introduction,1,1,0.20519514378202022,other,1.0,0.20519514378202022,0.20519514378202022,['superior'],"{""comparative_terms"": [""superior""]}",['comparative_terms'],[],alternative,disfavored,favored,['preferred_over'],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.20519514378202022, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.20519514378202022, 'final_confidence': 0.20519514378202022}"
med:pmid:37757995,med:pmid:37757995:sec:methods:sent:5,enalapril,ACEi,sacubitril_valsartan,ARNI,"We evaluated trends in the use of 7 classes of antihyperglycemic therapies (metformin, sulfonylureas, GLP-1RA, SGLT2-inhibitors, DPP-4 inhibitors, thiazolidinediones, and insulins) and 4 classes of HF therapies (evidence-based β-blockers, ACEi or ARB, MRA, and ARNI).",2023-09-25,,methods,5,1,0.20441727706058194,other,1.0,0.20441727706058194,0.20441727706058194,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.20441727706058194, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.20441727706058194, 'final_confidence': 0.20441727706058194}"
med:pmid:37705397,med:pmid:37705397:sec:conclusion:sent:10,enalapril,ACEIs,sacubitril_valsartan,ARNI,"Regardless of significant treatment response measured by either LVEF or LV reverse remodelling after 1 year of treatment, the extended utilization of ARNI demonstrated a more favourable prognosis than that of ACEIs/ARBs in patients with HFrEF.",2023-09-13,,conclusion,10,1,0.19981161147921275,other,1.0,0.19981161147921275,0.19981161147921275,[],,[],[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.19981161147921275, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.19981161147921275, 'final_confidence': 0.19981161147921275}"
med:pmid:37705397,med:pmid:37705397:sec:introduction:sent:3,enalapril,ACEIs,sacubitril_valsartan,ARNI,This study aimed to assess the impact of prolonged ARNI use compared with angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) in patients with and without significant treatment response after 1 year of heart failure (HF) treatment.,2023-09-13,,introduction,3,1,0.19981161147921275,other,1.0,0.19981161147921275,0.19981161147921275,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.19981161147921275, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.19981161147921275, 'final_confidence': 0.19981161147921275}"
med:pmid:37705397,med:pmid:37705397:sec:results:sent:4,enalapril,ACEIs,sacubitril_valsartan,ARNI,The present study enrolled patients with HF with reduced ejection fraction (HFrEF) who were treated with either ARNI or ACEIs/ARBs within 1 year of undergoing index echocardiography.,2023-09-13,,results,4,1,0.19981161147921275,other,1.0,0.19981161147921275,0.19981161147921275,[],,[],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.19981161147921275, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.19981161147921275, 'final_confidence': 0.19981161147921275}"
med:pmid:37705397,med:pmid:37705397:sec:results:sent:6,enalapril,ACEIs,sacubitril_valsartan,ARNI,The effect of ARNI versus that of ACEIs/ARBs in each group was assessed from the time of categorizing into new groups using the composite event of all-cause mortality and HF hospitalization.,2023-09-13,,results,6,1,0.19981161147921275,other,1.0,0.19981161147921275,0.19981161147921275,['versus'],"{""comparative_terms"": [""versus""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.19981161147921275, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.19981161147921275, 'final_confidence': 0.19981161147921275}"
med:pmid:37705397,med:pmid:37705397:sec:results:sent:8,enalapril,ACEIs,sacubitril_valsartan,ARNI,"ARNI had a significantly lower event rate than ACEIs/ARBs in patients with HF with improved ejection fraction (7.0% vs. 30.4%, P = 0.020) and those with persistent HFrEF (17.6% vs. 49.7%, P < 0.001).",2023-09-13,,results,8,1,0.19981161147921275,other,1.0,0.19981161147921275,0.19981161147921275,['vs'],"{""comparative_terms"": [""vs""]}",['comparative_terms'],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.19981161147921275, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.19981161147921275, 'final_confidence': 0.19981161147921275}"
med:pmid:37705397,med:pmid:37705397:sec:results:sent:9,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"Irrespective of whether patients exhibited LV reverse remodelling (15.8% vs. 31.1%, P = 0.001) or not (15.0% vs. 54.9%, P < 0.001), ARNIs were associated with a significantly lower event rate than ACEIs/ARBs.",2023-09-13,,results,9,1,0.19981161147921275,other,1.0,0.19981161147921275,0.19981161147921275,['vs'],"{""comparative_terms"": [""vs""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.19981161147921275, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.19981161147921275, 'final_confidence': 0.19981161147921275}"
med:pmid:37660348,med:pmid:37660348:sec:introduction:sent:2,enalapril,ACEI,sacubitril_valsartan,ARNI,Our retrospective monocentric observational study aimed to analyse the application ratio of combined neurohormonal antagonist therapy (RASi: ACEI/ARB/ARNI + βB + MRA) and 12-month all-cause mortality differences in terms of renal dysfunction among HFrEF patients hospitalized for heart failure.,2023-09-03,,introduction,2,1,0.19605292461436813,observational study,1.2,0.23526350953724173,0.23526350953724173,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.19605292461436813, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.23526350953724173, 'final_confidence': 0.23526350953724173}"
med:pmid:37646297,med:pmid:37646297:sec:results:sent:11,enalapril,ACEi,sacubitril_valsartan,ARNI,"Price, affordability, and access were substantially improved in all countries by substituting ARNI for ACEi/ARB.",2023-08-30,,results,11,1,0.1945693223828534,other,1.0,0.1945693223828534,0.1945693223828534,[],"{""access_terms"": [""access"", ""affordability""]}",['access_terms'],[],,,,[],access,coverage_access,0.65,POS,1.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.1945693223828534, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.1945693223828534, 'final_confidence': 0.1945693223828534}"
med:pmid:37646297,med:pmid:37646297:sec:results:sent:2,enalapril,ACEi,sacubitril_valsartan,ARNI,"In this cross-sectional survey, we investigated the price, affordability, and accessibility of four pivotal classes of HFrEF GDMT: angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB) or angiotensin-neprilysin inhibitors (ARNI); beta-blockers; mineralocorticoid receptor antagonists (MRA); and sodium glucose co-transporter 2 inhibitors (SGLT2i).",2023-08-30,,results,2,1,0.1945693223828534,other,1.0,0.1945693223828534,0.1945693223828534,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.1945693223828534, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.1945693223828534, 'final_confidence': 0.1945693223828534}"
med:pmid:37635080,med:pmid:37635080:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,The PARALLEL-HF study assessed the efficacy and safety of sacubitril/valsartan vs. enalapril in Japanese patients with chronic heart failure with reduced ejection fraction (HFrEF).,2023-08-26,,introduction,1,1,0.19309694709725492,other,1.0,0.19309694709725492,0.19309694709725492,"['vs', 'safety']","{""comparative_terms"": [""vs""], ""risk_terms"": [""safety""]}","['comparative_terms', 'risk_terms']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.19309694709725492, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.19309694709725492, 'final_confidence': 0.19309694709725492}"
med:pmid:37635080,med:pmid:37635080:sec:results:sent:7,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"At OLE baseline, higher concentrations of B-type natriuretic peptide (BNP) and urine cGMP, and lower concentrations of N-terminal pro B-type natriuretic peptide (NT-proBNP), were observed in the sacubitril/valsartan core group (patients who received sacubitril/valsartan in both the core and extension study) than in the enalapril core group (patients who received enalapril in the core study and were then transitioned to sacubitril/valsartan).",2023-08-26,,results,7,1,0.19309694709725492,other,1.0,0.19309694709725492,0.19309694709725492,['switching'],"{""switching"": [""transitioned to""]}",['relationship:switching'],[],switch,switch_source,switch_destination,['switch_to'],comparative,comparative_efficacy,0.6000000000000001,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.19309694709725492, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.19309694709725492, 'final_confidence': 0.19309694709725492}"
med:pmid:37640175,med:pmid:37640175:sec:abstract:sent:6,enalapril,Angiotensin Converting Enzyme inhibitors,sacubitril_valsartan,angiotensin receptor neprilysin inhibitor,"For patients with HF or EF ≤ 40%, OMT included BB, spironolactone, and either Angiotensin Converting Enzyme inhibitors (ACEi)/angiotensin receptor blockers or angiotensin receptor neprilysin inhibitor (ARNI).",2023-08-26,,abstract,6,1,0.19309694709725492,review,0.9,0.17378725238752943,0.17378725238752943,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.19309694709725492, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.17378725238752943, 'final_confidence': 0.17378725238752943}"
med:pmid:37640175,med:pmid:37640175:sec:abstract:sent:7,enalapril,ACEi,sacubitril_valsartan,ARNI,"For CAD patients with normal EF, OMT also included ACEi/ARB/ARNI if they also had diabetes type 2.",2023-08-26,,abstract,7,1,0.19309694709725492,review,0.9,0.17378725238752943,0.17378725238752943,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.19309694709725492, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.17378725238752943, 'final_confidence': 0.17378725238752943}"
med:pmid:37619492,med:pmid:37619492:sec:abstract:sent:4,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"We systematically searched PubMed, Embase, Cochrane, and ClinicalTrials.gov for studies comparing ARNIs with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in terms of myocardial infarction, stroke, angina pectoris, peripheral artery disease, and the composite end point in patients with HF.",2023-08-22,,abstract,4,1,0.19163571379927855,review,0.9,0.1724721424193507,0.1724721424193507,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.19163571379927855, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.1724721424193507, 'final_confidence': 0.1724721424193507}"
med:pmid:37619492,med:pmid:37619492:sec:abstract:sent:5,enalapril,ACEi,sacubitril_valsartan,ARNI,"A total of 8 randomized controlled trials were included, with 17,541 patients assigned to either the ARNI (8,764 patients) or ACEi/ARB (8,777 patients) groups.",2023-08-22,,abstract,5,1,0.19163571379927855,review,0.9,0.1724721424193507,0.1724721424193507,['randomized'],"{""study_context"": [""randomized""]}",['study_context'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.19163571379927855, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.1724721424193507, 'final_confidence': 0.1724721424193507}"
med:pmid:37619492,med:pmid:37619492:sec:abstract:sent:6,enalapril,ACEi,sacubitril_valsartan,ARNI,"The incidence of composite end point (risk ratio [RR] 1.03, 95% confidence interval [CI] 0.93 to 1.13, p = 0.63), myocardial infarction (RR 1.02, 95% CI 0.81 to 1.30, p = 0.85), angina pectoris (RR 0.96, 95% CI 0.80 to 1.17, p = 0.70), and stroke (RR 0.99, 95% CI 0.85 to 1.16, p = 0.93) were not statistically different between the ARNI and ACEi/ARB groups.",2023-08-22,,abstract,6,1,0.19163571379927855,review,0.9,0.1724721424193507,0.1724721424193507,['risk'],"{""risk_terms"": [""risk""]}",['risk_terms'],[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.19163571379927855, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.1724721424193507, 'final_confidence': 0.1724721424193507}"
med:pmid:37573615,med:pmid:37573615:sec:abstract:sent:10,enalapril,ACEI,sacubitril_valsartan,ARNI,"At last follow-up, 51.2% were on a BB, 35.4% were on an ACEI/ARB/ARNI, and 43.9% were on an MRA.",2023-08-11,,abstract,10,1,0.1876740870238177,other,1.0,0.1876740870238177,0.1876740870238177,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.1876740870238177, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.1876740870238177, 'final_confidence': 0.1876740870238177}"
med:pmid:37573615,med:pmid:37573615:sec:abstract:sent:12,enalapril,ACEI,sacubitril_valsartan,ARNI,"There was no association with hospitalization or mortality for baseline or follow-up BB, ACEI/ARB/ARNI, or MRA use.",2023-08-11,,abstract,12,1,0.1876740870238177,other,1.0,0.1876740870238177,0.1876740870238177,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.1876740870238177, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.1876740870238177, 'final_confidence': 0.1876740870238177}"
med:pmid:37573615,med:pmid:37573615:sec:abstract:sent:13,enalapril,ACEI,sacubitril_valsartan,ARNIs,"In conclusion, BBs, ACEI/ARB/ARNIs, and MRAs may be safely used in this population.",2023-08-11,,abstract,13,1,0.1876740870238177,other,1.0,0.1876740870238177,0.1876740870238177,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.1876740870238177, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.1876740870238177, 'final_confidence': 0.1876740870238177}"
med:pmid:37573615,med:pmid:37573615:sec:abstract:sent:6,enalapril,ACEI,sacubitril_valsartan,angiotensin receptor neprilysin inhibitors,"The primary outcomes of interest were medication use patterns (for β blockers [BB], angiotensin-converting enzyme inhibitors [ACEI], angiotensin receptor blockers [ARBs], angiotensin receptor neprilysin inhibitors [ARNI], and mineralocorticoid receptor antagonists [MRAs]); potential medication side effects (symptomatic bradycardia, fatigue, hypotension, lightheadedness, and syncope); hospitalization; and death.",2023-08-11,,abstract,6,1,0.1876740870238177,other,1.0,0.1876740870238177,0.1876740870238177,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.1876740870238177, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.1876740870238177, 'final_confidence': 0.1876740870238177}"
med:pmid:37573615,med:pmid:37573615:sec:abstract:sent:7,enalapril,ACEI,sacubitril_valsartan,ARNI,"The associations of BB, ACEI/ARB/ARNI, and MRA use with clinical outcomes were evaluated using Kaplan-Meier and Cox proportional hazards regression.",2023-08-11,,abstract,7,1,0.1876740870238177,other,1.0,0.1876740870238177,0.1876740870238177,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.1876740870238177, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.1876740870238177, 'final_confidence': 0.1876740870238177}"
med:pmid:37573615,med:pmid:37573615:sec:abstract:sent:9,enalapril,ACEI,sacubitril_valsartan,ARNI,"At time of cardiac amyloidosis diagnosis, 63.4% were on a BB, 51.2% were on an ACEI/ARB/ARNI, and 43.9% were on an MRA.",2023-08-11,,abstract,9,1,0.1876740870238177,other,1.0,0.1876740870238177,0.1876740870238177,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.1876740870238177, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.1876740870238177, 'final_confidence': 0.1876740870238177}"
med:pmid:37558137,med:pmid:37558137:sec:results:sent:6,enalapril,ACE inhibitors,sacubitril_valsartan,ARNI,"216 DCM patients were enrolled (52 years, 78% male, NYHA I-II 82%, LVEF 32%, 94% on ACE inhibitors/ARNI, 95% on beta-blockers).",2023-08-08,,results,6,1,0.18660792884981628,other,1.0,0.18660792884981628,0.18660792884981628,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.18660792884981628, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.18660792884981628, 'final_confidence': 0.18660792884981628}"
med:pmid:37544137,med:pmid:37544137:sec:abstract:sent:1,enalapril,ACEis,sacubitril_valsartan,Sacubitril/valsartan,Sacubitril/valsartan improves outcomes in patients with heart failure with reduced ejection fraction (HFrEF) compared with angiotensin-converting enzyme inhibitors (ACEis).,2023-08-04,,abstract,1,1,0.1851958002615563,other,1.0,0.1851958002615563,0.1851958002615563,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.1851958002615563, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.1851958002615563, 'final_confidence': 0.1851958002615563}"
med:pmid:37544137,med:pmid:37544137:sec:abstract:sent:6,enalapril,ACEis,sacubitril_valsartan,sacubitril/valsartan,"Among 3,572 patients with HFrEF and who are naïve to RASi therapy, at discharge, 290 (8.1%) were prescribed sacubitril/valsartan and 1,390 (38.9%) were prescribed ACEis and angiotensin receptor blockers.",2023-08-04,,abstract,6,1,0.1851958002615563,other,1.0,0.1851958002615563,0.1851958002615563,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.1851958002615563, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.1851958002615563, 'final_confidence': 0.1851958002615563}"
med:pmid:37544137,med:pmid:37544137:sec:abstract:sent:9,enalapril,ACEis,sacubitril_valsartan,sacubitril/valsartan,"In a restricted comparison of patients discharged on sacubitril/valsartan versus ACEis and angiotensin receptor blockers, there were no significant differences in the outcomes.",2023-08-04,,abstract,9,1,0.1851958002615563,other,1.0,0.1851958002615563,0.1851958002615563,['versus'],"{""comparative_terms"": [""versus""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.1851958002615563, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.1851958002615563, 'final_confidence': 0.1851958002615563}"
med:pmid:37601056,med:pmid:37601056:sec:abstract:sent:1,enalapril,ACEIs,sacubitril_valsartan,sacubitril/valsartan,<b>Purpose:</b> To systematically assess the efficacy and safety of sacubitril/valsartan (SV) by comparison with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) for the treatment of heart failure caused by acute myocardial infarction (HF-AMI) based on current randomized controlled trials (RCTs).,2023-08-04,,abstract,1,1,0.1851958002615563,review,0.9,0.16667622023540068,0.16667622023540068,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.1851958002615563, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.16667622023540068, 'final_confidence': 0.16667622023540068}"
med:pmid:37601056,med:pmid:37601056:sec:title:sent:0,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,The efficacy and safety of sacubitril/valsartan compared with ACEI/ARB in the treatment of heart failure following acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.,2023-08-04,,title,0,1,0.1851958002615563,review,0.9,0.16667622023540068,0.16667622023540068,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.1851958002615563, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.16667622023540068, 'final_confidence': 0.16667622023540068}"
med:pmid:37435776,med:pmid:37435776:sec:results:sent:7,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"SGLT-2 inhibitors reduced the risk of CV death or hospitalization for HF regardless of background use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs), angiotensin receptor-neprilysin inhibitors (ARNIs), b-blockers, diuretics, mineralocorticoid receptor antagonists (MRAs), or triple combination therapy of either an ACEI/ARB plus b-blocker plus MRA, or an ARNI plus b-blocker plus MRA (HRs ranged from 0.61 to 0.83; P > .1 for each subgroup interaction).",2023-07-12,,results,7,1,0.1772809704476384,review,0.9,0.15955287340287458,0.15955287340287458,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.1772809704476384, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.15955287340287458, 'final_confidence': 0.15955287340287458}"
med:pmid:37429446,med:pmid:37429446:sec:introduction:sent:3,enalapril,angiotensin converting enzyme inhibitor,sacubitril_valsartan,ARNI,"<h4>Method</h4> In this retrospective cohort study, we compared the temporal change in chamber function and heart failure indices between 35 patients that received ARNI for >6 months, and a propensity matched control group (n = 70) of patients that received angiotensin converting enzyme inhibitor or angiotensin-II receptor blocker (ACEI/ARB) within the same period.",2023-07-08,,introduction,3,1,0.17593942227191725,randomized controlled trial,1.6,0.2815030756350676,0.2815030756350676,"['cohort', 'retrospective']","{""study_context"": [""cohort"", ""retrospective""], ""real_world_terms"": [""retrospective""]}","['study_context', 'real_world_terms']",[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.17593942227191725, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.2815030756350676, 'final_confidence': 0.2815030756350676}"
med:pmid:37429446,med:pmid:37429446:sec:results:sent:5,enalapril,ACEI,sacubitril_valsartan,ARNI,"Compared to the ACEI/ARB group, the ARNI group had greater relative improvement in LV global longitudinal strain (GLS) (28% versus 11% increase from baseline, p < 0.001) and RV-GLS (11% versus 4% increase from baseline, p < 0.001), and greater relative improvement in New York Heart Association functional class (-14 versus -2% change from baseline, p = 0.006) and N-terminal pro-brain natriuretic peptide levels (-29% versus -13% change from baseline, p < 0.001).",2023-07-08,,results,5,1,0.17593942227191725,randomized controlled trial,1.6,0.2815030756350676,0.2815030756350676,"['compared to', 'versus']","{""comparative_terms"": [""compared to"", ""versus""]}",['comparative_terms'],[],,,,[],,,,POS,4.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.17593942227191725, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.2815030756350676, 'final_confidence': 0.2815030756350676}"
med:pmid:37416920,med:pmid:37416920:sec:methods:sent:5,enalapril,angiotensin converting enzyme inhibitor,sacubitril_valsartan,ARNI,"We evaluated the predictive performance of machine learning algorithms to predict prescription of four types of medications for adults with HFrEF: angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACE/ARB), angiotensin receptor-neprilysin inhibitor (ARNI), evidence-based beta blocker (BB), or mineralocorticoid receptor antagonist (MRA).",2023-06-21,,methods,5,1,0.1703501759261667,other,1.0,0.1703501759261667,0.1703501759261667,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.1703501759261667, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.1703501759261667, 'final_confidence': 0.1703501759261667}"
med:pmid:37374004,med:pmid:37374004:sec:conclusion:sent:12,enalapril,ACEI,sacubitril_valsartan,ARNI,"In current clinical practice, the majority of patients with reduced and mildly-reduced LVEF are treated by ACEI/ARB and beta-blockers early following ACS, whereas MRA is underutilized and the adoption of SGLT2I and ARNI is low.",2023-06-19,,conclusion,12,1,0.16970440171142753,other,1.0,0.16970440171142753,0.16970440171142753,[],,[],[],,,,[],,,,POS,2.0,lexicon_v1,2026-01-08T18:51:51.544025+00:00,"{'recency_weight': 0.16970440171142753, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.16970440171142753, 'final_confidence': 0.16970440171142753}"
med:pmid:37374004,med:pmid:37374004:sec:methods:sent:4,enalapril,ACEI,sacubitril_valsartan,ARNI,"Drug classes included: (a) angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB) or angiotensin receptor-neprilysin inhibitors (ARNI); (b) beta-blockers; (c) mineralocorticoid receptor antagonist (MRA) and (d) sodium-glucose cotransporter-2 inhibitors (SGLT2I).",2023-06-19,,methods,4,1,0.16970440171142753,other,1.0,0.16970440171142753,0.16970440171142753,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.16970440171142753, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.16970440171142753, 'final_confidence': 0.16970440171142753}"
med:pmid:37374004,med:pmid:37374004:sec:results:sent:7,enalapril,ACEI,sacubitril_valsartan,ARNI,"ACEI/ARB/ARNI and beta-blockers were used by the majority of patients in both LVEF groups, though ARNI was prescribed to only 3.9% (LVEF ≤ 40%).",2023-06-19,,results,7,1,0.16970440171142753,other,1.0,0.16970440171142753,0.16970440171142753,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.544025+00:00,"{'recency_weight': 0.16970440171142753, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.16970440171142753, 'final_confidence': 0.16970440171142753}"
med:pmid:37311917,med:pmid:37311917:sec:abstract:sent:10,enalapril,ACEi,sacubitril_valsartan,ARNi,GDMT: guideline-directed medical therapy; ACEi: angiotensin-converting enzyme inhibitor; ARB: Angiotensin II receptor blocker; ARNi: angiotensin receptor-neprilysin inhibitor; BB: beta-blocker; MRA: mineralocorticoid receptor antagonist; SGLT2i: sodium-glucose co-transporter 2 inhibitor.,2023-06-14,,abstract,10,1,0.16810065606627714,review,0.9,0.15129059045964943,0.15129059045964943,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.16810065606627714, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.15129059045964943, 'final_confidence': 0.15129059045964943}"
med:pmid:38938237,med:pmid:38938237:sec:conclusion:sent:10,enalapril,ACEI,sacubitril_valsartan,Sacubitril/valsartan,Sacubitril/valsartan was associated with lower 3-year rates of neurocognitive disorders when compared to ACEI/ARBs in patients with HFrEF.,2023-06-07,,conclusion,10,1,0.16588084172076423,other,1.0,0.16588084172076423,0.16588084172076423,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.16588084172076423, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.16588084172076423, 'final_confidence': 0.16588084172076423}"
med:pmid:38938237,med:pmid:38938237:sec:introduction:sent:3,enalapril,ACEIs,sacubitril_valsartan,sacubitril/valsartan,The purpose of this study was to compare 3-year cognitive outcomes in patients with HFrEF who receive sacubitril/valsartan vs angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs).,2023-06-07,,introduction,3,1,0.16588084172076423,other,1.0,0.16588084172076423,0.16588084172076423,['vs'],"{""comparative_terms"": [""vs""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.16588084172076423, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.16588084172076423, 'final_confidence': 0.16588084172076423}"
med:pmid:38938237,med:pmid:38938237:sec:methods:sent:4,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"Retrospective cohort study of: 1) 11,313 adults with HFrEF (International Classification of Diseases-10th Revision-Clinical Modification [ICD-10-CM] codes: I50.2 or I50.4) started on sacubitril/valsartan between 1/1/2015 and 12/31/2019; and 2) 11,313 propensity matched patients receiving ACEI/ARB during that time.",2023-06-07,,methods,4,1,0.16588084172076423,other,1.0,0.16588084172076423,0.16588084172076423,"['cohort', 'retrospective']","{""study_context"": [""cohort"", ""retrospective""], ""real_world_terms"": [""retrospective""]}","['study_context', 'real_world_terms']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.16588084172076423, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.16588084172076423, 'final_confidence': 0.16588084172076423}"
med:pmid:38938237,med:pmid:38938237:sec:results:sent:7,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"At 3 years, 858 patients on sacubitril/valsartan met the primary endpoint vs 1,209 on ACEI/ARB (3-year incidence: 10.7% vs 15.0%; HR: 0.69; 95% CI: 0.63-0.75; <i>P</i> < 0.001), with consistently lower rates of cognitive decline (9.5% vs 13.3%; HR: 0.69; 95% CI: 0.63-0.76; <i>P</i> < 0.001), dementia (3.4% vs 5.0%; HR: 0.65; 95% CI: 0.57-0.77; <i>P</i> < 0.001), and Alzheimer's disease (0.6% vs 1.3%; HR: 0.48; 95% CI: 0.35-0.66; <i>P</i> < 0.001) in the sacubitril/valsartan cohort.",2023-06-07,,results,7,1,0.16588084172076423,other,1.0,0.16588084172076423,0.16588084172076423,"['vs', 'cohort']","{""comparative_terms"": [""vs""], ""study_context"": [""cohort""], ""endpoint_terms"": [""primary endpoint""], ""claim_strength_terms"": {""confirmatory"": [""met the primary endpoint""]}}","['comparative_terms', 'study_context', 'endpoint_terms', 'claim_strength:confirmatory']",[],,,,[],comparative,comparative_efficacy,0.39999999999999997,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.16588084172076423, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.16588084172076423, 'final_confidence': 0.16588084172076423}"
med:pmid:38938237,med:pmid:38938237:sec:results:sent:9,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,Three-year mortality was 22.0% on sacubitril/valsartan vs 24.6% on ACEI/ARB (HR: 0.89; 95% CI: 0.84-0.94; <i>P</i> < 0.001).,2023-06-07,,results,9,1,0.16588084172076423,other,1.0,0.16588084172076423,0.16588084172076423,['vs'],"{""comparative_terms"": [""vs""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.39999999999999997,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.562243+00:00,"{'recency_weight': 0.16588084172076423, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.16588084172076423, 'final_confidence': 0.16588084172076423}"
med:pmid:37278232,med:pmid:37278232:sec:methods:sent:4,enalapril,ACE inhibitor,sacubitril_valsartan,ARNi,We investigate the cost-effectiveness of sequentially adding the SGLT2i and ARNi to form quadruple therapy as compared with the previous standard of care with ACE inhibitor/mineralocorticoid receptor antagonist/beta blocker.,2023-06-06,,methods,4,1,0.16556612738775175,other,1.0,0.16556612738775175,0.16556612738775175,"['compared with', 'combination']","{""comparative_terms"": [""compared with""], ""combination"": [""quadruple therapy""]}","['comparative_terms', 'relationship:combination']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.543025+00:00,"{'recency_weight': 0.16556612738775175, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.16556612738775175, 'final_confidence': 0.16556612738775175}"
med:pmid:37051752,med:pmid:37051752:sec:results:sent:2,enalapril,ACEI,sacubitril_valsartan,ARNI,CKD-EPI creatinine-cystatin C equation (creatinine-cystatin) was compared to creatinine-only (creatinine) equation in a subpopulation of Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure (PARADIGM-HF).,2023-06-01,,results,2,1,0.16400148938717687,randomized controlled trial,1.6,0.262402383019483,0.262402383019483,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],['chronic kidney disease'],,,,[],comparative,comparative_efficacy,0.6,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.538025+00:00,"{'recency_weight': 0.16400148938717687, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.262402383019483, 'final_confidence': 0.262402383019483}"
med:pmid:37217135,med:pmid:37217135:sec:results:sent:8,enalapril,ACEI,sacubitril_valsartan,ARNi,"The proportion of patients receiving an angiotensin-converting enzyme inhibitor (ACEI)/ angiotensin II receptor blockers (ARB), an angiotensin receptor-neprilysin inhibitor (ARNi), a sodium-glucose cotransporter 2 inhibitor (SGLT2i), or a mineralocorticoid receptor antagonist (MRA) progressively decreased with lower eGFR categories.",2023-05-20,,results,8,1,0.16030642003773068,other,1.0,0.16030642003773068,0.16030642003773068,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.16030642003773068, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.16030642003773068, 'final_confidence': 0.16030642003773068}"
med:pmid:37217135,med:pmid:37217135:sec:results:sent:9,enalapril,ACEI,sacubitril_valsartan,ARNi,"Notably, 32% of the patients with HFrEF and an eGFR <30 mL/min/1.73 m<sup>2</sup> received the combination of ACEI/ARB/ARNi+beta-blockers+MRA+SGLT2i.",2023-05-20,,results,9,1,0.16030642003773068,other,1.0,0.16030642003773068,0.16030642003773068,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.543025+00:00,"{'recency_weight': 0.16030642003773068, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.16030642003773068, 'final_confidence': 0.16030642003773068}"
med:pmid:37195574,med:pmid:37195574:sec:methods:sent:4,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"The Embase, PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) that compared sacubitril/valsartan with ACEI/ARBs in patients with CKD whose estimated glomerular filtration rate (eGFR) was below 60 mL/min/1.73 m<sup>2</sup>.",2023-05-17,,methods,4,1,0.15939573490917353,review,0.9,0.14345616141825618,0.14345616141825618,['randomized'],"{""study_context"": [""randomized""]}",['study_context'],['chronic kidney disease'],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.542025+00:00,"{'recency_weight': 0.15939573490917353, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.14345616141825618, 'final_confidence': 0.14345616141825618}"
med:pmid:37195574,med:pmid:37195574:sec:results:sent:10,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"Subgroup analysis about eGFR demonstrated that with long follow-up, sacubitril/valsartan significantly decreased the number of patients with more than 50% reduction in eGFR compared with ACEI/ARBs (OR: 0.52, 95% CI 0.32-0.84, P = 0.008, I<sup>2</sup> = 9%).",2023-05-17,,results,10,1,0.15939573490917353,review,0.9,0.14345616141825618,0.14345616141825618,['compared with'],"{""comparative_terms"": [""compared with""], ""claim_strength_terms"": {""suggestive"": [""subgroup analysis""]}}","['comparative_terms', 'claim_strength:suggestive']",[],,,,[],comparative,comparative_efficacy,0.39999999999999997,POS,1.0,lexicon_v1,2026-01-08T18:51:51.542025+00:00,"{'recency_weight': 0.15939573490917353, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.14345616141825618, 'final_confidence': 0.14345616141825618}"
med:pmid:37313196,med:pmid:37313196:sec:conclusion:sent:12,enalapril,ACEI,sacubitril_valsartan,Sacubitril/valsartan,"Sacubitril/valsartan had better clinical, intermediate, and renal outcomes in HF in comparison to ACEI or ARB.",2023-05-14,,conclusion,12,1,0.1584902232939615,review,0.9,0.14264120096456537,0.14264120096456537,[],,[],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.543025+00:00,"{'recency_weight': 0.1584902232939615, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.14264120096456537, 'final_confidence': 0.14264120096456537}"
med:pmid:37313196,med:pmid:37313196:sec:introduction:sent:2,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,of the study was to assess the benefits and harms of sacubitril/valsartan (S/V) compared to angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) in patients with HF.,2023-05-14,,introduction,2,1,0.1584902232939615,review,0.9,0.14264120096456537,0.14264120096456537,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.544025+00:00,"{'recency_weight': 0.1584902232939615, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.14264120096456537, 'final_confidence': 0.14264120096456537}"
med:pmid:37240819,med:pmid:37240819:sec:abstract:sent:1,enalapril,enalapril,sacubitril_valsartan,Sacubitril/valsartan,Sacubitril/valsartan (Sac/Val) reduces mortality in patients with heart failure with reduced ejection fraction (HFrEF) compared to enalapril.,2023-05-12,,abstract,1,1,0.15788940853732833,other,1.0,0.15788940853732833,0.15788940853732833,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.543025+00:00,"{'recency_weight': 0.15788940853732833, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.15788940853732833, 'final_confidence': 0.15788940853732833}"
med:pmid:37164146,med:pmid:37164146:sec:methods:sent:3,enalapril,ACEi,sacubitril_valsartan,ARNI,"We characterized the change over time in the use of evidence-based therapies to reduce cardiovascular risk in US patients with T2D.   Data from a longitudinal outpatient diabetes registry were used to calculate the prescription of SGLT2i or GLP-1RA over time and among those with high-risk comorbidities (atherosclerotic cardiovascular disease [ASCVD], heart failure [HF], chronic kidney disease [CKD]) and a diabetes cardiovascular composite score (DCCS; calculated as: #eligible medications prescribed/#eligible medications x 100 for SGLT2i, GLP-1RA, statin, antiplatelet/anticoagulant therapy, ACEi/ARB/ARNI).",2023-05-08,,methods,3,1,0.15669460320963802,other,1.0,0.15669460320963802,0.15669460320963802,[],,[],"['cardiovascular disease', 'chronic kidney disease', 'type 2 diabetes']",,,,[],,,,,,,,"{'recency_weight': 0.15669460320963802, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.15669460320963802, 'final_confidence': 0.15669460320963802}"
med:pmid:37146072,med:pmid:37146072:sec:methods:sent:6,enalapril,angiotensin converting enzyme inhibitor,sacubitril_valsartan,angiotensin receptor neprilysin inhibitors,"Four databases were searched, and randomized controlled trials (RCTs) of Danshen decoction combined with conventional treatment (CT) of HF were screened, CT included medical treatments other than Danshen Decoction to which the patient was treated (including but not limited to angiotensin converting enzyme inhibitor, angiotensin receptor blocker, angiotensin receptor neprilysin inhibitors, β-blockers, diuretics, mineralcorticoid recept antagonist etc.).",2023-05-05,,methods,6,1,0.15580443646001815,review,0.9,0.14022399281401635,0.14022399281401635,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.15580443646001815, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.14022399281401635, 'final_confidence': 0.14022399281401635}"
med:pmid:37137558,med:pmid:37137558:sec:introduction:sent:8,enalapril,ACE inhibitor,sacubitril_valsartan,angiotensin receptor neprilysin inhibitor,"We will include patients taking RAS inhibitors-including ACE inhibitor, angiotensin receptor blocker and angiotensin receptor neprilysin inhibitor and exclude the patients undergoing renal replacement therapy (RRT), adolescents (under 18 years of age) and patients with acute infectious diseases.",2023-05-03,,introduction,8,1,0.15521380315388378,other,1.0,0.15521380315388378,0.15521380315388378,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.15521380315388378, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.15521380315388378, 'final_confidence': 0.15521380315388378}"
med:pmid:37125529,med:pmid:37125529:sec:introduction:sent:2,enalapril,ACE Inhibitor,sacubitril_valsartan,ARNI,"We evaluated the prognostic importance of NT-proBNP in patients with acute myocardial infarction (MI) complicated by left ventricular systolic dysfunction, pulmonary congestion, or both and ≥1 of 8 risk-augmenting factors enrolled in the PARADISE-MI trial (Prospective ARNI vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After Myocardial Infarction).",2023-05-01,,introduction,2,1,0.15462540885782022,randomized controlled trial,1.6,0.24740065417251236,0.24740065417251236,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.15462540885782022, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.24740065417251236, 'final_confidence': 0.24740065417251236}"
med:pmid:37115135,med:pmid:37115135:sec:methods:sent:3,enalapril,ACEIs,sacubitril_valsartan,angiotensin receptor neprilysin inhibitors,"Baseline use, dose, and intolerances of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), angiotensin receptor neprilysin inhibitors (ARNIs), beta-blockers, and mineralocorticoid receptor antagonists (MRAs) were analyzed in patients with left ventricular ejection fraction (LVEF) ≤40%, in whom maximally tolerated doses of these agents as assessed by an independent HF specialist were required before enrollment.",2023-04-26,,methods,3,1,0.1531641631648122,other,1.0,0.1531641631648122,0.1531641631648122,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.1531641631648122, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.1531641631648122, 'final_confidence': 0.1531641631648122}"
med:pmid:37115135,med:pmid:37115135:sec:results:sent:6,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"Beta-blockers were the most frequently tolerated GDMT (93.1%), followed by ACEIs/ARBs/ARNIs (68.5%), and then MRAs (55.0%).",2023-04-26,,results,6,1,0.1531641631648122,other,1.0,0.1531641631648122,0.1531641631648122,['combination'],"{""combination"": [""gdmt""]}",['relationship:combination'],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.540025+00:00,"{'recency_weight': 0.1531641631648122, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.1531641631648122, 'final_confidence': 0.1531641631648122}"
med:pmid:37115135,med:pmid:37115135:sec:results:sent:8,enalapril,ACEIs,sacubitril_valsartan,ARNIs,Goal doses were uncommonly achieved for beta-blockers (32.3%) and ACEIs/ARBs/ARNIs (10.2%) due to intolerances limiting titration.,2023-04-26,,results,8,1,0.1531641631648122,other,1.0,0.1531641631648122,0.1531641631648122,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.541025+00:00,"{'recency_weight': 0.1531641631648122, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.1531641631648122, 'final_confidence': 0.1531641631648122}"
med:pmid:37104912,med:pmid:37104912:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,This study aimed to estimate the financial and economic impact of sacubitril/valsartan compared with enalapril for the treatment and prevention of hospitalization/rehospitalization because of heart failure with reduced ejection fraction (HFrEF).,2023-04-25,,introduction,1,1,0.15287357531300366,other,1.0,0.15287357531300366,0.15287357531300366,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.15287357531300366, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.15287357531300366, 'final_confidence': 0.15287357531300366}"
med:pmid:37104912,med:pmid:37104912:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In 5 years, the total cost of treating patients with HFrEF with sacubitril/valsartan at current market coverage and annual growth conditions is ₱15.430 billion, which is ₱11.077 billion higher than fully treating with enalapril only.",2023-04-25,,results,8,1,0.15287357531300366,other,1.0,0.15287357531300366,0.15287357531300366,[],"{""access_terms"": [""coverage""]}",['access_terms'],[],,,,[],access,coverage_access,0.65,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.540025+00:00,"{'recency_weight': 0.15287357531300366, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.15287357531300366, 'final_confidence': 0.15287357531300366}"
med:pmid:37104912,med:pmid:37104912:sec:results:sent:9,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The total required additional investment with treatment of sacubitril/valsartan compared with the full enalapril arm are ₱407 million (at 30-day coverage), ₱800 million (at 60-day coverage), and ₱1.181 billion (at 90-day coverage).",2023-04-25,,results,9,1,0.15287357531300366,other,1.0,0.15287357531300366,0.15287357531300366,['compared with'],"{""comparative_terms"": [""compared with""], ""access_terms"": [""coverage""]}","['comparative_terms', 'access_terms']",[],,,,[],access,coverage_access,0.65,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.540025+00:00,"{'recency_weight': 0.15287357531300366, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.15287357531300366, 'final_confidence': 0.15287357531300366}"
med:pmid:37062869,med:pmid:37062869:sec:results:sent:5,enalapril,ACEI,sacubitril_valsartan,ARNI,Using two clinical trials in HF - the Prospective comparison of ARNI (Angiotensin Receptor-Neprilysin Inhibitor) with ACEI (Angiotensin-Converting Enzyme Inhibitor) to Determine Impact on Global Mortality and morbidity in HF trial (PARADIGM-HF) and the Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure trials (ATMOSPHERE) - we identified the 10 most common comorbidities and examined 45 possible pairs.,2023-04-24,,results,5,1,0.15258353877357703,other,1.0,0.15258353877357703,0.15258353877357703,['trial'],"{""study_context"": [""trial""]}",['study_context'],[],,,,[],evidence,clinical_trial,0.7,NEU,-0.5,lexicon_v1,2026-01-08T18:51:51.539025+00:00,"{'recency_weight': 0.15258353877357703, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.15258353877357703, 'final_confidence': 0.15258353877357703}"
med:pmid:37066800,med:pmid:37066800:sec:abstract:sent:3,enalapril,ACEI,sacubitril_valsartan,ARNI,ARNI has demonstrated superior cardioprotective effects compared with renin-angiotensin system inhibitors (RAS-Is) in large clinical trials such as the PARADIGM-HF (Prospective Comparison of ARNI With ACEI [Angiotensin-Converting Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial.,2023-04-17,,abstract,3,1,0.15056863213261082,review,0.9,0.13551176891934974,0.13551176891934974,"['compared with', 'superior', 'trial']","{""comparative_terms"": [""compared with"", ""superior""], ""study_context"": [""trial""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.539025+00:00,"{'recency_weight': 0.15056863213261082, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.13551176891934974, 'final_confidence': 0.13551176891934974}"
med:pmid:37043670,med:pmid:37043670:sec:abstract:sent:10,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,The results of this study show that sacubitril/valsartan can be used in patients with AMI instead of enalapril.,2023-04-12,,abstract,10,1,0.14914572391312025,other,1.0,0.14914572391312025,0.14914572391312025,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.538025+00:00,"{'recency_weight': 0.14914572391312025, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.14914572391312025, 'final_confidence': 0.14914572391312025}"
med:pmid:37043670,med:pmid:37043670:sec:abstract:sent:2,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"This study focuses on the relevant indexes of VR in patients with AMI, in which, the intervention effects of sacubitril/valsartan and enalapril were compared, guiding the clinical treatment.",2023-04-12,,abstract,2,1,0.14914572391312025,other,1.0,0.14914572391312025,0.14914572391312025,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.14914572391312025, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.14914572391312025, 'final_confidence': 0.14914572391312025}"
med:pmid:37407154,med:pmid:37407154:sec:conclusion:sent:13,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Irrespective of anemia status, sacubitril/valsartan compared with enalapril, decreased mortality and hospitalization.",2023-04-12,,conclusion,13,1,0.14914572391312025,randomized controlled trial,1.6,0.2386331582609924,0.2386331582609924,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.544025+00:00,"{'recency_weight': 0.14914572391312025, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.2386331582609924, 'final_confidence': 0.2386331582609924}"
med:pmid:37407154,med:pmid:37407154:sec:conclusion:sent:15,enalapril,ACEI,sacubitril_valsartan,ARNI,Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure [PARADIGM-HF] trial; NCT01035255).,2023-04-12,,conclusion,15,1,0.14914572391312025,randomized controlled trial,1.6,0.2386331582609924,0.2386331582609924,['trial'],"{""study_context"": [""trial""]}",['study_context'],[],,,,[],evidence,clinical_trial,0.7,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.545014+00:00,"{'recency_weight': 0.14914572391312025, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.2386331582609924, 'final_confidence': 0.2386331582609924}"
med:pmid:37407154,med:pmid:37407154:sec:introduction:sent:3,enalapril,ACEI,sacubitril_valsartan,ARNI,The authors investigated whether concomitant neprilysin inhibition might ameliorate this effect of renin-angiotensin system blockers in PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure).,2023-04-12,,introduction,3,1,0.14914572391312025,randomized controlled trial,1.6,0.2386331582609924,0.2386331582609924,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.14914572391312025, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.2386331582609924, 'final_confidence': 0.2386331582609924}"
med:pmid:37407154,med:pmid:37407154:sec:results:sent:10,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Patients assigned to sacubitril/valsartan were less likely to develop anemia at 12 months (321 of 2,806 [11.4%]) compared with patients randomized to enalapril (440 of 2,824 [15.6%]) (OR: 0.70 [95% CI: 0.60-0.81]; P < 0.001).",2023-04-12,,results,10,1,0.14914572391312025,randomized controlled trial,1.6,0.2386331582609924,0.2386331582609924,"['compared with', 'randomized']","{""comparative_terms"": [""compared with""], ""study_context"": [""randomized""]}","['comparative_terms', 'study_context']",[],,,,[],evidence,clinical_trial,0.49999999999999994,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.545014+00:00,"{'recency_weight': 0.14914572391312025, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.2386331582609924, 'final_confidence': 0.2386331582609924}"
med:pmid:37407154,med:pmid:37407154:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,Sacubitril/valsartan,"Sacubitril/valsartan, compared with enalapril, decreased the risk of cardiovascular death or heart failure hospitalization similarly in patients with (HR: 0.84; 95% CI: 0.71-1.00) and without anemia (HR: 0.78 [95% CI: 0.71-0.87]; P value for interaction = 0.478).",2023-04-12,,results,8,1,0.14914572391312025,randomized controlled trial,1.6,0.2386331582609924,0.2386331582609924,"['compared with', 'risk']","{""comparative_terms"": [""compared with""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}, ""claim_strength_terms"": {""confirmatory"": [""p value""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment', 'claim_strength:confirmatory']",[],,,,[],comparative,comparative_efficacy,0.39999999999999997,NEG,-2.0,lexicon_v1,2026-01-08T18:51:51.545014+00:00,"{'recency_weight': 0.14914572391312025, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.2386331582609924, 'final_confidence': 0.2386331582609924}"
med:pmid:37407154,med:pmid:37407154:sec:results:sent:9,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Between baseline and 12 months, hemoglobin decreased by 1.5 g/L (95% CI: 1.2-1.7 g/L) with sacubitril/valsartan compared with 2.3 g/L (95% CI: 2.0-2.6 g/L) with enalapril: mean difference 0.8 g/L (95% CI: 0.5-1.2 g/L; P < 0.001).",2023-04-12,,results,9,1,0.14914572391312025,randomized controlled trial,1.6,0.2386331582609924,0.2386331582609924,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.546015+00:00,"{'recency_weight': 0.14914572391312025, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.2386331582609924, 'final_confidence': 0.2386331582609924}"
med:pmid:37042870,med:pmid:37042870:sec:abstract:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"They received sacubitril/valsartan or valsartan instead of the more commonly used angiotensin-converting enzyme inhibitor enalapril for heart failure, in addition to standard medical therapy for heart failure.",2023-04-07,,abstract,3,1,0.14773626250371497,other,1.0,0.14773626250371497,0.14773626250371497,[],,[],[],add_on,add_on,backbone,['add_on_to'],,,,NEG,-2.0,lexicon_v1,2026-01-08T18:51:51.538025+00:00,"{'recency_weight': 0.14773626250371497, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.14773626250371497, 'final_confidence': 0.14773626250371497}"
med:pmid:37077749,med:pmid:37077749:sec:abstract:sent:1,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,We aimed to compare therapies of sacubitril/valsartan + spironolactone (S/V + S) with angiotensin-converting enzyme inhibitors + spironolactone (ACEI + S) on the left-sided cardiac reverse remodeling (L-CRR).,2023-04-03,,abstract,1,1,0.14661828964430834,other,1.0,0.14661828964430834,0.14661828964430834,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.14661828964430834, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.14661828964430834, 'final_confidence': 0.14661828964430834}"
med:pmid:36944496,med:pmid:36944496:sec:results:sent:2,enalapril,ACEI,sacubitril_valsartan,ARNI,The prognostic value of several newer anthropometric indices was compared with that of BMI in patients with heart failure (HF) and reduced ejection fraction (HFrEF) enrolled in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure.,2023-04-01,,results,2,1,0.1460624797641795,other,1.0,0.1460624797641795,0.1460624797641795,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.538025+00:00,"{'recency_weight': 0.1460624797641795, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.1460624797641795, 'final_confidence': 0.1460624797641795}"
med:pmid:36972959,med:pmid:36972959:sec:introduction:sent:7,enalapril,ACE inhibitor,sacubitril_valsartan,angiotensin receptor neprilysin inhibitor,"The primary endpoint, assessed at 6 months, will be the difference between groups in the proportion of participants being prescribed five guideline-recommended treatments; (1) ACE inhibitor/angiotensin receptor blocker/angiotensin receptor neprilysin inhibitor at least 50% of target dose, (2) beta-blocker at least 50% of target dose, (3) mineralocorticoid receptor antagonist at any dose, (4) anticoagulation for patients diagnosed with atrial fibrillation, (5) referral to cardiac rehabilitation.",2023-03-27,,introduction,7,1,0.14468215572143608,other,1.0,0.14468215572143608,0.14468215572143608,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.14468215572143608, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.14468215572143608, 'final_confidence': 0.14468215572143608}"
med:pmid:36942494,med:pmid:36942494:sec:methods:sent:4,enalapril,ACE inhibitors,sacubitril_valsartan,ARNI,"Seventeen patients switched from ACE inhibitors or ARBs to an ARNI (ARNI group), and the other 17 patients continued treatment with ACE inhibitors or ARBs (control group).",2023-03-21,,methods,4,1,0.1430429745829581,other,1.0,0.1430429745829581,0.1430429745829581,[],,[],[],switch,switch_destination,switch_source,['switch_from'],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.536014+00:00,"{'recency_weight': 0.1430429745829581, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.1430429745829581, 'final_confidence': 0.1430429745829581}"
med:pmid:37090394,med:pmid:37090394:sec:abstract:sent:1,enalapril,ACEi,sacubitril_valsartan,ARNI,The present meta-analysis was conducted to compare the safety and efficacy of angiontensin receptor neprilysin inhibitor (ARNI) with angiotensin receptor blockers (ARBs) and angiotensin-converting-enzyme inhibitors (ACEi) in patients with heart failure with reduced ejection fraction (HFrEF).,2023-03-20,,abstract,1,1,0.14277158896741016,review,0.9,0.12849443007066916,0.12849443007066916,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.14277158896741016, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.12849443007066916, 'final_confidence': 0.12849443007066916}"
med:pmid:36871177,med:pmid:36871177:sec:conclusion:sent:15,enalapril,ACEIs,sacubitril_valsartan,sacubitril/valsartan,"Although sacubitril/valsartan reduces mortality compared to ACEIs/ARBs in HF patients, they do not reduce AF risk compared to these drugs.",2023-03-16,,conclusion,15,1,0.14169118555896526,review,0.9,0.12752206700306873,0.12752206700306873,"['compared to', 'risk']","{""comparative_terms"": [""compared to""], ""risk_terms"": [""risk""]}","['comparative_terms', 'risk_terms']",[],,,,[],comparative,comparative_efficacy,0.6,POS,1.0,lexicon_v1,2026-01-08T18:51:51.532882+00:00,"{'recency_weight': 0.14169118555896526, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.12752206700306873, 'final_confidence': 0.12752206700306873}"
med:pmid:36871177,med:pmid:36871177:sec:introduction:sent:1,enalapril,ACEIs,sacubitril_valsartan,Sacubitril/valsartan,Sacubitril/valsartan reduces all-cause mortality in heart failure (HF) patients compared to angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).,2023-03-16,,introduction,1,1,0.14169118555896526,review,0.9,0.12752206700306873,0.12752206700306873,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.532882+00:00,"{'recency_weight': 0.14169118555896526, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.12752206700306873, 'final_confidence': 0.12752206700306873}"
med:pmid:36871177,med:pmid:36871177:sec:results:sent:10,enalapril,ACEIs,sacubitril_valsartan,sacubitril/valsartan,A total of 284 AF events were reported in the sacubitril/valsartan group compared to 256 AF events in ACEIs/ARBs.,2023-03-16,,results,10,1,0.14169118555896526,review,0.9,0.12752206700306873,0.12752206700306873,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.534024+00:00,"{'recency_weight': 0.14169118555896526, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.12752206700306873, 'final_confidence': 0.12752206700306873}"
med:pmid:36871177,med:pmid:36871177:sec:results:sent:11,enalapril,ACEIs,sacubitril_valsartan,sacubitril/valsartan,"Patients on sacubitril/valsartan were as likely as patients on ACEIs/ARBs to develop AF (pooled odds ratio [OR] = 1.091, 95% confidence interval [CI] = 0.917-1.298, p = .324).",2023-03-16,,results,11,1,0.14169118555896526,review,0.9,0.12752206700306873,0.12752206700306873,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.534024+00:00,"{'recency_weight': 0.14169118555896526, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.12752206700306873, 'final_confidence': 0.12752206700306873}"
med:pmid:36871177,med:pmid:36871177:sec:results:sent:12,enalapril,ACEi,sacubitril_valsartan,sacubitril/valsartan,Six atrial flutter (AFl) events were reported in six trials; 48 out of 9165 patients in the sacubitril/valsartan group developed AFl compared to 46 out of 8759 in ACEi/ARBs group.,2023-03-16,,results,12,1,0.14169118555896526,review,0.9,0.12752206700306873,0.12752206700306873,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.534024+00:00,"{'recency_weight': 0.14169118555896526, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.12752206700306873, 'final_confidence': 0.12752206700306873}"
med:pmid:36871177,med:pmid:36871177:sec:results:sent:14,enalapril,ACEi,sacubitril_valsartan,sacubitril/valsartan,"Finally, sacubitril/valsartan did not reduce the risk of atrial arrhythmias (AF + AFl) compared to ACEi/ARBs (pooled OR = 1.081, 95% CI = 0.922-1.269, p = .337).",2023-03-16,,results,14,1,0.14169118555896526,review,0.9,0.12752206700306873,0.12752206700306873,"['compared to', 'risk']","{""comparative_terms"": [""compared to""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T18:51:51.535014+00:00,"{'recency_weight': 0.14169118555896526, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.12752206700306873, 'final_confidence': 0.12752206700306873}"
med:pmid:36871177,med:pmid:36871177:sec:results:sent:9,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"A total of 11 trials including 11,458 patients on sacubitril/valsartan and 10,128 patients on ACEI/ARBs were identified.",2023-03-16,,results,9,1,0.14169118555896526,review,0.9,0.12752206700306873,0.12752206700306873,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.535014+00:00,"{'recency_weight': 0.14169118555896526, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.12752206700306873, 'final_confidence': 0.12752206700306873}"
med:pmid:36896801,med:pmid:36896801:sec:introduction:sent:3,enalapril,ACEi,sacubitril_valsartan,angiotensin receptor neprilysin inhibitor,"A network meta-analysis (NMA) was performed to compare treatment effect of mineralocorticoid receptor antagonists (MRA), angiotensin receptor neprilysin inhibitor (ARNi), angiotensin receptor blockers (ARB), angiotensin-converting-enzyme inhibitors (ACEi), sodium-glucose cotransporter-2 inhibitors (SGLT2i), and beta-blockers (BB) in HFmrEF cardiovascular (CV) outcomes.",2023-03-10,,introduction,3,1,0.14008589071317917,other,1.0,0.14008589071317917,0.14008589071317917,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.14008589071317917, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.14008589071317917, 'final_confidence': 0.14008589071317917}"
med:pmid:36896801,med:pmid:36896801:sec:results:sent:9,enalapril,ACEi,sacubitril_valsartan,ARNi,"In HF hospitalizations, the impact of the pharmacological therapies was more notorious, and ARNi reduced in 40% the risk of HF hospitalizations (HR 0.60, 95% CI 0.39-0.92), SGLT2i in 26% (HR 0.74, 95% CI 0.59-0.93) and renin-angiotensin system inhibition (RASi) with ARB and ACEi in 28% (HR 0.72, 95% CI 0.53-0.98).",2023-03-10,,results,9,1,0.14008589071317917,other,1.0,0.14008589071317917,0.14008589071317917,['risk'],"{""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['risk_terms', 'risk_posture:acknowledgment']",[],,,,[],comparative,comparative_efficacy,0.8,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.535014+00:00,"{'recency_weight': 0.14008589071317917, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.14008589071317917, 'final_confidence': 0.14008589071317917}"
med:pmid:36892492,med:pmid:36892492:sec:methods:sent:4,enalapril,ACEI,sacubitril_valsartan,ARNI,"Using a 2-state Markov model, the authors performed a cost-effectiveness study using simulated populations of 1,000 patients with HFrEF based on the participants in the PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure) trial and compared them by treatment strategy (quadruple therapy vs triple and double therapy) from a United States health care system perspective.",2023-03-01,,methods,4,1,0.137711985035724,other,1.0,0.137711985035724,0.137711985035724,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.137711985035724, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.137711985035724, 'final_confidence': 0.137711985035724}"
med:pmid:36852608,med:pmid:36852608:sec:results:sent:12,enalapril,angiotensin converting enzyme inhibitor,sacubitril_valsartan,angiotensin receptor neprilysin inhibitor,"In patients with HFrEF or recovered HFrEF, fundamental treatments were prescribed in 86% for angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or angiotensin receptor neprilysin inhibitor (ARNI), in 82% for beta-blocker, in 38% for mineralocorticoid receptor antagonist (MRA), and in 12% for sodium-glucose co-transporter-2 inhibitor (SGLT2i).",2023-02-28,,results,12,1,0.13745071354066307,other,1.0,0.13745071354066307,0.13745071354066307,[],,[],[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.532882+00:00,"{'recency_weight': 0.13745071354066307, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.13745071354066307, 'final_confidence': 0.13745071354066307}"
med:pmid:36852608,med:pmid:36852608:sec:results:sent:14,enalapril,ACEI,sacubitril_valsartan,ARNI,"In patients with HFmrEF or HFpEF, an ACEI, ARB, or ARNI was prescribed in 67%, beta-blocker in 67%, MRA in 22%, and SGLT2i in 7.4% with significantly lower probability of treatment compared to patients with HFrEF or recovered HFrEF [OR point estimates 0.33 to 0.57, all P-values < 0.05].",2023-02-28,,results,14,1,0.13745071354066307,other,1.0,0.13745071354066307,0.13745071354066307,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],evidence,real_world,0.7,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.532882+00:00,"{'recency_weight': 0.13745071354066307, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.13745071354066307, 'final_confidence': 0.13745071354066307}"
med:pmid:36812948,med:pmid:36812948:sec:methods:sent:4,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In sequential run-in phases, patients were titrated to enalapril 10 mg twice daily and then sacubitril/valsartan 97 mg/103 mg twice daily (in PARADIGM-HF) or valsartan 80 mg twice daily and then sacubitril/valsartan 49 mg/51 mg twice daily (in PARAGON-HF).",2023-02-20,,methods,4,1,0.13537830773627857,other,1.0,0.13537830773627857,0.13537830773627857,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.516751+00:00,"{'recency_weight': 0.13537830773627857, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.13537830773627857, 'final_confidence': 0.13537830773627857}"
med:pmid:36808581,med:pmid:36808581:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,Sacubitril/valsartan,Sacubitril/valsartan (an Angiotensin receptor-neprilysin inhibitor-ARNI) is one of the cornerstones in the management of patients with heart failure with reduced ejection fraction (HFrEF) having demonstrated significant reductions in both mortality and hospitalisations as compared with enalapril.,2023-02-18,,introduction,1,1,0.13486510709004618,other,1.0,0.13486510709004618,0.13486510709004618,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.516751+00:00,"{'recency_weight': 0.13486510709004618, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.13486510709004618, 'final_confidence': 0.13486510709004618}"
med:pmid:36808581,med:pmid:36808581:sec:results:sent:13,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In Argentina the cost-per quality adjusted life-year (QALY) gained for sacubitril/valsartan versus enalapril was 391,158 ARS and 376,665 ARS for a social security and a private payer, respectively, at a 30- year horizon.",2023-02-18,,results,13,1,0.13486510709004618,other,1.0,0.13486510709004618,0.13486510709004618,['versus'],"{""comparative_terms"": [""versus""], ""access_terms"": [""payer""]}","['comparative_terms', 'access_terms']",[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.516751+00:00,"{'recency_weight': 0.13486510709004618, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.13486510709004618, 'final_confidence': 0.13486510709004618}"
ppr:doi:10.21203/rs.3.rs-2552934/v1,ppr:doi:10.21203/rs.3.rs-2552934/v1:sec:introduction:sent:2,enalapril,ACEIs,sacubitril_valsartan,Angiotensin receptor Neprilysin inhibitors,"New drugs have been introduced, including the group of drugs called Angiotensin receptor Neprilysin inhibitors (ARNI), but due to their high cost, angiotensin-converting enzymes inhibitors (ACEIs) and Angiotensin receptor blockers (ARBs) have been mostly used in Tanzania.",2023-02-07,,introduction,2,1,0.13207708178552,other,1.0,0.13207708178552,0.13207708178552,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.13207708178552, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.13207708178552, 'final_confidence': 0.13207708178552}"
med:pmid:36818914,med:pmid:36818914:sec:methods:sent:4,enalapril,ACEi,sacubitril_valsartan,ARNi,The putative ARNi-induced pro-arteriogenic effects were further investigated and compared with an angiotensin-converting enzyme inhibitor (ACEi).,2023-02-03,,methods,4,1,0.13107760751777128,other,1.0,0.13107760751777128,0.13107760751777128,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.516751+00:00,"{'recency_weight': 0.13107760751777128, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.13107760751777128, 'final_confidence': 0.13107760751777128}"
med:pmid:36769667,med:pmid:36769667:sec:abstract:sent:2,enalapril,angiotensin converting enzyme inhibitors,sacubitril_valsartan,angiotensin receptor neprilysin inhibitors,"Current guidelines indicate to start therapy with angiotensin converting enzyme inhibitors/angiotensin receptor neprilysin inhibitors (ACEi/ARNI), beta blockers (BB), mineralocorticoid receptor antagonists (MRAs) and sodium glucose cotransporter 2 inhibitors (SGLT2i) to reduce the risk of death and hospitalization due to HF.",2023-01-28,,abstract,2,1,0.12959255954590088,other,1.0,0.12959255954590088,0.12959255954590088,['risk'],"{""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['risk_terms', 'risk_posture:acknowledgment']",[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T18:51:51.516751+00:00,"{'recency_weight': 0.12959255954590088, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.12959255954590088, 'final_confidence': 0.12959255954590088}"
med:pmid:36769667,med:pmid:36769667:sec:abstract:sent:8,enalapril,ACEi,sacubitril_valsartan,ARNI,"Some authors suggest starting with SGLT2i and BB, others with ACEi or ARNI, while one of the most recent approach proposes to start with all four drugs together at low doses.",2023-01-28,,abstract,8,1,0.12959255954590088,other,1.0,0.12959255954590088,0.12959255954590088,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T18:51:51.516751+00:00,"{'recency_weight': 0.12959255954590088, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.12959255954590088, 'final_confidence': 0.12959255954590088}"
